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This thesis focuses on the development of novel nanomaterials for biomedical imaging using
both iron oxide nanoparticles and cadmium based quantum dots, and two different coating
methods. The first approach involved a coating ligand consisting of the stealth molecule
polyethylene glycol, and a bisphosphonate enabling strong binding to the nanoparticle sur-
face. This polymer conjugate was chosen in order to reduce undesirable reticuloendothelial
system uptake, and hence increase blood circulation times allowing for efficient delivery of
particles to specific in vivo vascular targets. The second route employed a naturally occur-
ring amphiphilic protein, hydrophobin, as an encapsulation agent affording water solubility
of nanomaterials and potential for bioconjugation.
The first part of the study involved the synthesis of novel iron oxide nanomaterials of small
size distribution and a near-zero surface charge resulting in dispersions that were stable in
solution for several months. Both longitudinal (r1) and transverse (r2) relaxivity measure-
ments were performed at a clinically relevant magnetic field of 3 T, revealing a low r2/r1
ratio of 2.97 showing the particles to have optimal properties for efficient T 1 -weighted mag-
netic resonance imaging. The strong T 1 effect was validated in vivo, revealing a long blood
circulation time and a 6-fold enhancement of its signal, allowing for high resolution visualisa-
tion of vessels and vascularised organs. The low reticuloendothelial system uptake observed
was confirmed by radiolabelling the particles, hence affording dual-modality contrast, and
performing in vivo single photon emission computed tomography. From this study, the blood
half-life was calculated to be 2.97 h. In vitro targeting studies using three different cardio-
vascular/cancer biomarkers (VCAM-1, PSMA, and p32) were conducted, showing specific
uptake of the targeted particles to relevant cell lines.
The second section examines the potential for applying the polyethylene glycol-bisphosphonate
coating to other inorganic nanomaterials. CdZnSeS alloyed quantum dots were successfully
synthesised, with the resulting particles exhibiting red emission (∼604.0 nm) and no sig-
nificant shift after phase transfer into aqueous solution. Preliminary in vitro cell studies
revealed particle emission at the expected wavelength.
Finally, the synthesised nanoparticles were successfully coated with the amphiphilic protein
(hydrophobin). The resulting nanoparticles exhibited no change in core size or morphology
as determined by transmission electron microscopy, as well as no shift in emission (∼627.0
nm). In vitro studies were performed allowing for visualisation of the quantum dots in a
biological environment after incubation at physiological temperature. In addition, particles
were injected intratumourly into a live mouse model, with emission detected up to 24 h post
injection. Lastly, radiolabelling with iodine-131 was achieved; confirming the possibility of
utilising exposed residues on the protein to further functionalise the surface.
In conclusion, the described methods and nanoparticles synthesised represent a promising
platform for the development of targeted agents for multimodal medical imaging and other
bio-applications.
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1.1 Introduction and thesis outline
This thesis focuses on the development of novel nanomaterials for biomedical imaging using
both iron oxide nanoparticles (NPs) and cadmium based quantum dots (QDs).
Chapter one gives an introduction to the main concepts of the thesis, and provides a
background on current imaging techniques and contrast materials. Firstly, the principles
behind clinically used diagnostic imaging will be presented, as well as the rationale behind
the recent interest in the combination of different molecular imaging techniques. This will
be followed by a summary of different imaging probes available, and the reasoning behind
the use of NPs. Finally, the properties of magnetite and semiconductor particles will be
described, concluding with an outline of available coating molecules coordinated to the
surface of these nanocrystals (NCs) in order to provide stabilisation.
Chapter two concentrates on the development of targeted bimodal contrast agents, with
low reticuloendothelial system (RES) uptake in vivo, based on magnetite NPs for use in
positron emission tomography/single photon emission computed tomography-magnetic res-
onance (PET/SPECT-MR) imaging. The synthesis of novel iron oxide nanomaterials based
in a polyethylene glycol-bisphosphonate (PEG-BP) coating will be described. In addition,
full characterisation of the water soluble NPs is shown, including transmission electron mi-
croscopy (TEM), dynamic light scattering (DLS), infra-red (IR) spectroscopy, X-ray diffrac-
tion (XRD), and relaxivity measurements. Analysis of in vivo MR and SPECT imaging will
then be presented, and finally the results from in vitro targeting studies of three different
biomarkers will be detailed.
Chapter three describes the work undertaken on applying the previously mentioned PEG-
BP coating to CdZnSeS alloyed QDs. The optical properties of the semiconductor NCs
before and after surface ligand exchange is presented, followed by preliminary results from
an in vitro macrophage study.
Chapter four focuses on applying amphiphilic proteins called hydrophobins as a method
of phase transferring inorganic NPs. Optical analysis and size characterisation before and
after encapsulation is given, followed by details of in vitro/in vivo studies involving ovarian
and breast cancer cells, in addition to HeLa cells. This chapter concludes with results
from functionalisation of the protein coated QDs using the radioactive isotope iodine-131
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(131I).
Chapter five describes future work.
Chapter six outlines the experimental procedures used in chapters two, three and four.
Appendices present the DLS number distributions for chapters two, three and four.
1.2 Imaging techniques
1.2.1 General introduction to in vivo imaging
Medical imaging techniques allow us to look inside the human body and detect diseased tissue
without the need of surgery [1–3]. Two clinically available imaging techniques are single
photon emission computed tomography and positron emission tomography. These modalities
rely on the properties of radionuclides [4]. Other routinely used techniques include computed
tomography (CT) which relies on the attenuation of X-rays to give anatomical information,
and magnetic resonance imaging (MRI) in which magnetic fields are used to detect water
molecules in different tissue environments [5,6]. In addition, optical imaging techniques such
as optical coherence tomography (OCT) allow for high resolution and functional imaging of
biological tissues [7].
In the following sections, the theory behind each of these techniques as well as their strengths
and weaknesses will be briefly described.
1.2.2 Computed tomography
Basic principles behind computed tomography
Modern day CT instruments comprise of one X-ray source mounted opposite to several
detectors, as shown in figure 1.1. Once the X-ray photons have passed through the body,
they are detected by the detector system producing electrical signals. As both the radiation
source and detectors rotate, the patient is moved through the scanner at a steady rate,
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allowing for a rapid 3D image acquisition [8, 9].
Figure 1.1: Schematic representation of a CT scanner.
Advantages and disadvantages of computed tomography
There are several benefits to using CT as a diagnostic tool, including the previously men-
tioned short scan times [10, 11]. When comparing against the first X-ray techniques imple-
mented which involved one photographic plate detecting the X-ray beam, it is clear that CT
significantly minimises (i) detail lost when superimposing 3D structural information on to a
2D film display, (ii) the noise-to-signal ratio which is high due to radiation scattering from
the patient, and (iii) the difficulty in distinguishing between certain biological tissues [12,13].
One particular area where CT is an accomplished diagnostic approach is in cardiac imaging
where it provides important evaluation of disease of large vessels, as well as in abnormal
coronary arteries [10].
As with any imaging procedure there are disadvantages, the main one being the exposure to
ionising radiation. However, in most cases the diagnostic advantages outweigh the possible
harmful effects from the X-ray beam [13]. Secondly, the temporal resolution of the images
acquired is impaired due to collecting data from several rotations [14]. In addition, the
imaging agents occasionally administered to enhance the contrast of the scan can exacerbate
kidney function in patients with renal disease [10].
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1.2.3 Magnetic resonance imaging
Basic principles behind magnetic resonance imaging
MRI (scanner shown in figure 1.2) works using the principles of nuclear magnetic resonance
(NMR), whereby protons are aligned in an external magnetic field and disturbed when
electromagnetic (EM) radiation of a certain frequency is applied. Once this EM wave has
been removed, these protons relax back to the original alignment. In relation to MRI, this
means the image acquired is essentially a representation of the relaxation times of water
protons in tissues [15, 16]. Other biologically relevant nuclei, for example 13C, 19F and
31P, are MRI responsive, however their lower sensitivities and tissue concentrations present
difficulties for imaging applications [17].
Figure 1.2: Schematic representation of an MRI machine [18].
There are two different types of relaxation times, and in order to explain these in slightly
more detail, it is important to note some fundamental physics principles. All protons possess
a positive electric charge and a spin, and hence induce a small magnetic field. Therefore,
when an external magnetic field is applied, it is possible for these protons to align with it
in two directions - parallel or anti-parallel to the field, with a slightly higher proportion
aligning with the lower energy state (as demonstrated in figure 1.3a). In addition, the
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protons will precess along the external magnetic field lines with a frequency, known as the
Larmor frequency, given by equation 1.1 (depicted in figure 1.3b) [19].
(a) (b)
Figure 1.3: (a) Alignment of protons both parallel and anti-parallel to an external magnetic
field; (b) Precession of protons in an external magnetic field.
ω0 = γB0 (1.1)
where ω0 = Larmor frequency (Hz)
γ = gyro-magnetic ratio
B0 = external magnetic field strength (T)
When a radio frequency (RF) pulse is applied to the system, some protons will move up an
energy level, i.e. from parallel to the field to anti-parallel, hence decreasing the longitudinal
magnetisation vector (orange arrow) as illustrated in figure 1.4. The time taken for the
protons to realign with the external magnetic field once this RF pulse has been removed is
known as the longitudinal, or spin-lattice, relaxation time (T 1) [19]. During this process,
protons emit thermal energy to the surrounding lattice [15]. Figure 1.6a gives an example
of the intensity variation of a vial of water during a T 1 sequence. In addition, the RF pulse
causes all the protons to precess in phase, as shown in figure 1.5, initiating the formation of
a transverse magnetisation vector (purple arrow). Once the pulse is withdrawn, the protons
lose phase coherence, and this is the transverse, or spin-spin (as protons exchange energy
with other nuclei during this time), relaxation time (T 2) [15, 16]. Figure 1.6b shows how
the intensity of a vial of water changes during a T 2 sequence.
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Figure 1.4: Schematic representation of longitudinal relaxation with only the protons aligned
parallel to the external magnetic field shown: (a) the RF pulse is applied moving some
protons up to a higher energy level, i.e. anti-parallel alignment, (b) the RF pulse is removed
and the protons begin to relax, in turn increasing the longitudinal magnetisation vector, and
(c) all protons have relaxed back down to the lower energy state, i.e. parallel alignment.
Figure 1.5: Schematic representation of transverse relaxation with only the protons aligned
parallel to the external magnetic field shown: (a) the RF pulse is applied causing all protons
to precess in phase, initiating the formation of a transverse magnetisation vector, (b) the
RF pulse is removed and the protons begin to lose phase coherence, in turn decreasing the




Figure 1.6: Variation of the measured intensity of a vial of water during a (a) T 1 sequence,
and (b) T 2 sequence.
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Advantages and disadvantages of magnetic resonance imaging
There are several advantages to using MR as an imaging technique. It allows for the acqui-
sition of soft tissue images with high three-dimensional spatial resolution (<0.1 cm), and
can be considered as a non-invasive procedure delivering no ionising radiation dose [20,21].
Additionally, the intensity of the signal, and hence contrast of the image, can be deter-
mined by several parameters. Firstly, intrinsic properties such as both the longitudinal and
transverse relaxation rates, as well as the proton density. Secondly, instrumental factors
including magnetic field strength and the sequencing technique used. Altering these can
emphasise differences between tissues. The fact that there are many parameters influencing
the overall contrast of the image allows for very different images of the same region to be
captured [21,22].
Although there are clear advantages for the use of MRI it does have its limitations. Perhaps
the main limitation is its low sensitivity when using contrast agents, which limits its potential
for molecular imaging. The low signal intensity per mole has to be compensated for by the
use of large amounts of an agent [20]. For example, the dose of Magnevist (described fully
in a later section; figure 1.19) for a 60 kg adult contains 11 g of the contrast agent, which
includes 2 g of the toxic metal gadolinium. However, it should be noted that contrast agent
material available for MRI is considered safer than iodinated agents utilised in CT [10, 23].
In addition, long scanning times combined with loud noises in a confined space make the
imaging procedure uncomfortable for the patient [10].
1.2.4 Positron emission tomography and single photon emission
computed tomography
Basic principles behind positron emission tomography
For PET, a radioactive nuclide undergoing beta decay due to an inadequate number of
neutrons, resulting in the release of a positron (e+) is required. This radioisotope, for
example fluorine-18 (18F), is injected into the patient prior to imaging. The theory behind
this technique is once the emitted positron has lost a sufficient amount of its kinetic energy,
it interacts with an electron (e− – located in the patients tissue) producing two annihilation
photons (γ). These photons travel in opposite directions, each with an energy of 511 keV.
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Detectors placed approximately 180 ◦ from each other (figure 1.7) will only register a valid
event if both photons are detected coincidently [24].
Figure 1.7: Schematic representation of a PET scanner.
The spatial resolution of this radionuclide imaging technique is dependent on instrumental
factors and the distance travelled by the emitted positron before a sufficient amount of
energy has been lost allowing annihilation to occur, known as the positron range (figure 1.8).
Although this distance varies slightly between different radioactive isotopes, the maximum
possible resolution is ∼4-5 mm, with ∼1.2 mm achieved in small animal imaging [1, 25,
26].
Figure 1.8: Dependence of PET resolution on the positron range (represented by x).
Basic principles behind single photon emission computed tomography
SPECT works on the same basis as PET in that a radioisotope is injected into the patient
initially and imaging is through the detection of gamma rays. The difference with this
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technique is the radiotracer injected decays emitting gamma radiation. As can be seen in
figure 1.9, it is these photons that are recorded by the detectors which rotate around the
patient (in contrast to the ring of detectors used in PET scanning) [27].
Figure 1.9: Schematic representation of a SPECT scanner.
Comparison of positron emission tomography and single photon emission computed tomog-
raphy
In comparison with nuclides required for PET, most SPECT isotopes have longer half-lives
allowing for in vivo biological processes which occur over several hours or days, for example
cell division or endogenous processes, to be observed [28]. In addition, SPECT tracers can
be produced at a more economical cost and it should be noted that the radiation-absorbed
dose per decay event is generally lower for gamma emitters than for positron emitters [29].
However, the collimators used in clinical SPECT imaging significantly reduce the number
of emitted photons reaching the detector [27]. This reduces the intensity of the signal by
approximately two to three orders of magnitude, and as a result the spatial resolution of
8-15 mm is lower than that of PET [1, 26, 30]. Furthermore, this loss of signal increases
the time needed per scan due to a lower signal-to-noise ratio, therefore implying PET is
the most effective technique. The shorter scans required for PET also allow for multiple
fields of view to be examined in a feasible length of time. This is particularly important
in fields such as clinical oncology [30]. In addition, when compared to the most commonly
used clinical SPECT isotope, technetium-99m (99mTc), PET has a larger tissue penetration
depth and improved quantification due to the higher energy gamma rays emitted (511 keV
in comparison to 140 keV for 99mTc) [24,29].
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Advantages and disadvantages of positron emission tomography/single photon emission com-
puted tomography
PET and SPECT imaging techniques are used to obtain metabolic and molecular informa-
tion. This is advantageous over anatomical imaging techniques, such as MRI, for the reason
that disease is a biomolecular process. This means it can be studied throughout its evo-
lution allowing for diagnosis, as well as development and monitoring of therapies [31]. For
example, using PET/SPECT imaging in cancer allows for the early identification of disease
in all organs, and to distinguish between malignant and benign lesions. Compared to tech-
niques such as CT and MRI, PET/SPECT has an 8-43 % higher diagnostic accuracy, and
changes treatment in 20-40 % of cases [32–42]. For instance, it has been reported that when
staging non-small cell lung cancer (NSCLC), PET has an accuracy of ∼83 % compared to
∼64 % for CT [43, 44]. In addition, Changlai et al. detailed a study whereby the staging
of patients with NSCLC were re-evaluated using PET rather than conventional techniques,
revealing a total of 37 % of cases being reclassified from resectable to unresectable or vice
versa [45].
Another main advantage is the higher signal intensity per mole of PET/SPECT imaging
agents when compared to agents used in MRI. Thus, for a typical PET or SPECT procedure
only nano- to micrograms are injected into the patient, whereas for MRI gram quantities
are needed. As a consequence, in general, there are fewer toxicity issues associated with the
use of radiopharmaceuticals.
Again, there are disadvantages associated with this procedure. First is the potential harmful
effects of handling radioactivity, although this is manageable and closely monitored by med-
ical physics/radiation protection teams. In addition, large amounts of radioactivity may be
required during synthesis to accommodate for radioactive decay as well as the possible low
radiolabelling yields. Furthermore, synthesis of suitable imaging agents is highly specialised
due to the need for facilities suitably equipped for radiolabelling procedures [46]. Further-
more, as was mentioned previously, the spatial and temporal resolution of these techniques
is lower in comparison with MR imaging.
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1.2.5 Optical
Optical imaging is a rapidly emerging modality in disease and therapy due to the ability
to investigate both structural and functional changes with a high spatial resolution [47].
There are two main optical imaging techniques implemented in in vivo applications, biolu-
minescence imaging and fluorescence imaging [48]. The principles behind each approach are
briefly described below.
Basic principles behind bioluminescence imaging
This imaging technique (figure 1.10) depends on the enzymatic generation of visible light
by living organisms, and for animal tumour model purposes this is primarily based on the
luciferase system derived from the North American firefly Photinus pyralis [49]. The oxida-
tion of luciferin (a small-molecule substrate responsible for bioluminescence, in this case it is
firefly luciferin) by luciferase (the enzyme catalysing the oxidation reaction) in the presence
of adenosine triphosphate (ATP, a nucleoside triphosphate responsible for transportation of
chemical energy within cells for metabolism) and molecular oxygen forms an electronically
excited oxy-luciferin species [50], which then emits light in the region of 530 nm following
relaxation to its ground state [51,52]. In order for luciferase to be expressed, cells can be be
transfected or transduced in vitro prior to in vivo implantation, alternatively, bioluminescent
transgenic tumour models may be generated via introduction of reporter gene expression
through the germline [50].
Basic principles behind fluorescence imaging
Fluorescence imaging is illustrated in figure 1.11 and is based on the simultaneous absorption
and re-emission of light by a substance [53]. A fluorescent imaging probe is exogenously
administered into the subject, excited at a specific wavelength and the consequent red-
shifted light is detected by an optical device [54].
Advantages and disadvantages of optical imaging
One main advantage of optical imaging is the high sensitivity of the contrast molecules used,
the lower limits of detection may require as little as femtomolar concentrations of an optical
reporter [55]. However, there is a major shortcoming with this imaging technique. Tissue
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Figure 1.10: Schematic representation of bioluminescence imaging involving the production
of light photons from the oxidation of the substrate luciferin in the presence of luciferase
expressed by engineered cells, ATP and oxygen.
Figure 1.11: Schematic representation of fluorescence imaging involving the production of
light photons by excitation of a fluorescent imaging probe at a particular wavelength.
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autofluorescence coupled with the attenuation and scattering of light in the visible region by
haemoglobin, lipids and other molecules significantly reduces optical signals, in some cases by
as much as 10-fold per centimetre of tissue [56–58]. An approach to overcome this problem
is the use of near-infrared (NIR) imaging agents which emit below a wavelength of 900
nm, in order to minimise absorption of light by water molecules, with the optimal emission
wavelength being at approximately 800 nm [59–61]. In this region of the spectrum, the
aforementioned processes are reduced resulting in a considerable improvement in the signal-
to-background ratio a point comparable to or exceeding that of other molecular techniques
[48]. This increase in sensitivity opens up the possibility of detecting tomographic optical
signals at significantly lower depths than currently possible [62]. A second disadvantage is
related to quantification of the detected signal. As the differential absorption of light skews
imaging toward the contrast probes accumulated near the surface of the subject, it is only
currently possible to obtain relative quantification rather than absolute as with radionuclide
imaging, although developments in 3D imaging and analysis techniques such as fluorescence
molecular tomography (FMT) are improving this limitation [63]. Finally, optical imaging
techniques are non-ionising, non-invasive, allow for near real-time acquisition of results as
well as utilising portable and economical equipment [47].
1.2.6 Combining imaging modalities
The development of instruments capable of imaging more than one modality is beneficial
in gaining both anatomical and physiological information simultaneously about a region of
interest. Not only does this reduce the overall scanning time, but it also allows for the more
accurate superimposition of images due to the lack of temporal changes and other factors
such as the involuntary movement of internal organs [64].
Positron emission tomography/single photon emission computed tomography-computed to-
mography
PET/SPECT-CT instruments have become conventional in the clinical environment. CT
gives anatomical information whilst metabolic information is gained from PET/SPECT.
Although software fusion of these two modalities is possible, there are several advantages to
fusion of hardware. Inaccuracy in the information obtained due to change in the patients
position (usually occurring during the moving from one instrument to the other) is reduced
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[65], registration accuracy is improved with no further alignment required, and transmission
scans are unnecessary due the relevant data needed for attenuation correction being available
from the CT acquisition [66,67].
Significant improvements in the clinical information gained for oncology patients from PET-
CT scanners have been reported from various studies, leading to enhanced diagnosis and
staging of cancer [68–70]. Furthermore, response to therapy can be monitored shortly after
treatment has begun, allowing for ineffective therapeutics to be identified early [71].
An example illustrating how PET-CT is an improvement upon the comparison between
separate PET and CT scans, and how this has contributed to the care of oncology patients,
is shown in figure 1.12. In this case, the patient had a history of colon cancer and an initial
PET scan (figure 1.12a) revealed the presence of recurrent lesions in the right abdomen.
However, two difficulties arise from using this single scanning mode: (i) they would be
assumed to be either serosal or nodal, with the possibility of resection, and (ii) identifying
their exact locations would be challenging. Fusing PET with CT (figure 1.12c) clearly
locates the lesions to the right psoas and iliacus muscles and classifies them as unresectable,
therefore altering the patients treatment [72].
Figure 1.12: PET-CT images of a patient being restaged for colon cancer. (a) PET image
shows 18F-FDG uptake consistent with recurrence (dashed circle) but localisation of cancer-
ous tumour is not possible, (b) CT and (c) fusion images indicate intraabdominal cancerous
region (arrow), as well as psoas and iliacus muscle lesions (arrowheads). Lesser activity
elsewhere is physiologic bowel uptake [72].
Although the combination of PET with CT offers advantages over using the techniques indi-
vidually, there are some associated disadvantages. The first being the increase in radiation
dose received by the patient, which can be 5 to 10 times greater than the average annual ex-
posure from naturally occurring radiation sources (∼25 mSv for a 18F-fluorodeoxyglucose,
18F-FDG, PET-CT [73]). This is accommodated for by using lower energy settings for
the CT scan, resulting in poorer quality images. In addition, PET-CT may not be suit-
able for some procedures such as those using iodinated contrast agents, which may cause
artefacts when reconstructing the PET images due to absorbance of the lower energy X-
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rays [72].
Positron emission tomography/single photon emission computed tomography-magnetic reso-
nance imaging
The combination of PET/SPECT with MRI will give both highly sensitive quantifiable
metabolic information and high resolution anatomical information in any orientation leading
to enhanced diagnostic precision, particularly in identifying cancerous cells. Regions of
interest can be established using PET/SPECT, which can then be examined in closer detail
using the high resolution of MRI. This then reduces (i) the amount of tissue to be scanned,
and (ii) the time it takes to run when compared to sequential scans [74,75]. There are several
reasons why using MRI rather than CT to obtain structural information in a bimodal system
is beneficial. MRI is viewed as the initial imaging procedure for diagnosis in oncological
examinations regarding tumours in the brain or neck region due to the clear differentiation
between closely neighbouring anatomical structures such lymph nodes, mucosa and blood
vessels [76,77]. In addition, MR can provide some functional information, such as perfusion
and spectroscopy used in the management of stroke patients, however the sensitivity of this
technique is lower than for PET/SPECT (∼10−5 mol/L for MRI vs. ∼10−12 mol/L for
PET/SPECT) making the radionuclide component essential. The combination of functional
information from two modalities can provide complimentary data which can aid diagnosis of
disease and hence treatment [78]. Secondly, with PET/SPECT-MRI there is the possibility
to acquire both image datasets simultaneously. This opens up the possibility of performing
motion correction of the PET image reducing artefacts which results in better resolution
and activity quantification [79, 80]. On top of this, when compared to current bimodal
systems such as PET-CT, the patient will acquire a lower dose of radiation [81]. Finally,
it has been reported that in a magnetic field, the distance travelled by a positron before
annihilation with an electron is reduced, leading to an improvement in the resolution PET
images acquired with PET-MRI scanners. This loss of resolution is proportional to the
strength of the magnetic field, for instance, when comparing 0 T and 4 T there is narrowing
of the positron range full width at half maximum (FWHM) by a factor of 1.22 [82].
An example demonstrating the limitations of PET-CT in comparison to PET-MRI is illus-
trated in figure 1.13 which shows the scans of a patient with a peripheral sarcoma. The
degree of invasion into adjacent muscles can be more accurately determined on PET-MRI
(figure 1.13b) than on PET-CT (figure 1.13d). However, the functional information gained
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by using the PET component is of limited use in this case [83]. A second case where the PET
and MRI combination provided essential information is shown in figure 1.14. These images
are of a patient with brain gliomatosis admitted for a tumour biopsy. The contrast-enhanced
T 1-weighted MRI in figure 1.14a revealed no enhancement of the tumour was indicated, sug-
gesting a low-grade carcinoma. However, carbon-11-methionine (11C-MET) PET imaging
and chemical shift imaging (CSI) mapping of choline/N -acetylaspartate (Cho/NAA) dis-
played hot spots in the basal frontal lobe on the left side and in the right insular region
respectively. As a result, biopsies were performed in both locations revealing anaplastic
glioma in the left frontal region and low-grade glioma in the right insular region [84].
Figure 1.13: PET-CT and PET-MRI comparison for imaging of peripheral osseous sarcoma.
(a) MRI, and (b) PET-MRI (retrospectively fused image) allows for clear assessment of
the tumour within the bone and adjacent muscles when compared with (c) CT, and (d)
PET-CT [83].
Again, as with any imaging technique and modality combination, there are some drawbacks.
As discussed previously, the examination times associated with MRI are significantly longer
(ranging from 20 min to 60 min for a whole-body scan) which varies between imaging
protocols depending on the number and type of sequences used [83]. Another challenge
facing PET-MRI are the higher running costs causing problems in procuring approval for
new imaging tests with regulatory agencies [85]. Additionally, on account of MRI contrast
being dependent on water content of tissues, it is not suitable for imaging of bone and the
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Figure 1.14: Standard contrast-enhanced T 1-weighted MRI (left) of brain gliomatosis in-
dicated a low-grade tumour due to no contrast enhancement, chemical shift imaging (CSI)
(echo time = 135 ms, centre) of choline/N-acetylaspartate (Cho/NAA) quotient revealed a
hot spot in the right insular region, and PET-MRI with 11C-methionine (right) displayed
uptake in the basal frontal lobe on left side. Due to this discrepancy, biopsy was performed in
locations suggested by CSI and PET-MRI revealing anaplastic glioma (World Health Organ-
isation grade III) in the frontal left region and low-grade glioma (World Health Organisation
grade II) in the right insular region [84].
lungs where CT is still the favoured technique [79]. Finally, despite the fact that research
into PET-MRI commenced at the same time as PET-CT, due to the challenging engineering
as well as the economical issues, the development of instruments capable of both PET and
MRI has been delayed [75]. There are two main difficulties to overcome when designing a
PET-MRI system. First, the magnetic-sensitive photomultiplier technology used to detect
gamma photons in the PET/SPECT set-up needs to be replaced by compact, solid state
silicon photo sensors - avalanche photodiodes - that are not susceptible to magnetic fields
and minimise potential interference with MR gradients or radio frequencies [86]. Secondly,
new procedures for PET attenuation correction need to be developed to be based on MRI
data alone [84].
Although there are technological and economical obstacles to overcome in the development
of PET-MRI, there are several preclinical and clinical applications where this combination
of modalities into a single instrument could prove invaluable. Focussing firstly on preclinical
studies, the lower radiation dose of PET-MRI compared to that of PET-CT is important
when imaging small animals due to the lower LD50 value (lethal dose for 50 %) for rodents.
For a typical whole-body mouse CT scan, the dose received is ∼0.6 Gy (equating to ∼5 % of
the LD50) and several studies have shown that a dose as low as 0.075 Gy can induce changes
in expression of some small proteins [87, 88]. With regards to clinical usage, simultaneous
mapping of MRI spectroscopy and functional changes could be of particular use in neurology,
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where it could lead to new insight into brain activation [89], and in pediatric patients.
Musculoskeletal imaging will be an area of particular clinical interest owing to false negative
results occurring in some cases of small metastases when using current PET-CT imaging.
Due to radiotracer uptake of normal bone and CT unable to visualise changes in bone
architecture in early stage tumours, MRI is required as it can be used to image bone marrow
with higher sensitivity and specificity [90–92]. In addition, there is potential for studying
the tumour response to new drugs and as result, treatment strategies may be optimised
[93].
The focus of the above section has been to identify the potential of PET-MRI and to
show how this has already been proved possible in preclinical research. It should be noted
however, that these systems are now becoming a reality in the clinical environment with two
instruments in the UK based at St Thomas’ Hospital and University College Hospital.
Magnetic resonance imaging-optical
The fusing of MRI with optical imaging is advantageous as it allows for the acquisition of
fluorescence based histology and anatomical evaluations simultaneously [94]. An example
of where this has been proven to aid the diagnosis of cancerous cells was demonstrated
by Rodriguez et al. using fluorescently tagged magnetic NPs. T 2-weighted MRI was used
to locate a prostate cancer xenograft alongside fluorescence microscopy to create histology
sections, which clearly showed particles embedded in the tumour tissue, confirming the
diagnosis of the cancerous nature of the cells (figure 1.15) [95]. In addition, it could be
possible to use the external magnetic field to physically manipulate the location of the
fluorescent particles [96].
Figure 1.15: (a) T 2-weighted imaging of mouse prostate xenograft; (b) Frozen tumour
section imaged by confocal microscopy [95].
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Positron emission tomography/single photon emission computed tomography-optical
Simultaneous radionuclide and optical imaging has the potential to provide complementary
information as well as for the tight correlation between both sets of contrast data [97]. For
example, during a drug delivery study fluorescence optical tomography (FOT) can be used
to monitor tumour response to therapy, with PET quantifying the distribution of the drug
throughout the subject [98]. Current research has demonstrated the feasibility of the combi-
nation PET/SPECT and optical systems, indicating the potential for this bimodal technique
to become a dynamic tool for a multitude of real-time imaging applications [99].
1.3 Imaging agents
1.3.1 General introduction to use of contrast agents
Imaging agents are used as a means to increase the signal of an imaging technique at an area
of interest. This is achieved by the accumulation of the probe at a desired region, sometimes
followed by the interaction of the agent with the target, improving the contrast of the
image [100]. Although many groups have researched the hardware aspect of multimodal
imaging in order to exploit this technique, imaging agents capable of being used for two
techniques simultaneously are also of interest.
When developing a contrast medium there are several initial stages to consider which include
identifying a suitable diagnostic opportunity and how the agent will be used in order to
determine the performance metrics required. In addition, once these factors have been
established chemical synthesis optimisation is necessary followed by preclinical and clinical
studies [101]. Figure 1.16 gives a more detailed summary of the development process [101].
Additional requirements that need to be addressed include the biocompatibility of the probe,
excretion time and route, solubility and stability in aqueous conditions, and the osmotic
potential when in solution [102,103]. Moreover, the costs of bringing an imaging agent from
the laboratory to the commercial market is substantial, it’s estimated to be in the range of
$100 million to $200 million [104].
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Figure 1.16: Discovery and development of diagnostic imaging agents [101].
The following section will outline current agents available for individual modality imag-
ing that have overcome the above mentioned development and economic issues, as well as
the mechanisms behind how they enhance contrast. Furthermore, the current preclinical
outcomes of combining several modalities into one probe will be described.
1.3.2 Magnetic resonance imaging
Relaxation theory of magnetic resonance imaging agents
MRI contrast agents have the ability to change relaxation times, the amount by which is
characterised by the relaxivity values, r1 (s
−1mM−1; the capacity to adjust the longitudinal
relaxation time) and r2 (s
−1mM−1; the capacity to adjust the transverse relaxation time).
As a particular material will affect both T 1 and T 2, it is the ratio of r2 to r1 which determines
whether an agent can be used as a T 1 agent or a T 2 agent. T 1 contrast agents (positive
contrast agents) brighten areas of uptake whereas T 2 (negative contrast agents) darken
these areas [16], an example of which is shown in figure 1.17 [105]. Contrast agents for MR
imaging are based on paramagnetic metals such as gadolinium and iron.
The three main contributions to the relaxation effects of MR imaging agents are inner
sphere (IS) relaxation, outer sphere (OS) relaxation, and diamagnetic relaxation, as shown in
equation 1.2. The latter being the relaxation of the solvent in the absence of a paramagnetic
species.
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Figure 1.17: MR imaging showing T 1 (left) and T 2 (right) sagittal complete spine stitch








where R1,2 = measured relaxation
RIS1,2 = inner sphere relaxation
ROS1,2 = outer sphere relaxation
R01,2 = diamagnetic relaxation
Inner sphere relaxation is described by the Soloman-Bloembergen-Morgan theory, equations
1.3 and 1.4 [106–108], and arises from the exchange between water molecules coordinated





T1m = f(τM, τR, Tie, r) (1.4)
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where q = number of water molecules coordinated to the metal ion
T 1M = longitudinal relaxation time of coordinated water molecules
τM = mean residence lifetime of coordinated water molecules
τR = rotational correlation time of the complex
T ie (i = 1, 2) = longitudinal and transverse electron spin relaxation times
r = distance between the metal ion and the protons of the coordinated water molecules
Outer sphere relaxation is outlined by the Freed theory [110,111] and is induced by the dif-
fusion of water molecules within the magnetic field gradients surrounding the paramagnetic
hydrated ion [109]. The dominant parameters influencing the OS relaxation are the mini-
mum distance of approach between non-bound water molecules and the metal ion, and the





where τD = diffusional correlation time
a = distance of closest approach of water molecules
D = relative diffusion coefficient of solute and solvent
Both inner sphere and outer sphere relaxation are dependent on the concentration of the
paramagnetic species [112]. In most cases, the IS contribution tends to be larger because
(1) the distance between the metal based complex and a coordinated water molecule is on
average smaller than that between the hydrated ion and a diffusing water molecule, (2) the
diffusion time is often shorter than the residence time on the binding site [109]. However, in
the absence of water exchange, for instance with nanoparticle based agents, the OS process
controls relaxation [113].
Figure 1.18 gives a summary of the principle physical properties mentioned above that affect
the relaxivity of imaging probes and should be considered when designing an MRI contrast
agent.
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Figure 1.18: Schematic representation of the principle parameters contributing to the relax-
ation effects of MR imaging probes.
Currently available agents
There are several agents commercially available for imaging, both consisting of iron oxide
(Fe3O4) nanoparticles and gadolinium-based agents. The lanthanide ion Gd(III) is generally
the ion of choice for T 1 MR imaging probes because it has a high magnetic moment (µ
2
= 63 µ2B) [22], whereas iron oxide is routinely used for T 2-weighted imaging. One example
of a gadolinium based agent is Magnevist (Bayer Schering Pharma AG, Germany), figure
1.19. This is a paramagnetic ion based agent containing the N-methylglucamine salt of the
gadolinium complex of diethylenetriamine pentaacetic acid [114]. It is used primarily to
image lesions with abnormal vascularity in the brain and the rest of the body [115]. At a
field strength of 3.0 T (in aqueous solution) it is found to have a r1 of 3.29 s
−1mM−1, a r2
of 4.8 s−1mM−1 and hence a r2/r1 of 1.46, therefore allowing this probe to be used in T 1
weighted imaging [116].
Figure 1.19: General structure of Magnevist.
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An example of a clinically available oral iron oxide nanoparticle is Lumirem (Guerbet,
France), which is used primarily for T 2-weighted imaging of the gastrointestinal (GI) tract
[117]. This imaging agent consists of superparamagnetic iron oxide crystals with a core size
of approximately 10 nm, which are siloxane-coated increasing the overall diameter to ca.
300 nm [118, 119]. The relaxivities have been found to be r1 of 3.2 s
−1mM−1 and r2 of 72
s−1mM−1 (at 0.47 T in aqueous solution), yielding an overall r2/r1 of 22.5 [120,121].
1.3.3 Positron emission tomography and single photon emission
computed tomography
Compared to agents for MR imaging, there are several more available for PET/SPECT. A
clinically used PET imaging agent is 18F-FDG used for the imaging of tumours as demon-
strated in figure 1.20a. As cancerous cells have an increased consumption of glucose and
because 18F-FDG cannot be metabolised by cells, the activity in these areas will be larger
and therefore the signal intensity will be higher [122]. Due to the short half-life of the
radioisotope (110 min), this agent is usually prepared on-site. A commonly used class of
SPECT radiopharmaceuticals are 99mTc-labelled phosphonates, which bind well to metabol-
ically active bone. As a consequence, 99mTc conjugated to phosphonates, such as methylene
diphosphonate (MDP), is routinely used in the SPECT imaging of bone metastases, as
illustrated in figure 1.20b [20,123].
1.3.4 Optical
A frequent dye used in fluorescence imaging applications is Cy5.5, the structure of which
is illustrated in figure 1.21 [126]. The excitation and emission maxima of this dye are 675
nm and 695 nm respectively, and hence the dye will perform optimally in the red region
of the spectrum [60]. It has previously been shown that this molecule can be conjugated
to antibodies in order to demonstrate the use of fluorescence imaging to detect cancerous
tumours in animal models [127]. However, due to a reduction in performance in the NIR, it
is best to use this dye in applications requiring a lower sensitivity [60].
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(a) (b)
Figure 1.20: (a) 18F-FDG PET image showing a transaxial slice of the brain, the red circled
region shows the location of a tumour [124]; (b) 99mTc-labelled MDP multiple-field-of-view
SPECT image showing multiple bone metastases [125].
Figure 1.21: General structure of a Cy5.5 N -Hydroxysuccinimide (NHS) ester [126].
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1.3.5 Why focus on nanoparticles
This work will focus on using NPs as a platform for the development of bimodal imaging
probes, and the following section will detail the reasons behind this. First, it should be noted
that nanomaterials have recently been defined as ‘a natural, incidental or manufactured
material containing particles, in an unbound state or as an aggregate or as an agglomerate
and where, for 50 % or more of the particles in the number size distribution, one or more
external dimensions is in the size range 1 nm to 100 nm’ by the European Commission [128].
Interest in the field of nanomedicine has grown exponentially in the past few years, increasing
from ten articles per year in the latter half of the 1980’s to over 1,200 in 2004, figure 1.22.
As can be seen from figure 1.23, the majority of these publications focus on drug delivery
aspects (76 %) with only 4 % concentrating on imaging applications. This figure is further
implemented when examining the commercial efforts represented in table 1.1 [129].
Figure 1.22: Nanomedicine publications and patents worldwide. Sources: Science Cita-
tion Index, VDI Technologiezentrum GmbH, Du¨sseldorf, Germany and EPODOC patent
database, European Patent Office, Rijswijk, The Netherlands [129].
Figure 1.23: Sectorial breakdown of nano medicine publications. Source: Science Citation
Index, 1984-2004, VDI Technologiezentrum GmbH, Du¨sseldorf, Germany [129].
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Table 1.1: Commercial efforts in nanomedicinea. Source: VDI Technologiezentrum GmbH,
Du¨sseldorf, Germany. aSales numbers of nanomedicines are estimates for the year 2004.
bDrugs where the product is in clinical phase 2/3 or 3 and for all other products where
market introduction is expected within two years [129].
The use of NPs as a basis for contrast agent design is preferable to other types of imaging
agents, such as small molecules or engineered protein/peptides, due to the ability to adjust
their properties by controlling characteristics such as size, structure and surface properties
which can influence their in in vivo function and biodistribution [130]. Moreover, the large
surface area to volume ratio (modified by altering the size of the particles) is advantageous as
it allows for optimisation of the functionalisation of the NPs, which is particularly important
in imaging applications involving drug delivery. Additionally, the complexities arising due
to conformation/unfolding of molecules or proteins are eliminated due to the solid surface of
the NPs, improving the degree of control over the design of the imaging probe [131]. Incor-
poration of various materials can produce NPs with several different features, for example
magnetic and luminescence properties [132–138]. Functionalisation of the NP surface allows
for the inclusion of addition modalities or of targeting to a specific region providing maxi-
mum enhancement of a particular area, whilst not significantly altering the properties of the
NP [139,140]. For instance, Kyle et al. describe the potential use of ligand-directed perfluo-
rocarbon (PFC) NPs in monitoring the therapeutic response of patients with cardiovascular
diseases such as stroke [141], whereas Kiessling et al. detailed the benefits offered by NPs
over molecular agents in the labelling of implants and grafts to review function over time
and depict potential failure [142]. Another example examines the use of Au NPs as pho-
todynamic therapy (PDT) drug delivery vectors for aqueous insoluble molecules providing
promise for future applications utilising drugs currently unavailable due to hydrophobicity
issues [131]. This feature of functionalisation is not easy with currently available contrast
agents, for example Gd3+ chelates. Other issues facing these molecular complex agents
include quick removal by the renal system and short accumulation times.
There are drawbacks to the use of NPs with the main disadvantage being that they are
quickly recognised and sequestered by circulating macrophages and Kupffer cells of the RES
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present in the liver and spleen. The process by which this occurs is known as opsonisation,
whereby xenobiotic materials are tagged with opsonin proteins to initiate association with
circulating/stationary macrophages as illustrated in figure 1.24 [143].
Figure 1.24: Schematic representation of (a) an opsonin tagged iron oxide NP, and (b)
association of opsonin tagged iron oxide NPs with a macrophage.
This uptake depends on several factors including size [144], geometry [145–147], overall
charge, and functional groups conjugated to the surface [148,149]. Secondly, they are prone
to forming aggregates with large diameters that can be irreversibly trapped in the capillaries
of the lungs [150]. These two effects represent a potential toxicity threat for the patient and
also results in short circulation times and failure to reach the intended target. In addition,
the NPs need to be non-toxic or be excreted as fast as possible after the procedure. During
the past decade, a number of toxicity reports have highlighted some risks to biological sys-
tems exposed to nanomaterials, and more research is needed in order to fully understand the
processes taking place [151,152]. However, toxicity is a problem faced by all pharmaceuticals,
whether it be a small molecule, a genetically engineered protein or a nanoparticle.
1.3.6 Ultrasmall superparamagnetic iron oxide nanoparticles
The most successful NP platform for in vivo imaging to date is based on iron oxide materials,
in particular superparamagnetic iron oxide nanoparticles (SPIOs). SPIOs are classified by
a hydrodynamic diameter larger than ∼60 nm, with some having overall sizes of up to 150
nm [119]. Most iron oxide nanomaterials are quickly recognised by the macrophages of
the RES, making them useful for imaging of the spleen and liver. However, for alternative
imaging applications it is desirable to extend their circulation time by minimising this RES
uptake. A well-established strategy for doing this is to use ultrasmall SPIOs (USPIOs),
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which are SPIOs with a hydrodynamic diameter of less than 40 nm [113].
Structure
The iron oxide focused on here is magnetite, Fe3O4, a ferrimagnetic material which has an
inverse spinel crystal structure with the unit cell (a = 0.839 nm) comprising of 32 oxygen
atoms in a face-centred cubic (fcc) arrangement as illustrated in figure 1.25a [153]. The
octahedral sites are occupied alternately by Fe2+ and Fe3+ ions, with only Fe3+ ions lo-
cated in the tetrahedral sites [113, 154]. Due to superexchange oxygen-mediated coupling,
the magnetic moments of the iron ions occupying the tetrahedral and octahedral sites are
aligned in opposite directions [155] (figure 1.25b), meaning the Fe3+ ions compensate for
each other and the magnetic properties of magnetite arise due to uncompensated octahedral
Fe2+ [113].
Magnetic properties
Iron oxide crystals consist of multiple regions, within which the magnetic dipoles interact
and align together, known as Weiss domains. Ordered bulk magnetite will exhibit a zero
magnetic moment when no external magnetic field is applied due to the negating effect of
the magnetically random orientation of the Weiss domains [156]. This is indicated by point
1 of the top hysteresis curve in figure 1.26. Once an external magnetic field ~H is applied,
the Weiss domains begin to align with the field increasing the net magnetisation moment
until a saturation point, M S (defined as the maximum magnetisation in a sufficiently large
magnetic field [162]), is reached when all dipoles are oriented in the same direction as the
applied field (as illustrated by point 2 of the top diagram in figure 1.26) [156]. When the
external field is then removed, the Weiss domains will attempt to return to their original
randomly orientated states. However, a frictional force arising between the domains will
be encountered preventing this, and as a result, the material will retain a remanent field,
M r, corresponding to point 3 on the top hysteresis curve in figure 1.26. Point 4 gives the





Figure 1.25: Schematic diagram for (a) a unit cell of magnetite (Fe3O4) [153], and (b)
ferrimagnetic organisation in magnetite (illustration of [1,1,1] plane) [113]. Blue circles
= Fe3+ (tetrahedral coordination), black/white striped circles = Fe2+/Fe3+ (octahedral
coordination), and yellow circles = oxygen.
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Figure 1.26: Schematic representation of size dependency of magnetic properties of iron
oxide crystals on size. A larger crystal (top diagram) will contain multiple Weiss domains,
the number of which decreases with crystal size, in turn increasing the M S [156].
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As the size of an iron oxide nanocrystal decreases, so does the number of Weiss domain
boundaries (shown by the second diagram in figure 1.26). This decreases the measure of
resistance to the recovery of the original random orientation, therefore decreasing M r and
HC. When the size of the nanocrystal is below the size of a single Weiss domain (∼10-50 nm),
all magnetic dipoles within the crystal will be parallel, and hence there will be no remanent
magnetic field or coercive field (third hysteresis curve in figure 1.26) [156]. It should be
noted that although at ~H = 0 all magnetic dipoles are aligned in parallel resulting in a non-
zero magnetic moment, the energy required to alter the dipole orientation is lower than the
thermal energy absorbed from the environment. As a consequence, the orientation oscillates
rapidly (known as Ne´el relaxation [157]), leading to an average zero-sum magnetic state.
When an external field is applied, this oscillation remains present but points preferentially
in the direction of the applied field. This is termed superparamagnetism, and results in
materials with large saturation magnetisations [156].
There are several parameters affecting superparamagnetism, these including particle size.
As the size of the particle decreases, the surface to volume ratio increases, and hence the
number of the total atoms in the NP becoming surface atoms increases, which in turn
means the influence of surface and interface effects becomes greater [158]. For example, in
the case of ionic compounds, the orientation of the magnetic moment per surface atom can
become altered which may result in a reduced average net moment in comparison to the
bulk material [159–161]. In addition, shape anisotropy, composition and assembly can be
used to tailor the magnetic properties of UPSIOs [130]. Furthermore, surface modification
has an effect on the saturation magnetisation. It has been reported that steric stabilisation
reduces the M S of SPIOs which is most probably due to the interaction between anchors and
surface bound iron ions [163,164]. Amstad et al. have recently shown through EPR studies
that these strong coordinations lead to magnetically decoupled Fe3+ ions at the nanoparticle
surface [163].
Preparation
There are several methods of USPIO fabrication. The first main synthesis procedure is via
coprecipitation whereby magnetite is either precipitated from a basic aqueous solution of
ferric and ferrous salts [165], or ferrous hydroxide suspensions are partially oxidised using
oxidising agents [166]. An early example implementing this method was performed by Sug-
imoto et al. using iron(II) sulfate (FeSO4) and potassium hydroxide (KOH) in the presence
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of nitrate ions (this being the oxidant) [167]. Despite the ease of this type of synthesis and
the ability to produce large quantities of NPs, the resulting particles lack consistency in size
and morphology, and there has been limited success in controlling parameters such as pH
and reactant concentrations to tailor these properties [168].
A second synthetic route is thermal decomposition of iron containing compounds such as iron
carboxylate salts and iron(III) chloride hexahydrate (FeCl3 ·6 H2O) at high temperatures in
the presence of surfactants, which has been shown to produce monodispersed particles with
high crystallinity [169–171]. Although this method is favourable due to control of size and
NP morphology, as well as the yield being high and scalable, there is major drawback in
that the subsequent particles are only dispersible in organic solvents, and additional surface
modification is required to allow for solubility in an aqueous phase [169,172].
A third technique is the use of a microemulsion, an isotropic and thermodynamically stable
dispersion of two immiscible liquids [173], whereby it is possible to control the average size
and composition of the resulting particles to a certain degree due to the ability to measure
the exact amount of the metal containing compound in each droplet, as demonstrated by
Okoli et al. [174,175].
Finally, the sol-gel method, roughly defined as the formation of an inorganic solid from a
precursor solution by chemical means including hydroylsis and polycondensation [176,177],
can be used to synthesis spherical magnetite particles with a narrow size distribution [178].
This process generates homogeneous NPs with a high purity, however cannot be applied to
large-scale and economic production, because they require expensive and often toxic reagents
and complicated synthetic steps [179].
Advantages over Gd as an MR imaging probe
Although a major problem with many particles is toxicity, Fe3O4 NPs have the added
benefit of dissolving to form Fe3+ ions, which join the body’s natural iron storage (for an
adult human this is in the range of 3-5 g of iron) [75,180]. This increase in iron is negligible
meaning the NPs are biocompatible [119,181–183] as has been shown by cytotoxicity studies
resulting in cell viability remaining above 91 % after incubation with USPIOs [184–186].
Iron oxide NPs received Food and Drug Administration (FDA) approval and have been used
clinically for many years, for example in the treatment of anaemia, hence it is well known that
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there are no associated harmful effects. When considering the hurdles of getting a material
approved for biomedical use, this is a major advantage. NPs containing Gd complexes have
been studied but the synthesis involved is elaborate and the outcome tends to be an agent
with a less dramatic enhancement effect. In addition, dissociation of Gd(III) can cause toxic
effects due to irreversible association with Ca(II) binding sites, more often with a higher
affinity owing to its greater charge/radius ratio, and as a result Ca(II) mediated signalling
becomes disrupted [16, 112, 187]. As an example, Gd2O3 NPs have been synthesised with
relaxivities necessary for T 1-weighted images but on account of toxicity, the concentrations
needed are too high for use in vivo [130,188,189], particularly in patients with pre-existing
kidney conditions because of the significant increase in the risk of acute kidney injury (AKI)
and nephrogenic systemic fibrosis (NSF) [190, 191]. Furthermore, given the low number of
MRI contrast agents approved to date, particles containing potentially toxic metals such as
Gd, Co or Mn with favourable magnetic properties [192] may find difficulty in obtaining
clinical approval [193].
Each USPIO contains a high number of magnetic ions, this improves MR contrast due to
each vectorised particle exhibiting a large magnetic moment when compared to a single
gadolinium ion, and in turn decreases the bodies burden of agent required for a given effect
[113, 194]. In addition, the efficiency of gadolinium is limited at high magnetic fields due
to its magnetic moment not reaching saturation [113]. SPIOs, however, remain relatively
unaffected by increasing magnetic fields. Furthermore, paramagnetic ion relaxation effects
are highly reliant on the proximity of protons with sufficient exchange rates, whereas USPIOs
disturb the magnetic field independent of environment and hence can be used anywhere
within a supporting matrix [195].
Low toxicity, larger relaxation effects for a single particle in comparison to a single param-
agnetic ion and economical advantages (due to the inexpensive of iron metals [196]) means
incorporation of iron into MR contrast agents is favourable over the gadolinium counter-
part.
Benefits in using ultrasmall superparamagnetic iron oxide nanoparticles in medical applica-
tions
There are several applications which benefit from contrast enhanced by USPIOs compared
to gadolinium agents due to uptake by macrophages (other than those present in the RES)
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combined with higher relaxivities and an intravascular distribution [197]. It has been re-
ported that iron oxide particles hold advantages in vascular imaging, in particular in the
imaging of the portal venous system [198] and deep venous thrombosis (DVT) [199, 200]
owing to the non-specificity of the vascular enhancement resulting in both the arteries and
veins displaying an increase in signal [197]. A second cardiovascular application is in the
evaluation of inflammatory processes. Areas of inflammation are known to be associated
with escalated macrophage activity, and as it is well known that iron oxide particles are read-
ily taken up by macrophages of the RES, uptake by macrophages of other parts of the body
is also conceivable [197]. Couple this to the intravascular nature of USPIOs, monitoring of
cardiac transplant rejection is possible [201].
1.3.7 Quantum dots
Another category of nanoparticle also utilised in imaging applications, specifically optical
imaging, are semiconductor nanocrystals, known as quantum dots. These particles are
made from a variety of materials, such as cadmium selenide and cadmium telluride, and are
used to absorb and emit at particular wavelengths of light which depends on size, shape
and composition [202, 203]. In recent years, these particles have been preferred as bio-
markers for research purposes over conventional organic dyes and proteins for several reasons,
for instance the broad range of tuneable fluorescing properties of QDs covers both the
visible and near-infrared parts of the spectrum [100, 204, 205]. In addition they exhibit
unique features including large absorption coefficients, and multicolour capability under
single source excitation which is possible due to their broad absorption profiles and narrow
emission spectra [100,206–208]. Furthermore, they display enhanced chemical and metabolic
stability, and increased solubility, as well as a higher photobleaching threshold which has
been demonstrated by Maysinger et al. using in vivo imaging techniques over several days
[209–211].
Applications
One of the most successful applications of QDs in biology is in immunofluorescence labelling
of cells and tissues, fundamental work of which was performed by Alivisatos et al. [212]
and Chan and Nie [213], and this success is primarily due to the small number of particles
needed to produce a signal [214, 215]. An example of this is in the diagnosis and staging of
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cancerous tumours, where multiplexed molecular profiling is required due to the need for a
panel of biomarkers to accurately classify the progression of the disease [216]. Secondly, it
has been shown that QDs can be used to label and track membrane proteins on living cells,
allowing for further understanding of cellular dynamics [204].
1.4 Nanoparticle coatings
1.4.1 General introduction to importance of correct coating
Nanoparticles are coated in order to improve several properties, including biocompatibil-
ity, and to modulate interactions both between the particles and with other biological
molecules [188, 217]. Dispersant molecules are divided into two components: the anchor
and the spacer. Ideally, anchors need to have a high binding affinity and low desorption rate
in order to irreversibly conjugate the spacer to the NP surface. In addition, it is necessary for
the chosen coating molecule to have the ability to replace the hydrophobic surfactants nor-
mally used during synthesis [217]. Furthermore, it is essential that spacers provide sufficient
steric stabilisation to prevent aggregation of particles in an aqueous phase by overcoming
attractive van der Waals and magnetic potentials (as shown in figure 1.27a), as well as al-
lowing for further functionalisation [100, 217]. It is also preferable that the chosen surface
ligand provides in vivo stability and an extended blood circulation time by reducing the
opsonisation process (the mechanism by which is illustrated in figure 1.27b) to allow for use
in biomedical applications [218]. The most successful strategy to minimise aggregation and
RES uptake, is to coat the NP surface with hydrophilic polymers, and below details some
of the most commonly used coatings.
1.4.2 Anchors
Carboxylic acids
Carboxylic acids have been used as surfactants for decades, with oleic acid coated magnetite
NPs being reported as far back as 1973 [219]. Binding to the NP surface occurs via the hy-
droxyl group, however it has been shown that in some cases involving oleic acid coordination
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(a) (b)
Figure 1.27: Schematic representation illustrating the mechanism behind hydrophilic poly-
mers reducing (a) aggregation of particles, and (b) the opsonisation process.
can take place through the double bond in the alkyl chain [220]. These molecules have been
shown to be effective stabilisers for both magnetic and luminescent materials, and for oleic
acid, its solubility in both polar and non-polar solvents makes it highly versatile [221]. How-
ever, due to their poor stability, coatings utilising this anchor are only useful as temporary
coatings rather than for long-term applications.
Catechols
Catechols (figure 1.28) have recently been investigated as anchor groups in the stabilisation
of Fe3O4 NPs. These molecules are well known to bind very strongly to iron oxides and
other materials. In fact, catechols are the active groups in the glue proteins that mussels use
to stick to surfaces. Catechol bonding to the metallic surface occurs through two adjacent
hydroxyl groups, and their vicinal positions in the aromatic ring which results in a high
dispersant packing density, as well as improved stability in physiological conditions [222,
223]. While the strong bonding to metallic surface is a major advantage, catechols may
react through a redox mechanism with the surface of iron oxide nanoparticles in protic
environments, leading to decomposition and precipitation of the nanoparticles [224].
Figure 1.28: General structure of a catechol.
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Bisphosphonates
A recent and yet unexplored approach to coat iron oxide NPs is the use of bisphosphonates
(BPs). BPs (figure 1.29 with R1 and R2 being an alkyl or functional group) are well known
molecules in the osteoporosis and oncology fields due to the fact that they bind avidly
to the calcium in hydroxyapatite (the main mineral component of bone) at the surface of
metabolically-active bone [225, 226]. Recently, BPs have begun to be incorporated into
coatings for use on iron oxide nanomaterials due to their particularly strong binding to
metallic surfaces, which can stabilise particles in solution for at least one month [227–234].
In this study, a BP was chosen as the anchor due to this strong binding to the iron oxide
surface and stability both in vitro and in vivo [81]. In addition, our group has recently shown
that bifunctional BPs can be radiolabled with no detrimental effect to the in vivo binding
to bone [235]. This will allow for the radionuclide modality to be easily incorporated into
the coating of the USPIOs without effecting the ability of the BP to bind to the NP surface,
a concept that has been demonstrated in our group using 64Cu and a dextran coated iron
oxide particle [79].
Figure 1.29: General structure of a bisphosphonate.
1.4.3 Coatings
Dextran
Dextran, figure 1.30, is a polymer of anhydroglucose. It interacts with the metal surface via
the hydroxyl groups and although a single bond is weak, the large number of hydroxyl groups
per molecule available for bonding to the iron oxide increases the overall stability of the coat-
ing [236]. However, the high numbers of anchoring groups of dextran results in aggregation
of several nanocrystals, increasing the hydrodynamic diameter of the particles/aggregates
to up to 150 nm [236,237]. The advantages of using dextran is its high biocompatibility and
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relatively ease of functionalisation via standard bioconjugation techniques. Its weakness,
however, is that the non covalent NP-dextran binding is weak and may result in lack of
stability in vivo [238]. This dissociation may be overcome by crosslinking the dextran shell
for example with epichlorohydrin, yet this may then result in particles that are less suitable
for biological applications due to the toxicity of the crosslinking agent [239,240].
Figure 1.30: General structure of dextran.
Polyethylene glycol
Polyethylene glycol (PEG) is a coating molecule that has been used to successfully provide
a non-ionic hydrophilic layer around various inorganic nanoparticle materials such as metal
oxides and silica [241–245]. A wide range of molecular weights of PEG can be synthesised
(400 Da up to 50 kDa) with a small distribution of molecular sizes [246–248]. The main
reason behind the preference of a PEG as a coating for a NP designed for biomedical ap-
plications is due to its stealth behaviour, which has been shown to reduce RES uptake and
prolong blood circulation times by up to 10 times [249, 250]. Furthermore, a PEG coating
adjusts the overall charge of the particle in such a way as to lessen protein adsorption on to
the NP surface [150]. The solubility of PEG in organic solvents allows for facile modification
of end groups, whilst its high solubility in water, low toxicity, and immunogenicity combined
with desirable excretion kinetics make it ideally suited for biological applications [251–256].
Moreover, this polymer has received FDA approval, and has been used in several pharma-
ceutical applications, such as organ storage and in the conjugation to proteins in order to
improve pharmacokinetics [257–259]. Not only this, but PEG is a frequent component in
a variety of cosmetics from toothpaste and shampoos to fragrances and make-up [260,261].
Finally, in addition to the biocompatibility of PEG, it also has the benefit of being low-
cost [262].
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Figure 1.31: General structure of polyethylene glycol.
Hydrophobins
Hydrophobins are amphiphilic proteins that have received recent interest for coating in-
organic nanomaterials due to their ability to self-assemble into monolayers on hydropho-
bic materials [263, 264]. They have a molecular mass below 20 kDa with a diameter of
ca. 1.2 nm and consist of approximately 100 amino acids characteristic of filamentous
fungi [265–267]. These proteins comprise of eight cysteine residues, forming four intramolec-
ular disulphide bonds, specifically ordered creating a hydrophilic region which contributes to
the hydrophobin’s distinguishing features and structural robustness, whilst the hydrophobic
area arises due to aliphatic side-chains in the loop region of the protein, yielding an am-
phiphilic structure [263, 268–270]. There are two principle classifications of hydrophobins
categorised by their hydropathy and the distance between cysteine residues [271]. Class I
hydrophobins (figure 1.32a [272]) have a high stability in harsh solvents and conditions, for
example the protein remains intact after boiling in a 2 % sodium dodecyl sulfate (SDS) for a
short period of time. Formic acid and trifluoroacetic acid being the only chemicals capable
of dissociation. Class II hydrophobins (figure 1.32b [273]) however, have a far lower stability
and can readily be dissolved by SDS [270]. Due to their potential biocompatibility combined
with resistance against pH and ionic salts arising in biological environments, hydrophobins
have recently become of interest as coatings for nanoparticles [274]. Several groups have
reported successfully phase transfers into aqueous solution with various nanomaterials, no-
tably hybrid nanostructures formed from single-walled carbon nanotubes bound to gold
nanoparticles [275], graphene sheets [276], and silicon particles [277,278]. Furthermore, the
exposed amino acid residues on the protein allow for additional functionalisation for use in
vivo applications, for example targeted imaging. Whilst hydrophobins have traditionally
been difficult to obtain, new advances in recombinant processing have made hydrophobins
a realistic option for use in phase transfer.
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This chapter aims to detail the development of a SPECT-MR imaging probe based on
USPIOs and BP-anchored coatings. Iron oxide NPs were chosen as the platform for the
contrast agent due to their biocompatibility as proved by previous use in the clinic as liver
MR imaging agents and also due to the ability to functionalise the NP surface allowing for
use in specific applications. The development of the synthesis to produce iron oxide cores,
followed by the ligand exchange method used to introduce a biocompatible coating will be
described. Characterisation of the particles before and after exchange of surface ligands
will be analysed, as will the introduction of a radionuclide allowing for both in vivo MRI
and SPECT imaging studies to be performed. Finally, the incorporation of a targeting
modality into the particle coating will be outlined and the subsequent in vitro analysis will
be presented.
2.2 Oleylamine coated ultrasmall superparamagnetic iron
oxide nanoparticles
2.2.1 Initial synthetic method
The original synthesis used to produce USPIOs involved the primary amine oleylamine
(OAm) as the surfactant, figure 2.1, which has previously been shown to be an excellent
coating for metallic NPs [1–5]. This choice of using OAm as a capping ligand is a result of
the binding to the surface of the Fe3O4 NPs via a lone pair on the amine group (figure 2.2).
This is preferable to using oleic acid (OA), as used in many iron oxide preparations [6–8] (and
has been shown to form a stronger bond to the NP surface [9,10]), as it results in a weaker
bond allowing for easier ligand exchange. OAm and OA share some similar properties.
Firstly, washing strategies following NP synthesis become simplified due to the liquid state
of OAm/OA at room temperature. The high boiling point allows strong heating conditions
to be applied during synthesis [11]. Secondly, it has been reported that the C=C bond in
the middle of the molecules may alter the morphology and crystallinity of NPs, as a result
of the less restricted coordination to the particle surface [12]. In addition, an important
advantage of using OAm over OA and other stabilisers such as trioctylphosphine (TOP) and
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trioctylphosphine oxide (TOPO) is its ability to be used as both a reducing and capping
agent. Evidence of this has been reported by several groups. Liu et al. detailed studies
whereby IR spectroscopy was used to show the oxidation of the amine group to an amide
group during the reduction of Au(III) to either Au(I) or Au(0) in the formation of gold
NPs [13]. A similar effect has also been demonstrated in the formation of hollow fcc cobalt
nanoparallelepipeds via thermolysis of solid fcc cobalt oxide NPs in OAm [14]. As has
previously been described, iron oxide (magnetite, Fe3O4) consists of both Fe(II) and Fe(III),
with the ratio of Fe(II)/Fe(III) being 0.5 in stoichiometric magnetite (but this is not normally
the case) [15]. This mixture arises due to a proportion of Fe(III) present in the iron(III)
acetylacetonate (Fe(acac)3) being reduced to Fe(II) by donation of an electron from the
amino group of the oleylamine.
Figure 2.1: General structure of oleylamine.
Figure 2.2: Schematic representation of oleylamine binding to a Fe3O4 NP via a lone pair
on the amine group.
The synthesis of the magnetite NPs was based on a previously reported method involving
the thermal decomposition of Fe(acac)3 in benzyl ether and oleylamine, shown in scheme
2.1 [16]. This synthetic route of thermal decomposition of iron containing precursors was
the first reported procedure to be an adequate way to synthesise monodispersed Fe3O4 NPs
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[17,18]. Figure 2.3a shows a transmission electron (TE) micrograph of the NPs synthesised
by reproducing the exact method stated by Xu et al. [16]. From TEM, it was found that the
resulting particles in hexane (note the NPs are also dispersible in other non-polar solvents)
had a core size (DTEM) of 4.2 ± 0.7 nm (based on measurement of 41 particles), but it can
be seen that large agglomerations had formed.
Scheme 2.1: Reaction scheme for the original synthesis of oleylamine coated NPs [16].
(a) (b)
Figure 2.3: Characterisation of oleylamine coated Fe3O4 NPs: TEM micrograph of a dis-
persion (a) in hexane synthesised using the original method shown (DTEM = 4.2 ± 0.7
nm based on measurement of 41 particles, and (b) in DCM synthesised using an improved
method involving heating across three different stages followed by ageing at a lower tem-
perature (DTEM = 5.5 ± 0.6 nm based on measurement of 200 particles). Scale bars are 20
nm.
After one week in hexane, the particles began precipitating out of solution showing there
was a need to develop the synthesis. After several slight modifications to the initial method,
it was found that heating across three different stages followed by ageing the particles at
a lower temperature for less time enhanced the quality of the sample produced. Figure
2.3b shows a very concentrated monodisperse sample of NPs soluble in dichloromethane
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(DCM) with a DTEM of 5.5 ± 0.6 nm based on the measurement of 200 particles, and a
hydrodynamic diameter (DH) of 10.0 ± 3.8 nm as determined by DLS. Measuring DH allows
for the determination of the overall size when in solution which is not possible with TEM
because the sample preparation method causes the coating of the NPs to collapse [19]. In
addition, the polydispersity index (PDI) of a sample is calculated as a measurement of the
particle size distribution, and was found to be 0.15 for this synthesis. A number of groups
have previously reported that a PDI higher than 0.3 indicates a population with a high
heterogeneity [20–22]. These results showed a considerable improvement when compared
against the TEM for the first sample (figure 2.3a). It should be noted here that as the
hydrodynamic diameter measured was less than 40 nm, these particles can be classified as
USPIOs (see page 31 of the introduction for a more detailed explanation).
2.2.2 Changing ramping rate
Once the improved synthesis had been established, investigations into parameters control-
ling the size distribution and regularity of the shape of the NPs was performed. As the
intended application of these USPIOs was as a MR contrast agent, it was interesting to
identify possible approaches to alter the morphology of the particles in order to optimise the
relaxation properties. The first parameter explored was the ramping rate for each heating
stage. It is known that ageing at a high temperature increases the particle size due to Os-
walt ripening, the process by which dissolved sol particles redeposit on the surface of larger
particles [27,28]. Nakaya et al. investigated the effect ageing had on the overall size of iron
oxide NPs via thermal decomposition, and found that longer reaction times led to increased
particle growth, up until a maximum of 20 nm [29]. Not only does extending the reaction
time alter the NP size, it has also been reported to increase the M S of the particles [30].
Hence for this study both decreasing and increasing the time of each heating stage was
assessed.
Doubling ramping rate
The synthesis was carried out with the ramping rate for each step doubled, hence halving
the time each stage took. The average DTEM remained approximately the same (5.3 ±




Figure 2.4: Characterisation of oleylamine coated Fe3O4 NPs: TEM micrograph of a disper-
sion in DCM synthesised with (a) the ramping rate doubled (DTEM = 5.3 ± 1.5 nm based
on measurement of 100 particles), and (b) the ramping rate halved (DTEM = 5.0 ± 0.9 nm
based on measurement of 100 particles). Scale bars are 20 nm.
Halving ramping rate
On this occasion, the procedure was repeated with the ramping rate for each stage halved,
consequently doubling the duration of heating. Again, the average DTEM had a similar
value of 5.0 ± 0.9 nm (based on the measurement of 100 particles) with an undesirable size
distribution and variations in shape as shown in figure 2.4b.
Although it has been reported by several other groups that varying reaction time can sig-
nificantly alter the size of NPs synthesised, it can be seen from the above results that
decreasing/increasing ageing time does not appear to have a beneficial effect for this partic-
ular scheme. Rather, it was found that the size distribution of the particles broadened, and
the NP shape became less spherical.
2.2.3 Changing precursor ratio
Xu et al., and others, stated that the size of the NPs produced was dependent on the volume
ratios of the capping agent and solvent (in this case oleylamine and benzyl ether) used,
whilst keeping the total volume constant. To be more precise, the particle size decreases as
larger quantities of surfactant are used because it acts as a nucleating agent which favours
the formation of a larger number of smaller nuclei [16, 23, 24]. To identify whether this
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statement held true for this synthesis, a ratio of 2:1, i.e. 20 mL of oleylamine and 10 mL of
benzyl ether, was explored in order to observe any difference from a 1:1 ratio. In addition, a
reaction involving oleylamine only was attempted as the effect the benzyl ether had on the
NPs produced was unknown. Solventless thermal decomposition methods have previously
been used to successfully synthesise iron oxide particles [25,26].
2:1 Oleylamine to benzyl ether
A 2:1 ratio of oleylamine to benzyl ether resulted in NPs with a slightly larger average DTEM
of 6.7 ± 1.4 nm, established from the measurement of 100 particles (figure 2.5a). It can also
be seen that the acquired sample was polydispersed and irregular in shape.
(a) (b)
Figure 2.5: Characterisation of oleylamine coated Fe3O4 NPs: TEM micrograph of a dis-
persion in DCM synthesised using (a) a 2:1 ratio of oleylamine to benzyl ether (DTEM = 6.7
± 1.4 nm based on measurement of 100 particles), and (b) using oleylamine only (DTEM =
5.2 ± 0.6 nm based on measurement of 200 particles). Scale bars are 20 nm.
Oleylamine only
The DTEM obtained for the synthesis using oleylamine only was 5.2 ± 0.6 nm (based on 200
particles). Figure 2.5b shows the NPs have a small size distribution and a regular spherical
shape.
It can be seen from the above results that higher quality particles are achieved using oley-
lamine only, hence for the remainder of this study, benzyl ether was removed.
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2.2.4 Final synthetic method
The synthetic studies described above allowed for an improved synthesis to be designed
that provided USPIOs of consistent quality throughout the remainder of this study. Scheme
2.2 represents the final reaction employed to prepare the iron oxide NPs, which was reli-
ably reproduced a multitude of times with little differences in the particles produced, as
determined via TEM and DLS analysis. In order to ensure that the heating rates for each
step were consistent each time, equipment was used which allowed for the required ramping
rates to be programmed. The plot in figure 2.6 is an example of the programmed heating
rate alongside the actual temperatures recorded throughout a synthesis and displays a high
degree of accuracy.
Scheme 2.2: Reaction scheme for the finalised standard synthesis of oleylamine coated NPs.
Volume of oleylamine 30 mL
Volume of benzyl ether 0 mL
Heating stages
25 ◦C → 128 ◦C at 363.5 ◦C/h
128 ◦C → 180 ◦C at 52 ◦C/h
180 ◦C → 270 ◦C at 396 ◦C/h
Table 2.1: Reaction conditions for the final synthetic method for oleylamine coated NPs.
Once this final method had been established, the nature of the synthesised Fe3O4 NPs was
determined. The DTEM was measured to be 5.2 ± 0.7 (based on the measurement of 100
particles), with a corresponding DH of 13.0 ± 3.2 and a PDI of 0.23. The USPIOs are shown
in figure 2.7 and it can be seen there is a high concentration of particles with some degree
of self assembly occurring which may be visible due to the preparation of the TEM grids
involving drying the NPs [31].
Further confirmation of the monodispersity of the sample was achieved by performing size-
selective precipitation of the USPIOs in DCM. Methanol was used as the cosolvent due to
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Figure 2.6: Comparison of ramping rates: Graphical representation of programmed heating
rate compared to actual heating rate during synthesis of Fe3O4 NPs.
Figure 2.7: Characterisation of oleylamine coated Fe3O4 NPs: TEM micrograph of a dis-
persion in DCM synthesised using the final developed method (DTEM = 5.2 ± 0.7 nm based
on measurement of 100 particles). Scale bar is 20 nm.
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it being more polar than DCM, and increasing the overall polarity of the solution caused
the larger particles/aggregates to precipitate out as they are less stable. It was found that
no precipitate formed, suggesting the sample was monodispersed and the particles were of
a small size.
2.3 Polyethylene glycol phase transfer of ultrasmall su-
perparamagnetic iron oxide nanoparticles
In order to enhance water solubility of the NPs, the oleylamine coating was replaced with
a coating of PEG, a non-ionic hydrophilic polymer which was used to reduce aggregation
and hence increase the stability of particles in aqueous solutions. PEG was conjugated to
the iron oxide surface via a BP. The rational behind using both these molecules has been
described previously in the introduction (see introduction, pages 41 and 40 respectively).
The structure of the PEG-BP is given in figure 2.8 and when performing certain studies, for
example radiolabelling, various lengths of PEG were explored.
Figure 2.8: General structure of PEG-BP.
2.3.1 Initial synthetic method
The first method investigated for PEGylating the particles involved sonicating the PEG2000-
BP (PEG(2)-BP) and oleylamine coated NPs in water until all had evaporated, followed by
redispersing in H2O as shown in scheme 2.3. Although this method seems implausible due
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to the particles being coated in a hydrophobic molecule, the ligand exchange occurs rapidly
(as observed by the immediate formation of a pale brown solution) which forces the NPs
into water. It was found that this method was time consuming due to length of time taken
for the evaporation of the water. Furthermore, the particles produced from this approach
of ligand exchange appeared to PEGylate in clusters (figure 2.9) resulting in aggregates
with large diameters. Additionally, during the water evaporation step it was noticed that
some precipitate settled on the bottom of the vial suggesting not all particles were phase
transferred. From this, it was determined that the best way to proceed would be to use a
more volatile solvent for the first step of dispersing the PEG-BP and USPIOs. It is important
to note that due to the in vivo application of the USPIOs, selecting the correct PEG chain
length is essential in preventing aggregation processes induced by plasma proteins. It has
been shown that using a molecular weight of 5000 Da significantly increases the blood half
time of coated USPIOs [33,34], thus this was the PEG length used throughout the remainder
of this study.
Scheme 2.3: Reaction scheme for the method of PEGylation of iron oxide NPs using water
or DCM (represented by X).
2.3.2 Final synthetic method
The final method of PEGylation was kept the same as that shown in scheme 2.3, with the
exception of using DCM in place of water. In addition, a lower mass of NPs was used
initially as it was found with previous attempts at the phase transfer process, there was a
large excess of oleylamine coated Fe3O4 remaining once PEGylation was complete. Using an
excess of PEG5000-BP (PEG(5)-BP) increased the possibility of maximising the dispersant
packing density, which is known to result in particles with a high colloidal stability [19]. This
process of functionalisation allowed for high yields to be reached in a short time and at room
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Figure 2.9: Characterisation of PEGylated Fe3O4 NPs: TEM micrograph of a dispersion in
water phase transferred using the initial method. Scale bar is 100 nm.
temperature, in contrast to other reported methods [32,34]. For example, Kim et al. heated
to a temperature of 70 ◦C for 5 h, whereas Hu et al. required 2 days to purify the PEGylated
particles (compared to only 1 h of centrifugation needed using this method) [35,36].
TEM images were collected of the particles after PEGylation in order to ensure no change in
the core size and sample dispersity has occurred. Figure 2.10 revealed there was no significant
difference in the measured DTEM (5.5 ± 0.7 nm based on the measurement of 200 particles)
indicating the BPs do not etch the particle surface which has been shown to occur when
using other anchor groups such as mimosine or dopamine derivatives [37, 38]. It is thought
that this was due to the stability of complexes formed as a result of the high affinity of some
catechols toward Fe3+ ions. Furthermore, toxic free radical species have been observed to
form at the catechol-iron oxide surfaces [39]. However, it has recently been shown that these
adverse effects can be overcome by introducing a strong electron-withdrawing nitro group to
the aromatic ring, thus modifying the electronic properties of the anchors [34,37]. Moreover
the monodispersity and spherical shape remained unaffected. It was previously mentioned
that a degree of self assembly was observed potentially due to the drying procedure when
preparing the TEM grids (figure 2.7), however once the particles are PEGylated, this no
longer arises, and the sample remains unclustered. Figure 2.11 shows the phase transfer of
the Fe3O4 NPs. The vial on the left contains the USPIOs in hexane, and the vial on the





Figure 2.10: Characterisation of PEGylated Fe3O4 NPs: (a) TEM micrograph of a disper-
sion in water phase transferred using the final method (DTEM = 5.5 ± 0.7 nm based on
the measurement of 200 particles). Scale bar is 100 nm; (b) Histogram of the diameter
distribution of 200 particles.
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Figure 2.11: Confirmation of PEG-BP binding to the surface of Fe3O4 NPs: Phase transfer
of a dispersion. The vial on the left contains the particles before PEGylation in hexane
(bottom layer is water), and the vial on the right contains the particles after PEGylation in
water (top layer is hexane).
It was measured that the average DH in water after PEGylation was 23.5 ± 6.5 nm (PDI
of 0.36), and in saline 23.9 ± 6.4 nm (PDI of 0.36), as shown in figures 2.12a and 2.12b
respectively. This was an important result as it demonstrated the stability of the NPs when
in the presence of salts which readily come into contact with the USPIO surface in biological
environments. This result showed that the particles could still be classified as USPIOs due
to the overall diameter remaining below 40 nm.
The size of PEG(5)-BP-USPIO was compared with other reported hydrodynamic diameters
of PEG coated Fe3O4 NPs (around 50 nm for PEG3000 and 60 nm for PEG6000 [40]), it
could be seen that the hydrodynamic diameter for our PEGylated particles was relatively
small. A potential reason for this is that the PEG molecules were not fully extended on the
surface of the NPs. An unfolded 5 kDa PEG chain has a length of ∼38 nm, which would
result in an overall average particle DH of 80 nm. Thus, it is believed that the polymers
folded to a 1/4 of their extended length forming an expanded coil conformation [41].





Figure 2.12: Characterisation of PEGylated Fe3O4 NPs: DLS number distribution of a
dispersion in (a) water (DH = 23.5 ± 6.5 nm, PDI = 0.36), and (b) saline (DH = 23.9 ±





where n = number of monomers per polymer chain
α = length of one monomer (A˚)
For PEG5000, n = 114 and α = 3.5 A˚, yielding an F value of 6.0 nm. If the distance between
anchors on the surface of the particle is larger than the Flory radius, i.e. the packing density
is low, then it is expected that the polymers will fold into expanded coils on the particle
surface [42]. As this is the polymer conformation implied from the hydrodynamic diameter
measured, it suggests there is a low quantity of PEG(5)-BP bound to the USPIO.
2.3.3 Dispersant packing density
By using the amount of non-bound PEG(5)-BP recovered after the synthesis of PEG(5)-BP-
USPIO, the PEG(5)-BP packing density on the surface of the USPIOs could be estimated.
It should be noted that the below calculations assume the USPIOs were spheres of a fixed
diameter of 5.5 nm and were composed of Fe3O4.
Calculation of mass of each USPIO and number of Fe atoms/USPIO
The mass of each 5.5 nm USPIO is 4.5 x 10−19 g, by using the density of Fe3O4 (5.17
g/cm3).
As the molecular weight of Fe3O4 is 232 g/mol, the number of moles can be calculated
to be 1.939 x 10−21 moles of Fe3O4, and the number of Fe3O4 units per USPIO is 1.939
x 10−21 x NA = 1168. Hence, the number of Fe atoms/USPIO is 1168 x 3 = 3504 Fe
atoms/USPIO.
Calculation of number of PEG molecules bound to USPIOs
Using the mass of the non-bound PEG(5)-BP (obtained from the washings during the pu-
rification process following PEGylation) it was found that 2.4 mg of PEG(5)-BP was bound
to the USPIOs. Hence, using the average PEG(5)-BP molecular weight value of 5307 g/mol,
it was calculated that this corresponds to approximately 2.72 x 1017 molecules.
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Calculation of number of USPIOs
Method 1. Using the Fe concentration
The Fe concentration of the PEG(5)-BP-USPIO dispersion was 26.62 mM (measured using
inductively coupled plasma mass spectrometry, ICP-MS) in 300 µL, which corresponds to
7.98 x 10−6 moles and 4.81 x 1018 Fe atoms. Hence, as it has previously been calculated that
there are 3504 Fe atoms/USPIO, it follows that there are 1.37 x 1015 USPIOs in total.
Method 2. Using the thermogravimetric analysis
From the thermogravimetric analysis (TGA) study (figure 2.13) it could be seen that out
of the 2 mg of oleylamine-USPIOs, 19 % corresponds to oleylamine. Hence, 1.6 mg is the
weight of the Fe3O4 NPs in the oleylamine-USPIOs, and consequently in the PEG(5)-BP-
USPIOs (as all USPIOs were capped with PEG(5)-BP and transferred into the aqueous
phase). This then corresponds to 3.55 x 1015 USPIOs if dividing by the value of 4.5 x 10−19
g/USPIO calculated earlier.
Figure 2.13: TGA study with oleylamine-USPIOs (black line) and PEG(5)-BP-USPIOs
(red line). The heating rate was 10 ◦C/min under a N2 flow. The vertical line indicates the
temperature at which it is considered most of the absorbed water has evaporated (125 ◦C).
Calculation of number of PEGs/USPIO
Using method 1. 2.72 x 1017 PEGs/1.37 x 1015 USPIOs = 198 PEGs/USPIO
Using method 2. 2.72 x 1017 PEGs/3.6 x 1015 USPIOs = 76 PEGs/USPIO
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Calculation of theoretical maximum density of BPs/USPIO
The surface area of a 5.5 nm sphere is 95 nm2 and the footprint of a BP is approximately
0.85 nm2 (calculated from a computational model using Chem3D, Cambridge Software).
Using these values, the theoretical maximum number of BPs that can bind to a 5.5 nm
sphere is 112.
Thus, these estimations result in density values that range from 76 to 198 PEGs/USPIO.
However, given that the calculations of the theoretical maximum number of BP groups that
each 5.5 nm USPIO can accommodate is 112, the true density is likely to be a value in the
range between 76 and 112 PEGs/USPIO, which corresponds to a surface density of 68 % to
100 %, or 0.80-1.18 PEGs/nm2.
TGA measurements (figure 2.13) were carried out to validate these estimations. The results
confirm that 67 % of the weight of PEG(5)-BP-USPIO (assuming that the weight loss before
125 ◦C is due to absorbed water) is due to PEG(5)-BP. This corresponds to 2.68 mg PEG(5)-
BP (note that this value is close to the 2.4 mg of non-bound PEG(5)-BP recovered from
the reaction). Therefore, it follows that (2.68 x 10−3 g/5307 g/mol) x NA = 304.2 x 1015
molecules of PEG(5)-BP. Dividing 304.2 x 1015 molecules of PEG(5)-BP by 3.55 x 1015
USPIOs obtains the result that each USPIO is bound to 86 PEG(5)-BP molecules, which
corresponds to 0.9 PEG/nm2, using the surface area of a 5.5 nm diameter sphere.
It is important to note that the high density value found is counterintuitive, particularly
when the DLS results suggest the PEG chains are likely to be present as folded extended
coils that will impact negatively on the density. However, these calculations assume a flat
surface area and recent studies have demonstrated that the curvature of USPIOs and other
nanomaterials allows for significant higher densities [34]. In addition, sources of error such
as the assumption that the particles are homogeneous spheres of 5.5 nm diameter and not
taking into account the small variations in diameter/surface areas may also influence the
calculations.
This relatively high dispersant packing density may be accounted for by the use of BPs. It
has previously been reported by Daou et al. that phosphonate coupling agents allow for a
higher grafting rate than other common anchors such as carboxylates [43]. It is important
to achieve a high density of PEG on the surface of UPSIOs as this inhibits the adsorption
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of smaller proteins on to the surface of the particles, which in turn promotes NP clearance
[19].
2.4 Further characterisation of polyethylene glycol-coated
ultrasmall superparamagnetic iron oxide nanoparti-
cles
2.4.1 Lattice fringe spacing
Further high resolution TEM (HRTEM) was performed in order to determine the interplanar
spacing (d) enabling the structure of the iron oxide particles to be confirmed. The images
revealed clear lattice fringes indicating a single crystal structure [44] with an average d of
0.261 ± 0.005 nm. This value was slightly higher than the interplanar spacing of bulk
magnetite (d311 = 0.2531 nm; JCPDS file no. 79-0417 [45]), which is most likely explained
by the measurement being performed on a different lattice plane as has been observed by
several groups [46–48]. Furthermore, it is known that for maghemite (γ-Fe2O3) d311 =
0.2517 nm (JCPDS file no. 39-1346 [49]), therefore verifying the magnetite nature of the
USPIOs.
2.4.2 Zeta potential
The zeta potential (ζ-potential) of the PEGylated Fe3O4 NPs in phosphate buffered saline
(PBS) at physiological pH was measured to be -1.24 ± 4.92 mV (figure 2.15) showing that the
particles have an approximately neutral surface making them useful for in vivo applications.
This near zero value is ideal as it has been demonstrated that negative NP surfaces favour
uptake by RES macrophages whereas positive NP surfaces result in plasma protein binding,
aggregation and uptake in the lungs and liver [50,51]. A near neutral surface charge reduces
the protein adsorption process opsonisation and hence prolongs the circulation time of the
particles [19].
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Figure 2.14: Characterisation of PEGylated Fe3O4 NPs: HRTEM micrographs of a disper-
sion in water with (a) d = 0.254 nm, (b) d = 0.260 nm, (c) d = 0.268 nm, and (d) d =
0.262 nm. Scale bar is 5 nm.
Figure 2.15: Characterisation of PEGylated Fe3O4 NPs: Zeta potential distribution of a
dispersion in PBS at pH 7.4 (ζ-potential = -1.24 ± 4.92 mV).
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2.4.3 Energy-dispersive X-ray spectroscopy
Several techniques were performed in order to confirm that PEG(5)-BP was bound to the
surface of the particles, and that all oleylamine had been removed after purification. The
first approach was to run energy-dispersive X-ray spectroscopy (EDX) on the PEGylated
sample of particles, figure 2.16. The peak representing phosphorus was present in the TEM
of the specimen indicating the presence of the BP group.
Figure 2.16: Characterisation of PEGylated Fe3O4 NPs: EDX spectrum showing presence
of iron and phosphorus in PEGylated NP sample.
2.4.4 Infra-red spectroscopy
Infra-red spectroscopy was the second technique used to ensure that the ligand exchange
during phase transfer was successful. Figure 2.17 shows the IR spectra of PEG(5)-BP and of
the PEGylated NPs. It can be seen there are peaks corresponding to the PEG present in the
sample of particles. Vibrations due to the Fe-O bonds in Fe3O4 occur around 591 cm
−1 and
hence are not shown in figure 2.17. Sharp peaks are present around 2850 cm−1 on all three
spectra. On figure 2.17a this represents the C–H bond stretching in oleylamine, whereas
on figures 2.17b and 2.17c it is due to the C–H stretching of PEG. The broad peak in the
region of 3400 cm−1 is assigned to stretching vibrations of N–H bonds and O–H stretching
of adsorbed water. Bending vibrations of N–H and C–H are represented by the bands in
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the range of 1385 cm−1 to 1610 cm−1 [52,53]. Confirmation of the success of PEGylation is
given by the presence of characteristic PEG vibrations: (ν(C–O) + ρ(–CH2–) = 1096 cm
−1;
ρ(–CH2–) + τ(–CH2–) = 946 cm
−1; τ(–CH2–) + ν(C–O) = 841 cm
−1) in the spectrum of
PEG(5)-BP-USPIO (figure 2.17c) [54].
Figure 2.17: Characterisation of PEGylated Fe3O4 NPs: (a) IR spectrum of oleylamine
coated NPs; (b) IR spectrum of PEG(5)-BP only; (c) IR spectrum of PEG(5)-BP coated
NPs. Drop lines indicate vibrations associated with PEG (ν(C–H) = 2850 cm−1; (ν(C–O)
+ ρ(–CH2–) = 1096 cm
−1; ρ(–CH2–) + τ(–CH2–) = 946 cm
−1; τ(–CH2–) + ν(C–O) = 841
cm−1).
Although this result demonstrates PEGylation of the USPIOs has been achieved, it does
not confirm complete oleylamine removal. This is despite the high PEG densities accom-
plished (76 %, vide supra) which strongly suggest that at least most oleylamine has been
displaced from the dispersion. The expected shift of –PO3 vibrations upon metal binding
was not observed due to the overlap with the more intense signals from the PEG methylene
groups.
2.4.5 X-ray diffraction
X-ray diffraction studies were used to identify the presence of PEG(5)-BP in the sample
after purification, in addition to confirming the removal of oleylamine. Figure 2.18 shows
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the characteristic peaks due to iron oxide (30.095 ◦, 35.422 ◦, 56.942 ◦ and 62.525 ◦; JCPDS
file no. 19-0629) [55] as well as PEG(5)-BP (19.2 ◦ and 23.3 ◦) [56, 57], which is probably
the result of its high density and ordered structure near the surface of the USPIOs.
XRD can also be used to estimate the mean diameter (τ) of the particles using the Scherrer
equation (equation 2.2). It was chosen to calculate the average NP size along the (311)
direction as this peak did not overlap with any others and measuring the width at half height
was simple. The particle size was calculated to be 7.2 nm from the oleylamine-USPIOs curve
and 7.1 nm from the PEG(5)-BP-USPIOs curve, as shown in the inset of figure 2.18. These
estimations are larger than those indicated by TEM which is due to crystal size not being







where K = shape factor, typically taken to be 0.9
λ = X-ray wavelength (A˚)
β = line broadening a half the maximum intensity (rad)
θ = Bragg angle (◦)
b = full width at half maximum (FWHM) of the NPs (rad)
b0 = FWHM of the standard crystal (rad)
Even though this XRD pattern indicated our sample consisted of Fe3O4, the structure of
γ-Fe2O3 gives some similar peaks with comparable intensities, namely at 30.272
◦, 35.597
◦, 57.166 ◦ and 62.726 ◦ (JCPDS file no. 04-0755) [55], making distinguishing between the
two difficult. Although there are three additional peaks for γ-Fe2O3 (23.836
◦, 32.172 ◦ and
38.783 ◦; JCPDS file no. 04-0755) [55] due to their low intensities, identification of these
peaks is challenging.
2.4.6 X-ray photoelectron spectroscopy
X-ray photoelectron spectroscopy (XPS) was the final technique used to confirm the presence
of PEG(5)-BP in the PEGylated NP sample. The full spectrum is given in figure 2.19a and
displays dominant C1s (282.2 eV, 283.5 eV and 286.2 eV, figure 2.19b) and O1s (529.7 eV,
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Figure 2.18: Characterisation of PEGylated Fe3O4 NPs: XRD patterns of oleylamine coated
USPIOs (bottom, black) and PEGylated USPIOs (top, red). The peaks corresponding to
PEG(5)-BP have been labeled with an asterix. The inset shows the peak corresponding to
the (311) plane and its mean size (τ (311)).
figure 2.19c) signals from the PEG chain and carbon dioxide adsorbed on the USPIO surface.
Additionally, the detectable P2p3/2 peak (129.7 eV, figure 2.19e) arising from the BP group
further confirms the presence of the PEG(5)-BP. Furthermore, iron displayed a signal at 708
eV (figure 2.19d). The weak signal of the iron and phosphorus was due to the coverage of
the PEG chain and the low abundance of P [59,60]. Similar signals have been observed with
other metallic surface-bound bis- and monophosphonates [61,62].
The combination of EDX, IR, XRD and XPS spectroscopies proved the presence of the
PEG(5)-BP on the surface of the USPIO after purification, was well as the removal of the
majority, if not all, of the oleylamine. The next step in the analysis of the PEGylated
USPIOs was to characterise the magnetic properties.
2.4.7 Magnetic properties
The magnetic properties of both oleylamine coated and PEGylated USPIOs were investi-
gated at 300 K using a SQUID-VSM instrument (figure 2.20) in order to identify any effect
of the ligand exchange on the magnetisation of the particles.
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Figure 2.19: Characterisation of PEGylated Fe3O4 NPs: (a) XPS spectrum of PEG(5)-BP
coated USPIOs (dominant C1s and O1s displayed); (b) XPS spectrum of carbon (282.2 eV,
283.5 eV and 286.2 eV); (c) XPS spectrum of oxygen (529.7 eV); (d) XPS spectrum of iron




Figure 2.20: Characterisation of oleylamine coated and PEGylated Fe3O4 NPs: (a) Mag-
netisation at several magnetic fields at 300 K for oleylamine coated USPIOs (M S = 65
emu/g); (b) Magnetisation at several magnetic fields at 300 K for PEG(5)-BP-USPIOs (M S
= 51 emu/g). The weight of iron oxide was calculated by subtracting the mass of oleylamine
and PEG as calculatedly TGA.
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The profiles of both samples clearly demonstrate superparamagnetic behaviour. Before and
after PEGylation, the mass magnetisation at saturation was found to be 65 emu/g iron
oxide and 51 emu/g iron oxide respectively, as calculated using a Langevin fit. The weight
of iron oxide was calculated by subtracting the mass of oleylamine/PEG as calculated by
TGA. Both these values are relatively low compared to that of bulk iron oxide (maghemite
(γ-Fe2O3, bulk M S = 74 emu/g) and magnetite (Fe3O4, bulk M S = 98)), and are consistent
with that found with other USPIOs of a similar size [35]. There are two potential reasons
as to why the PEG coating has reduced the M S. Firstly, the functionalisation with the
bisphosphonate group may have had an effect. However, it has been stated previously that
although this is may be the case for carboxylate molecules, the same is not observed for
phosphonate groups [63]. Therefore the second explanation of errors in both the weight
measured and the results from TGA analysis are deemed more likely.
2.4.8 Stability studies
In order to ensure the PEGylated NPs did not degrade once in dispersion, studies were
performed over time, temperature and washings to explore any change in the hydrodynamic
diameter. Several observations confirm the high colloidal stability of the BP-coated USPIOs.
Firstly, DLS of the NPs dispersed in both water and saline was performed once again several
months later in order to check the stability of the particles over time. It was observed that the
particles had a slightly smaller DH of 21.0 ± 3.0 nm and 22.7 ± 3.0 nm respectively (decrease
of 2.5 nm and 1.1 nm). These studies demonstrate that the hydrodynamic diameter of the
PEG(5)-BP-USPIOs stored in water or saline for at least 6 months remains unchanged, with
no aggregates forming during this time.
Secondly, heating dispersions of PEG(5)-BP-USPIOs in saline to 90 ◦C for 10 min and at
50 ◦C for 4 h, figure 2.21, resulted in no change in DH or aggregation. It is important to
note that for the stability study at 50 ◦C, a different batch of PEG(5)-BP-USPIOs with a
slightly larger hydrodynamic diameter was used.
An additional indication of the stability of the PEGylated USPIOs was given by the number
of washings that could be performed with large volumes of saline and water using 30 kDa
molecular weight cut-off (MWCO) filters without changes in DH (>8 times). In contrast,
USPIOs PEGylated using a PEG(5)-COOH (phase transferred using the same method as
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Figure 2.21: Stability of PEGylated Fe3O4 NPs: Temperature stability study over 4 h at
50 ◦C in saline (note a different batch of PEG(5)-BP-USPIOs with slightly larger DH was
used for this study).
with PEG(5)-BP) aggregated entirely after four washings. This aggregation occurred due to
the PEG molecules being removed from the retentate containing the particle dispersion into
the filtrate after desorption. Hence, inducing the formation of agglomerates. This method
has been previously used to evaluate the binding reversibility of several PEG coatings on
SPIOs by Amstad et al. It was reported that with PEG-COOH and weakly bound PEG-
catechols, aggregation occurred between the first and fourth filtration [34]. However, the
consistent DH after four filtrations with strongly bound catechol-PEG conjugates indicated
irreversible binding. Furthermore, the hydrodynamic diameter of PEG(5)-BP-USPIOs re-
mained constant after repeating the process at various time points during several months.
The possibility that the PEG polymer may be binding nonspecifically to the alkyl chains,
a method that has been successfully used with other systems [64], is also proved to be
unlikely by the lack of binding and stabilisation properties of PEG-COOH to oleylamine
USPIOs.
In order for the particles to be useful for in vivo imaging, stability in 10 % human serum at
37 ◦C also had to be confirmed. PEG(5)-BP-USPIOs were incubated for 0 h, 1 h, 24 h, and
48 h and DLS measurements were performed, showing no change in DH. It is important
to note that for this stability study a different batch of PEG(5)-BP-USPIOs with a slightly
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smaller hydrodynamic diameter was used. This result not only supports the stability of
the BP-iron oxide bond, but also indicates that blood serum proteins do not adsorb to the
nanoparticle surface. This is believed to be a consequence of a compact and stable PEG
coating and the neutral zeta potential achieved.
2.4.9 Comparison with FeraSpin XS
A comparison against a commercially-available preclinical iron oxide nanoparticle, FeraSpin
XS (Miltenyi Biotech GmbH), was run. This was chosen as a standard as FeraSpin XS has
been designed for use in the in vivo MRI of small animals. FeraSpin XS consists of ultra-
small superparamagnetic iron oxide nanoparticles coated with carboxydextran (DTEM of 5
nm and DH of 18 nm) which is used to visualise vasculature and to measure steady state
blood volume [65]. Figure 2.22 reveals large aggregates of particles, again this is most likely
due to drying procedures used in preparation of the TEM grids.
Figure 2.22: Characterisation of FeraSpin XS: TEM micrograph of a dispersion in water
(DTEM = 5 nm, DH = 18 nm as given by Miltenyi Biotech GmbH). Scale bar is 200 nm.
In addition, magnetic measurements were acquired and the M S calculated, again using
a Langevin fit. This was done in collaboration with Professor Yves Gossuin’s group in
Biomedical Physics at the University of Mons. Figure 2.23 shows the original experimental
measurements (performed on aqueous solutions of USPIOs) alongside data which has been
corrected for diamagnetism, a non negligible contribution from water [66]. It was found that
the M S is slightly higher than for the PEG(5)-BP-USPIOs at 71.9 emu/g. From this fit, it
was also possible to calculate the average particle size (DM). This was found to be 8.2 nm,
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somewhat larger than stated by the manufacturers. The most feasible explanation for this
is errors in the iron concentration measurement (which was made using ICP-MS) as well as
the assumption made during the Langevin fit that the sample is monodispersed, resulting
in an over estimation of the particle size.
Figure 2.23: Characterisation of FeraSpin XS: Magnetisation at several magnetic fields at
300 K for carboxydextran coated USPIOs (M S = 71.9 emu/g).
Once the PEG(5)-BP-USPIOs had been fully characterised and FeraSpin XS partially, the
next stage was to ascertain the MRI properties of the particles.
2.5 Relaxivity measurements
Experiments were performed in order to investigate the effect of different parameters on the
relaxivity values of the water soluble iron oxide.
2.5.1 Changing concentration
The initial parameter explored was the Fe concentration of the sample. Three concentrations
were measured at both 0.47 T and 1.41 T. The iron concentrations studied were 0.5 mM,
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0.75 mM and 1 mM, which again were measured using ICP-MS.
(a)
(b)
Figure 2.24: Relaxivity characterisation of PEGylated Fe3O4 NPs: Variation of spin-lattice
relaxation rate (R1; solid black line) and spin-spin relaxation rate (R2; dashed grey line)
with concentration for PEG(5)-BP-USPIOs at (a) 0.47 T, and (b) 1.41 T.
The general expression defining the ability of a contrast agent to adjust proton relaxation




1,2 + r1,2 · C (2.3)
where R1,2 = proton relaxation rate in the presence of the contrast agent (s
−1)
R01,2 = proton relaxation rate in the absence of the contrast agent (s
−1)
r1,2 = contrast agent relaxivity (s
−1mM−1)
C = contrast agent concentration (mM)
It can be seen from the above equation that as the concentration of the contrast agent is
increased, there is a direct increase in the proton relaxation rate. Figure 2.24 displays this
linear relationship for R1 and R2 for both samples.
2.5.2 Changing temperature
The next factor to be investigated was temperature, and the sample (with an iron concen-
tration of 0.5 mM) was measured at 26 ◦C and 37 ◦C at 0.66 T in order to observe the effect
on the R1 and R2 relaxation rates.
Figure 2.25 clearly shows a decrease in the relaxation rate (both longitudinal and transverse)
with increasing temperature. Kawaguchi et al. suggest that this decrease can be attributed
to the increase in motion, and hence an increase in the translation diffusion, of the neigh-
bouring water molecules [68]. It is well established that the superparamagnetic particle
effect on relaxation arises from water molecule diffusion in the vicinity of the core [69–71]
(more detail is given on page 24 of the introduction).
2.5.3 Longitudinal nuclear magnetic relaxation dispersion profiles
Longitudinal nuclear magnetic relaxation dispersion (NMRD) profiles allow the dependence
of the spin-lattice relaxation rate on magnetic field strength to be investigated in detail over
a short range of low field strengths. In this case, up to 40 MHz. The concentration used
was 2 mM and the measurement was taken at both 25 ◦C and 37 ◦C to reconfirm the effect
of temperature as seen above.
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Figure 2.25: Relaxivity characterisation of PEGylated Fe3O4 NPs: Variation of spin-lattice
relaxation rate (R1; solid black line) and spin-spin relaxation rate (R2; dashed grey line)
with temperature for PEG(5)-BP-USPIOs.
Figure 2.26: Relaxivity characterisation of PEGylated Fe3O4 NPs: NMRD profiles of
PEG(5)-BP-USPIOs at 25 ◦C (solid black line) and 37 ◦C (dashed grey line).
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It was found that increasing the field strength led to an initial increase in the spin-lattice
relaxation rate for both samples, but was followed by a decrease once the field had reached
∼0.47 T (as shown in figure 2.26). This correlates to a statement by Gossuin et al. which
reports that once the magnetic field strength is large enough, the longitudinal relaxation rate
drops to near zero [72]. The explanation for this is complex as the spin-lattice relaxation is
dependent on several parameters, one of which is the Ne´el relaxation time. Other factors
affecting the R1 of a nanoparticle include the core size of the particle, aggregation, and the
saturation magnetisation [72]. Again, the same effect of change in temperature was observed
as described above.
2.5.4 Changing field strength
The dependence of both the longitudinal and transverse relaxation rates on magnetic field
strength were then studied. In this case a larger range of field strengths were investigated:
0.47 T, 0.66 T, 0.92 T, 1.41 T and 7.04 T. All measurements were taken with an iron
concentration of 0.5 mM and at a temperature of 37 ◦C in order to replicate the physiological
conditions as much as possible.
Due to the larger field strengths examined, it was clear to see the spin-lattice relaxation
rate dropped to zero as expected, figure 2.27a. The general trend of the spin-spin relaxation
rates was observed to increase as the magnetic field strength was raised until approximately
6 T where the data appears to plateau, figure 2.27b. This can simply be accounted for by
the NP magnetisation increasing from zero to the saturation value [72]. This correlates to
the general form of the Langevin function.
Both the spin-lattice and spin-spin relaxation trends that have been observed here have
also been noted elsewhere with USPIOs. For example, a significant decrease in r1 of 15.5
s−1mM−1 to 6.6 s−1mM−1 (1.5 T and 3 T respectively) with r2 remaining constant has
been reported for Sinerem, dextran coated USPIOs intended for use in detection of metas-





Figure 2.27: Relaxivity characterisation of PEGylated Fe3O4 NPs: Variation of spin-lattice
relaxation rate (R1; solid black line) and spin-spin relaxation rate (R2; dashed grey line)
with magnetic field strength for PEG(5)-BP-USPIOs.
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2.5.5 Phantom studies
Phantom studies were then conducted in order to determine the r1 and r2 values of the
particles. A phantom is a specially designed object that is imaged to allow for analysis
and evaluation of various imaging devices. In this case, five vials of PEG(5)-BP-USPIO
containing varying concentrations of Fe and one of water were prepared. The longitudinal
and transverse relaxivities of the PEGylated USPIOs were then measured at 3 T in order
to evaluate at a clinically relevant field. As a result of their improved image resolutions, 3
T MRI scanners are increasingly becoming available in clinics, hence there is an interest of
developing USPIOs that retain high T 1 effects at these field strengths. Figure 2.28 shows
the Fe concentration against the calculated relaxation rates allowing the r1 and r2 to be
determined from the gradients. It was found that the particles have an r1 of 9.5 s
−1mM−1,
an r2 of 19.7 s
−1mM−1 and hence an overall r2/r1 of 2.1. For superparamagnetic materials,
the higher the r1 and lower the r2/r1 ratio, the more effective the contrast agent will be for
use in T 1-weighted imaging. On the other hand, for T 2-weighted imaging high r2 values
and a higher r2/r1 ratio is desirable. The substantial T 1 and low T 2 effect induced by
the PEG(5)-BP-USPIO was then confirmed by MR imaging of the same phantom samples
(figure 2.29).
The values obtained as well as those reported in the literature for other USPIOs at 3 T
are listed in table 2.2. This shows that PEG(5)-BP-USPIOs have optimal properties for
efficient T 1 contrast, and compare very favourably with other USPIOs approved for clinical
use measured under similar conditions. It is thought the strong T 1 effect of the PEG(5)-BP-
USPIOs at 3 T is the result of (1) small diameter NP cores of superparamagnetic iron oxide
that are known to yield USPIOs with low M S values and strong T 1 effects [32,35,75,76], (2)
a coating composed of two hydrophilic components, PEG and BP, that facilitate diffusion
of water molecules to reach the iron oxide surface and allow the relaxation of their protons,
and (3) a stable and compact PEG coating, provided by the strong BP-iron oxide bond,
that prevents aggregation that would increase r2 and hence the r2/r1 ratio.
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Figure 2.28: In vitro MRI studies of PEGylated Fe3O4 NPs: Relaxation rates (R=1/T )
of PEG(5)-BP-USPIOs as a function of Fe concentration at 3 T (r1 of 9.5 s
−1mM−1, solid
black line, and r2 of 19.7 s
−1mM−1, dashed grey line).
Figure 2.29: Characterisation of PEGylated Fe3O4 NPs: MR images of PEG(5)-BP-USPIO
phantom showing concentration-dependent effect in T 1- and T 2-weighted sequences. The
vial containing the highest Fe concentration (5.3 mM) is indicated by the arrow with con-
















































































































































































































































































































































































































































2.5.6 Comparison with FeraSpin XS
The phantom study was then repeated for the pre-clinical contrast agent, FeraSpin XS.
The study yielded a r1 of 5.4 s
−1mM−1, a r2 of 35.9 s−1mM−1, and hence a r2/r1 of 6.6,
exhibiting a significant decrease in the T 1-weighted imaging properties. This result was
promising as FeraSpin XS has been designed to increase the T 1 effect and have a longer
blood half life in contrast to other USPIOs.
Figure 2.30: In vitro MRI studies of FeraSpin XS: Relaxation rates (R=1/T ) of carboxy-
dextran coated USPIOs as a function of Fe concentration at 3 T (r1 of 5.4 s
−1mM−1, solid
black line, and r2 of 35.9 s
−1mM−1, dashed grey line).
2.6 Radiolabelling
To radiolabel the Fe3O4 NPs, the bisphosphonate dipicolylamine-alendronate (DPA-ale; fig-
ure 2.31) was conjugated to the gamma-emitting isotope 99mTc which bound to the particle
surface. Recent studies in the group have shown that BPs can be used to successfully radio-
label the metal ions on the surface of iron oxide nanoparticles with PET or SPECT isotopes
without affecting their coatings or surface properties [80,81]. The reason for this is based on
the high energy photons emitted providing a strong signal, meaning only small quantities
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(micrograms) of BP are required to be radiolabelled [82]. As a consequence, the radiola-
belled BPs are present in a much lower quantity than the NPs (and hence coating molecules),
therefore in the event that a coating molecule does become displaced, the changes would be
so insignificant the colloidal properties would not be affected. DPA-ale has recently been
shown to radiolabel iron oxide materials with high stability in vitro/vivo [82].
Figure 2.31: General structure of DPA-alendronate.
The radiolabel was produced in two stages. The first being the formation of technetium
tricarbonyl, [99mTc(CO)3(OH2)3]
+, and the second being the conjugation of this molecule
to DPA-ale. After the initial step, a thin layer chromatography (TLC) plate was run in order
to ensure the desired product had been formed. It was expected that there would be a broad
peak present at ∼30 mm (equivalent to a retention factor - Rf - of ∼0.3) if the technetium
tricarbonyl had been successfully produced. From figure 2.32 it can be seen there are two
regions, the first being the desired product and the second representing a small amount of
unreacted starting material, 99mTcO4
−. Table 2.3 gives the Rf values for each.
Region Rf % Total % ROI
1 0.392 95.90 98.35
2 0.969 1.60 1.65
Table 2.3: TLC characterisation of [99mTc(CO)3(OH2)3]
+: Rf values for each region of the
first TLC plate. Region 1 corresponds to [99mTc(CO)3(OH2)3]
+, region 2 corresponds to
unreacted 99mTcO4
−.
After the second step, a further TLC plate was then run as before as quality control to
ensure the [99mTc(CO)3(OH2)3]
+ had conjugated to the DPA-ale. It was expected that the
large broad peak from the previous TLC plate (figure 2.32) would become narrower and
shift to the left due to the lower Rf of the radiolabelled bisphosphonate. Figure 2.33 shows
the results from the second TLC plate, with table 2.4 giving the relevant values, confirming
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Figure 2.32: TLC characterisation of [99mTc(CO)3(OH2)3]
+: Graphical representation of
the first TLC plate. Region 1 corresponds to [99mTc(CO)3(OH2)3]
+, region 2 corresponds
to unreacted 99mTcO4
−.
the reaction was successful. It is thought that the radiolabelled BP appears as two peaks
due to the formation of protonated bisphosphonate species as a result of the acid present
in the mobile phase (1 % HCl in MeOH; for full details see experimental, page 206). In
addition, in vivo studies demonstrated that the product of this reaction resulted in bone
uptake, suggesting both peaks in the TLC are 99mTc-DPA-ale.
Region Rf % Total % ROI
1 0.070 45.54 48.89
2 0.229 47.60 41.11
Table 2.4: TLC characterisation of radiolabelled BP: Rf values for each region of the second
TLC plate. Regions 1 and 2 correspond to 99mTc-DPA-ale.
Scheme 2.4 shows how the USPIOs were radiolabelled, with the basic concept being that
the 99mTc-DPA-ale binds to exposed regions on the NP surface. In order to optimise the
radiolabelling yield achieved from this procedure, several parameters were explored as well
as different methods of purification. To start with it should be noted that reaction pH (6-9)
had no affect on the percentage of total activity incorporated into the NP system.
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Figure 2.33: TLC characterisation of radiolabelled BP: Graphical representation of the
second TLC plate. Regions 1 and 2 correspond to 99mTc-DPA-ale.
Scheme 2.4: Reaction scheme for radiolabelling PEGylated NPs with 99mTc-DPA-ale.
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2.6.1 Radiolabelling yield dependence on molecular weight and mass
of polyethylene glycol
To investigate the effect on the radiolabelling yield of the molecular weight and mass of PEG-
BP used in the initial PEGylation of the iron oxide nanoparticles, the following ratios (mass
of iron oxide:mass of PEG-BP, in mg) were studied: 0.01:5 of 2 kDa MW (molecular weight),
0.01:13 of 2 kDa MW, 0.01:17 of 5 kDa MW, 0.01:22 of 5 kDa MW and 0.01:57 of 10 kDa
MW. Each phase transfer was performed using USPIOs from the same synthesis (labeled
USPIO-2), excluding the initial PEGylation which was achieved using a different iron oxide
(labeled USPIO-1). All other radiolabelling conditions were kept consistent.
Once the particles had been radiolabelled, unbound 99mTc-DPA-ale was removed via cen-
trifugation with saline. Figure 2.34 shows how the activity associated with the particles
changed during the washing process, with table 2.5 giving the final radiolabelling yield for
each sample.
Figure 2.34: Characterisation of radiolabelled NPs: Graphical representation of the cen-
trifugation washings for radiolabelling of various PEG-coated USPIOs.
It can be seen that, in general, as the molecular weight of the PEG is increased, the radio-
labelling yield is increased. This is due to longer PEG chains decreasing the coating density
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Sample Final percentage activity in retentate, %
USPIO-1: 0.01:5 of 2 kDa MW 34.6
USPIO-2: 0.01:13 of 2 kDa MW 77.3
USPIO-2: 0.01:17 of 5 kDa MW 69.9
USPIO-2: 0.01:22 of 5 kDa MW 81.8
USPIO-2: 0.01:57 of 10 kDa MW 81.0
Table 2.5: Radiolabelling yields for different PEGylations of USPIOs
meaning there is a larger number of binding sites available for the radiolabel. Although this
result seems counterintuitive from the high dispersant packing density previously calculated,
the USPIOs investigated here were synthesised using a different method and were coated
with oleic acid (USPIO-2) as opposed to oleylamine (USPIO-1). This study was merely
used to examine the potential to increase the radiolabelling yield by varying the PEG chain
length. As the mass of PEG used to phase transfer the USPIOs is increased, so is the
radiolabelling yield. This can be explained in terms of aggregation of the particles. If less
PEG is used theres tends to be less surface area exposed to the radiolabel owing to the
agglomeration of USPIOs. This is demonstrated in figure 2.35.
(a) (b)
Figure 2.35: Characterisation of PEGylated Fe3O4 NPs: TEM micrograph of a dispersion
in water PEGylated using a mass iron oxide NP:mass PEG-BP ratio of (a) 0.01:57, and (b)
0.01:17. Scale bars are 20 nm.
2.6.2 Radiolabelling yield dependence on reaction time
The second factor to be studied was the dependence of the radiolabelling yield on the time
the USPIOs were reacted with the radiolabelled BP. The amount of bound radioactivity was
measured immediately after introducing the radiolabel, and then after 30 min of reacting
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at room temperature or 37 ◦C. It was found that the percentage of the total activity in
the retentate was 41.7 % and 42.3 % respectively. This shows that 99mTc-DPA-ale binds
rapidly and almost quantitatively to USPIOs, as has been previously found by de Rosales
et al. [80].
2.6.3 Radiolabelling yield dependence on heating
In this case, both samples were identical with the exception of the temperature at which the
radiolabel was reacted with the USPIOs. In one instance, the temperature heated at was 37
◦C and in the other a temperature gradient of 25 ◦C to 90 ◦C was used (both heating times
were 10 mins). Figure 2.36 show how the radiolabelling changed during the centrifugation
process.
Figure 2.36: Characterisation of radiolabelled NPs: Graphical representation of the cen-
trifugation washings for radiolabelling using different heating conditions.
For the sample heated at 37 ◦C, the final radiolabelling yield was 24.7 % whereas when
the reaction was heated from 25 ◦C to 90 ◦C the resulting yield was 46.7 %. It is thought
that the PEG will form a barrier limiting the accessibility of the iron oxide surface for
the radiolabel. It is therefore presumed that increasing the temperature will increase the
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exposure of the less-accessible metallic surface via two mechanisms: (1) ligand exchange
on the surface or (2) diffusion of 99mTc-DPA-ale through the PEG layer to reach exposed
gaps of the NP core (represented in scheme 2.4). Referring back to previous calculations
of dispersant packing density (approximately 76 % of the USPIO is coated with PEG-BP)
and taking into account the strong BP-iron oxide bond [80, 81, 83–90], it is believed that
mechanism (2) is most probable. In addition, it was found that using a heating gradient
resulted in less non-specifically bound radioactivity in the size exclusion filter.
2.6.4 Radiolabelling yield dependence on filter
Due to the difficulty in removing activity from the centrifugal concentrator used during the
washing step, an alternative filter was attempted to see if any difference was noticed. Initially
the filter used was a Vivaspin 500 with a 10 kDa MWCO and the second filter investigated
was a Vivaspin 2 with a 30 kDa MWCO. Table 2.6 reveals that repeating the experiment
with a different filter made no significant difference. The cause of the non-specific binding
to the centrifugal concentrator remains unknown.
Sample Activity in the retentate, % Radiolabelling yield, %
Vivaspin 500, 10 kDa MWCO 46 34
Vivaspin 2, 30 kDa MWCO 48 31
Table 2.6: Characterisation of radiolabeled NPs: Radiolabelling yields obtained for different
centrifugal filters.
2.6.5 Radiolabelling yield dependence on purification method
Due to the problem of the radiolabelled USPIOs non-specifically binding to the size exclusion
filter, an alternative route of purification was performed. In this case, once the labeling of
the NPs with 99mTc-DPA-ale had taken place, the reaction solution was passed through a
pre-conditioned size exclusion column (PD-10 desalting column, Sephadex G-25 medium).
The results of this can be seen in figure 2.37.
The size exclusion column revealed two distinct peaks, the first sharp peak corresponding
to the radiolabelled iron oxide NPs (fractions obtained at 1 mL and 1.5 mL) with the
second broader peak belonging to the free 99mTc-DPA-ale. This was the expected result due
to the large size of the radiolabelled USPIOs. The activity remaining in the column after
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Figure 2.37: Characterisation of radiolabelled NPs: Elution chromatogram of radiolabelled
NPs (0.5 mL fractions were collected from 0 to 3 mL, and 1 mL fractions were collected
thereafter).
purification was significantly less than for the filter (4.15 MBq compared to 15 MBq), proving
only a small amount of non-specific binding to the column matrix occurs. The coelution of
the first radioactive peak with PEG(5)-BP-USPIOs shows the association of radiolabel with
the particles which are clearly identified visually (inset of figure 2.38a). This demonstrates
that size exclusion chromatography is a viable option for the removal of unbound radiolabel.
However, although more of the radiolabelled NPs were retrieved, the particle fractions then
had to be centrifuged to ensure the small portion of 99mTc(CO3)-DPA-ale that eluted with
the particles had been removed resulting in a relatively low radiolabelling yield of 25.9
%.
2.6.6 Finalised standard radiolabelling method
The above studies were used to finalise the method of radiolabelling. Firstly, it was es-
tablished that 10 mg of PEG in the phase transfer would be optimal because, although
20 mg was shown to give a good radiolabelling yield, this is an unnecessarily large excess.
As for the heating of the reaction solution, the temperature gradient of 25 ◦C to 90 ◦C
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was continued with due to the improved removal of the activity after purification. Finally,
instead of using a PD-10 column followed by a filter, two PD-10 columns were used. The
fractions corresponding the radiolabelled particles collected from the first PD-10 column
were passed through the second to ensure all free 99mTc-DPA-ale had been removed (figure
2.38). This was decided to be an improvement on filtering the fractions from the initial
size exclusion column as with centrifugation, unbound 99mTc-DPA-ale never seemed to be
completely removed.
2.6.7 Characterisation of radiolabelled ultrasmall superparamag-
netic iron oxide nanoparticles
In order to ensure the radiolabelling procedure was not altering the hydrodynamic diameter
of the particles, DLS was run once the radioactivity of the NPs had decayed. It was found
that the DH was 24.9 ± 3.5 nm showing no change in size on the addition of the radiolabel
to the surface. Furthermore, 1H NMR of the residue after evaporation of the size exclusion
and filtration fractions/filtrates did not show any detectable PEG peaks confirming the low,
if any, PEG displacement after radiolabelling.
In order to ensure that the radiotracer was stable, a sample of radiolabelled particles was
left for 24 hours in PBS, and incubated at 37 ◦C for 48 h in human serum. These were
then centrifuged using a 100 kDa MWCO filter (as serum proteins were below this size,
hence ensuring they pass through to the filtrate) and the amount of activity remaining in
the retentate and that in the filtrate was measured as shown in tables 2.7 and 2.8. From this
the percentage of the radiolabel no longer bound to the iron oxide could be calculated.
Percentage activity, %
Filtrate 11.4
Retentate and filter 88.6
Table 2.7: Characterisation of radiolabelled NPs: Stability of radiolabelled PEG(5)-BP-
USPIOs in PBS after 24 hours at 37 ◦C.
Percentage activity, %
Filtrate 6.2
Retentate and filter 93.8
Table 2.8: Characterisation of radiolabelled NPs: Stability of radiolabelled PEG(5)-BP-




Figure 2.38: Characterisation of radiolabelled NPs: Results from (a) first (the inset is of the
first four fractions collected showing the presence of USPIOs), and (b) second size exclusion
column used to purify radiolabelled NPs.
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For PBS, it was calculated that the percentage of activity bound to the particles was 88.6
%, and for human serum 93.8 %. This result is consistent with previous findings using
dextran-coated SPIOs and other reports that have shown the high stability of the BP-iron
oxide bond (more than 4 weeks at pH 7) compared to other anchors such as carboxylates
[80, 88]. This suggests these radiolabelled particles are stable in physiological conditions
(temperature together with protein and salt concentrations) making them practical for in
vivo studies.
2.7 In vivo imaging
2.7.1 Magnetic resonance imaging
The ability of the PEG(5)-BP-USPIOs to be used as a T 1 contrast agent in vivo was then
assessed using a 3 T clinical scanner. It was found that the strong T 1 effect demonstrated in
the phantom studies was also observed in vivo. PEG(5)-BP-USPIOs were injected via the
tail vein into a BALB/c mouse leading to a significant increase in the signal intensity from
the blood. As can be seen in figure 2.39, this resulted in the vessels, heart compartments
and other highly vascularised organs such as the spleen to become clearly visible.
When designing contrast agents, a fundamental consideration is the dose required to obtain
signal enhancement. Remarkably, when compared to other USPIOs, PEG-(5)-BP-USPIOs
require a very low dose. For MR angiography in human and preclinical studies, a typical
dose of USPIOs is 40-70 µmol Fe/kg [35, 91–93]. However, administration of USPIOs at
60 µmol Fe/kg during a recent clinical study was reported to result in detrimental clinical
effects [93]. The high r1 relaxivity and low r2/r1 ratio of PEG(5)-BP-USPIOs, however,
allow us to obtain high signal enhancement with significantly lower doses. From figure
2.40 it can be seen that the dose of PEG(5)-BP-USPIOs required to obtain a similar signal
enhancement to FeraSpin XS was 4 times lower (10 µmol Fe/kg vs 40 µmol Fe/kg). This is
believed to be a result of both the optimal relaxation properties and long blood circulation
time. T 1-mapping studies of the aorta support this hypothesis. Thus, the normal relaxation
rate (R1) of blood is 0.74 ± 0.05 s−1. Forty minutes after injection of PEG(5)-BP-USPIOs,
the rate had increased more than 6-fold to 4.78 ± 1.90 s−1, whereas for FeraSpin XS this
value was 2.39 ± 0.33 s−1.
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Figure 2.39: In vivo T 1-weighted MRI studies of a mouse injected with PEG(5)-BP-USPIO
showing the increase in signal from blood in (a) the vessels, and (b) the heart at different
time points (t = 0 min, pre-injection). Labels: H = heart, S = spleen, K = kidney, A =
aorta, M = myocardium, LV = left ventricle.
Interestingly, throughout the 40 min experiment, the signal intensity in the blood when using
PEG(5)-BP-USPIOs remained constant. This is in contrast when using FeraSpin XS, where
a substantial decay of approximately 50 % was observed at the end of the 40 min time period
(figure 2.40). An important factor for blood pool MRI agents is an extended blood half-life
as it allows the acquisition of high-resolution images and could facilitate diagnosis of a series
of conditions such as tumour angiogenesis, aneurysms, and internal bleeding [94, 95]. In
addition, low RES uptake and extended circulation times are required when using targeted
USPIOs that bind to specific receptors.
The excretion route of the particles was examined using a T 2*-weighted gradient echo se-
quence. This particular sequence was chosen due to the high sensitivity in response to the
accumulation and changes in relaxivity of SPIOs in tissues [96]. T 2*-weighted imaging and
a mapping sequence were acquired before and 50 min after injection of PEG(5)-BP-USPIOs
(figure 2.41). It can be seen that there are indications of liver accumulation, and hence hep-
atic excretion which is expected for a NP of this DH. Taking into account the high signal
from the blood throughout the experiment, liver uptake must be minimal within the first
hour after injection. This low level of liver uptake can be attributed to the neutral surface
charge of the PEG(5)-BP-USPIOs and the small mean NP diameter (<50 nm) [97,98].
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Figure 2.40: Kinetic profile of the MRI signal intensity in blood obtained from PEG(5)-BP-
USPIO (black circles, 10 µmol Fe/kg dose) and FeraSpin XS (grey triangles, 40 µmol Fe/kg
dose).
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Figure 2.41: T 2* mapping of PEG(5)-BP-USPIOs before (left) and 50 min after (right)
showing accumulation of particles in the liver (highlighted area).
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2.7.2 Single photon emission computed tomography-computed to-
mography imaging
The biodistribution of the radiolabelled PEG(5)-BP-USPIOs and the fate of the BP coat-
ing was then studied using the high sensitivity of SPECT imaging. Figure 2.42 shows
the SPECT-CT imaging of live BALB/c mice 40 min and 200 min post intravenous injec-
tion.
(a) (b)
Figure 2.42: Maximum intensity projection SPECT-CT images (a) 40 min, and (b) 200
min post iv injection of radiolabelled USPIOs, colour bar for each image has the same
minimum/maximum setting. Labels: H = heart, J = jugular vein, AA = aortic arch, A =
aorta, VC = vena cava, L = liver, K = kidney, S = spleen, B = bladder.
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The SPECT-CT images obtained confirm the behaviour seen in the MR imaging. It can
clearly be seen that the majority of the radiolabelled particles remain in the bloodstream
for at least 200 min as evidenced by no decrease in the signal intensity of the heart as
well as major blood vessels and vascular organs. Figure 2.43 shows the pharmacokinetic
profile obtained from the SPECT-CT imaging performed. It was observed that the signal
of vascular organs reaches a maximum concentration before the first 45 min followed by an
elimination phase after 80 min. However, it can also be seen there is a continuous signal
increase in non-vascular organs such as the bladder and bones (knee). This is a result of
free 99mTc-DPA-ale which is released during the decomposition of PEG(5)-BP-USPIOs (vide
infra). Imaging at the first time point displayed a significant signal from the bladder which
may be a consequence of a small number of USPIOs that had a small enough DH to be
excreted with the urine [50]. A second reason may be due to a large fraction of 99mTc-DPA-
ale (∼7 % ID) detaches soon after injection. There are some indications, however, that this
option is less likely. It has been reported that injecting 99mTc-DPA-ale alone results in high
bone uptake, which would be expected at the first time point if 7 % of the injected dose
(% ID) suddenly detached from the iron oxide nanoparticles once in the bloodstream [82].
Furthermore, an immediate breaking of the BP-iron oxide bond after injection is not in
agreement with the slow rate of BP release found throughout the rest of the study and
the in vitro stability studies. A final argument is that there is a large proportion of non-
specifically bound radiolabelled BP in the injected dose but this is unlikely after the extensive





where t1/2 = elimination (blood) half-life (min)
λz = slope of the elimination phase
The blood half-life was calculated using the slope of the elimination phase in the heart
(assuming first-order single compartment pharmacokinetics, equation 2.4 [99]) and was found
to be 178 min (2.97 h). This long circulation time of the bimodal USPIOs is advantageous
as it increases the probability of reaching the destination site (e.g. tumour) before clearance
from the body [100]. Interestingly, there is no sign of significant accumulation in the liver.
On the other hand, the T 2*-weighted MRI studies in figure 2.41 reveal signs of uptake in
the liver. From reviewing previous studies, it is thought this is the result of a slow loss of
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Figure 2.43: Pharmacokinetic profile as obtained by quantification of the signal from several
tissues showing the changes in the % ID as a function of time. Data represents the mean ±
SD (n = 2 mice).
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the BP-based coating. The basis for this proposal is that throughout the duration of the
SPECT study (3.3 h), the images show a gradual increase in bone uptake due to the release
of 99mTc-DPA-ale into the bloodstream (figure 2.42b) [82]. Thus, as both PEG(5)-BP and
99mTc-DPA-ale share a BP anchoring group, it is reasonable to assume that PEG(5)-BP
is also being released. This would then increase RES uptake of the USPIOs because of
aggregation of the uncoated particles, which are only detectable by T 2*-weighted MRI, and
not SPECT scanning. Interestingly, the in vitro stability studies in human serum revealed
almost no degradation after 48 h at 37 ◦C (vide supra). This suggests that some action of
soft tissues in vivo is occurring causing the slow release of the BP components. SPECT
imaging also revealed substantial uptake in the kidneys, implying the BPs may detach
from the USPIOs via functions of the kidneys. Figure 2.44 (in addition to figures 2.42
and 2.43) supports this statement as the SPECT images clearly show accumulation in the
kidneys whereas no kidney retention is observed after injection of 99mTc-DPA-ale alone [82].
Additionally, during the experiment there was an increase in the radioactivity measured
in the urine. Particles with a hydrodynamic diameter in the range 10-50 nm are known
to be cleared through the renal system. There are two possible mechanisms by which this
may occur, either by tubular excretion or glomerular filtration. The latter being the most
ideal as particles are not metabolised internally. As this only happens for particles with
a diameter of less than 6 nm, it is most likely the clearance mechanism in this case is via
tubular excretion [19,101]. Further experiments are needed to clarify the role of the kidneys
and other tissues in the excretion and metabolism of PEG(5)-BP-USPIO.
Figure 2.44: SPECT-CT images of a mouse injected with 20 MBq of radiolabelled PEG(5)-
BP-USPIOs 40 min after injection. Close up of the abdominal area showing high signal in
the kidneys. Labels: VC = vena cava, K = kidney, IVC = inferior vena cava.
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2.7.3 Analysis of urine
Preliminary urine analysis with PEG(5)-BP-USPIOs was performed at the end of the SPECT
imaging study in order to further investigate the excretion route of the radiolabelled particles
(figures 2.45 and 2.46).
A sample of urine was collected following the 3.3 h in vivo study and passed through a size
exclusion column (as before during purification after radiolabelling), figure 2.45. As can be
seen most of the activity elutes as a broad peak in the small-molecule area. Studies using
both TLC and hydroxyapatite-binding confirmed this band to correspond to 99mTc-DPA-
ale. This indicates that if renal metabolism is taking place, it seems that a fraction of the
radioactivity is excreted in the urine once the BPs are released, whilst another is recycled
back into the bloodstream, where it binds to bone. This has previously been detailed for
other BPs [102]. Interestingly, there is also a small but detectable peak that elutes at
the same elution volume as radiolabelled PEG(5)-BP-USPIOs, suggesting a small fraction
of particles of very small size are excreted intact. This results correlates with previous
observations from the SPECT-CT imaging studies.
In addition to measuring the activity in each fraction eluted from the size exclusion column,
the iron concentration for each elution volume was evaluated, figure 2.46. A presence of
iron at 2 mL was found which corresponds to the radiolabelled NPs, as was seen previously.
There is also a high concentration found at 5 mL. This may be due to some of the radiotracer
being metabolised and therefore this peak represents smaller fragments of the probe.
2.7.4 Comparison with FeraSpin XS
Injection of radiolabelled FeraSpin XS revealed that the activity accumulated solely in the
liver and bladder 50 min after injection (figure 2.47, imaging of earlier time points could not
be achieved due to the low radiolabelling yields obtained). This is expected for FeraSpin XS
and other dextran-coated USPIOs, as this polysaccharide is avidly taken by macrophages,
providing a useful method to target these NPs to macrophage-rich tissues [103, 104]. This
result was also consistent with the MRI experiments using Feraspin XS in which there was
a 50 % reduction of signal from the blood in the first 30 min (vide supra). Other clinically
approved dextran-coated USPIOs also display short blood half-lives in mice (e.g., Sinerem,
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Figure 2.45: Characterisation of radiolabelled NPs: Size exclusion chromatogram of a urine
sample after 3.3 h injection of PEG(5)-BP-USPIO (note that 0.5 mL fractions were collected
until volume of 3 mL, whereas 1 mL fractions were collected thereafter). Most of the activity
elutes as 99mTc-DPA-ale (peak at 5 mL) whereas a small radioactive peak at 1-1.5 mL
suggests some PEG(5)-BP-USPIOs elute intact.
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Figure 2.46: Characterisation of radiolabelled NPs: Iron concentration of each fraction
collected from size exclusion column.
18 min) [77].
2.8 Targeting
The main focus of this work was vascular targets due to the long circulation time of the
particles that had previously been established. In order to add targeting ability to the
particles, it was necessary to introduce a group into the coating of the USPIOs which would
allow conjugation of biomolecules. In this case, maleimide (figure 2.48a) was chosen due
to its high stability in water and known binding to thiols which are present on the side
chain of cysteine residues [105]. Recent reports have detailed the successful conjugation of
antibodies to this imide for applications such as drug delivery as well as functionalisation
of gold NPs for potential biological uses [106,107,109]. Figure 2.48b shows the structure of
the maleimide-PEG-BP (mal-PEG(5)-BP, this has previously been shown to provide stable
functionalisation for NPs [110]) used alongside the PEG(5)-BP in the phase transfer of the
USPIOs. The method of PEGylation was identical to the previous scheme shown, with the
slight alteration of a ratio of PEG(5)-BP to mal-PEG(5)-BP being used (as shown in scheme
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Figure 2.47: SPECT-CT images of a mouse injected with 3 MBq of radiolabelled FeraSpin
XS 50 min after injection showing accumulation of particles in liver and the bladder. The
USPIOs were radiolabelled using 99mTc-DPA-ale (30 min incubation at 37 ◦C followed by




Figure 2.48: General structure of (a) maleimide, and (b) mal-PEG-BP.
Scheme 2.5: Reaction scheme for the method of PEGylation of iron oxide NPs using both
PEG(5)-BP and mal-PEG(5)-BP.
2.8.1 Characterisation of maleimide-polyethylene glycol-coated ul-
trasmall superparamagnetic iron oxide nanoparticles
Before conjugation to the targeting modality, it was necessary to ensure the introduction
of the maleimide hadn’t affected the properties of the particles. Figure 2.49 shows the
TEM obtained of the mal-PEG(5)-BP-USPIOs and the particle size was measured to be 5.6
± 0.8 nm (based on the measurement of 100 particles) showing no change in core size. IR
spectroscopy was attempted, however the maleimide peak was not visible. This was possibly
due to the low concentration of maleimide present in the sample, as well as the IR peaks
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occurring in similar positions to those for PEG. Nonetheless, the mal-PEG(5)-BP-USPIOs
reacted with a thiol-fluorophore, which demonstrated the presence of the maleimide group
on the NP surface.
Figure 2.49: Characterisation of maleimide-PEGylated Fe3O4 NPs: TEM micrograph of a
dispersion in water (DTEM = 5.6 ± 0.8 nm based on measurement of 100 particles). Scale
bar is 50 nm.
Once it had been established that the introduction of the maleimide into the coating had no
effect on the overall dimensions of the particles, relaxivity studies were performed to observe
any variation in the potential MR properties. It was found that relaxation rates at both
26 ◦C and 37 ◦C were significantly lower than those found for PEG(5)-BP. Likewise, this
was consistent across studies investigating concentration and field strength. This decrease
could be explained by a difference of hydrophilicity. If the USPIOs were coated with a more
hydrophobic molecule, the diffusion of water around the particle core would reduce resulting
in lower values for r1 and r2 [111].
In order to determine if non-specific uptake occurred, before introducing a targeting moiety,
the PEG(5)-BP-USPIOs and mal-PEG(5)-BP-USPIOs were incubated at 37 ◦C for 1 h with
a breast cancer cell line, MDA-MB-435 (although recent reports debate whether this is
the true tissue of origin for this cell line [112–115]). Both the PEGylated and maleimide-
PEGylated particles had a fluorescent component (fluorescein-mal-PEG(5)-BP) added to
the coating to allow for analysis via fluorescence-activated cell sorting (FACS). The FACS
data collected is shown in figure 2.51. There was an observed shift once the cells were
incubated with the fluorescent PEG(5)-BP-USPIOs corresponding to non-specific binding.
This is most likely due to pinocytosis processes taking place [116–119]. A further shift was
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Figure 2.50: Relaxivity characterisation of mal-PEGylated Fe3O4 NPs: Variation of spin-
lattice relaxation rate (R1; solid black line) and spin-spin relaxation rate (R2; dashed grey
line) with temperature for mal-PEG(5)-BP-USPIOs.
detected when the cells were incubated with the mal-PEG(5)-BP-USPIOs (with the free
maleimide groups on the surface), owing to binding with free thiols that are present on the
cell membrane [120–122]. This result was further confirmed by fluorescence cell imaging,
figure 2.52 displays the images captured, with figure 2.52a being MDA-MB-435’s only, and
figure 2.52b being the cells that were incubated with mal-PEG(5)-BP-USPIOs. The first
image is the transmitted light (TRANS), the second is the 4’,6-diamidino-2-phenylindole
(DAPI) showing the nuclei of the cells and the third is the green fluorescent channel (GFC).
The GFC images show that for the cells alone, no autofluorescence was revealed. However,
for the cells which have been incubated with the maleimide-PEG coated particles, there is
emission due to the fluorescein present. This agrees with the results found by FACS and
verifies there is some binding to the surface of the cells.
2.8.2 Prostate-Specific Membrane Antigen
The first target to investigate was the prostate-specific membrane antigen (PSMA). This is
a transmembrane protein expressed in all types of prostatic tissue with elevated expression
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Figure 2.51: In vitro characterisation of PEGylated Fe3O4 NPs: FACS data showing binding
of PEG(5)-BP-USPIOs and mal-PEG(5)-BP-USPIOs to MDA-MB-435 cells.
Figure 2.52: In vitro characterisation of PEGylated Fe3O4 NPs: Fluorescence microscopy
images of (a) MDA-MB-435 cells only, and (b) MDA-MB-435 cells incubated with mal-
PEG(5)-BP-USPIOs. All microscope/fluorescence settings were identical for both acquisi-
tions.
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found in all prostate cancers; the highest levels found in high-grade, hormone-refractory and
metastatic disease [123–129]. Several groups have recently published high-contrast images
of prostate cancer achieved using PSMA-targeted ligands [130, 131], and it has also been
proposed that the degree of PSMA expression may be an indicator of disease outcome
[132, 133]. In this case, a single chain variable fragment (scFv) was used, as depicted in
figure 2.53. The basic structure consists of variable regions of the heavy chain (VH) which
link to variable regions of the light chain (VL). The N-terminal at beginning of heavy
chain is an amine group and the C-terminal at end of the light chain is a carboxylic acid.
A fragment of the antibody J591 was used which has 6 consecutive histidines (a Histag)
and a cysteine conjugated to the C-terminal. Previous work in several groups, including
this group, has established the targeting ability of this antibody, and provided an ideal
starting point to evaluate the possibility of targeting to specific cell-surface receptors (i.e.
PSMA). [134–139].
Figure 2.53: General structure of (a) an antibody, and (b) a scFv.
This conjugation was performed in two steps as shown in scheme 2.6. The first was to reduce
J591 using dithiothreitol (DTT) in order to remove dimers which form due to disulfide bonds
between two cysteines. This was then passed through a size exclusion column to remove
excess DTT and the reduced J591 was eluted directly into the mal-PEG(5)-BP-USPIOs.
The incubation period was 2 h at room temperature, after which purification occurred via
an A¨KTA chromatography system (Superose 6, 10/300 GL Tricorn column). Figures 2.54
and 2.55 shows the size exclusion chromatograms for J591 in PBS, mal-PEG(5)-BP-USPIOs
and also for the conjugation solution containing J591 and mal-PEG(5)-BP-USPIOs. It can
be seen there is a good separation between the J591 conjugated USPIOs (first peak as known
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from figure 2.54a) and the excess J591 (later peaks at 15 mL, 17 mL and 20 mL, known
from figure 2.54b). This ensured there was no unbound scFv in the NP fractions. The
elution volume for J591 is expected to be present at 17 mL. It is thought that the small
peak observed at 15 mL is due a small population of reformed dimers, whereas the origin of
the peak at 20 mL is unknown.
Scheme 2.6: Reaction scheme for the method of targeting of mal-PEG(5)-BP-USPIOs.
Cell binding was tested using two relevant cell lines. The cell line chosen was DU145 which
are human prostate cancer cells [140]. The control run was the DU145 cells with no alter-
ations, with the cells then used to examine the targeting properties of the USPIOs being
DU145 transduced in order to express PSMA in high levels (DU145-PSMA). To measure
binding, FACS was performed requiring the introduction of a fluorophore. The fluorophore
was in the form of Penta ·His Alexa Fluor 488, a secondary (2◦) antibody that binds to the
J591 conjugated to the NPs. Three samples of cells where prepared for each cell line to allow
for the following to be run: (1) sample containing cells only, (2) sample containing cells in-
cubated with the secondary antibody only, and (3) sample incubated with targeted USPIOs
followed by the secondary antibody. The sample incubated with the secondary antibody
only was to ensure any uptake observed wasn’t from binding of the 2◦ antibody to PSMA.
The FACS results can be seen in figure 2.56. In figure 2.56a, the cells incubated with the 2◦
antibody only exhibit a shift in signal from the cells background indicating some non-specific
binding of Penta · His Alexa Fluor 488. The further shift with the sample containing both
the targeting NPs and the 2◦ antibody again demonstrates non-specific binding, this time




Figure 2.54: Characterisation of maleimide-PEGylated Fe3O4 NPs and J591: Size exclusion
chromatogram (intensity plot) of (a) mal-PEG(5)-BP-USPIOs in PBS, and (b) J591 in PBS.
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Figure 2.55: Characterisation of J591 targeted Fe3O4 NPs: Size exclusion chromatogram
(intensity plot) of J591 conjugated to mal-PEG(5)-BP-USPIOs in PBS.
DU145-PSMA, it was hoped that there would be an increase in the shift of the signal for
the J591-PEG(5)-BP-USPIOs. Focusing on figure 2.56b, it can be seen that there is again
the nonspecific binding of the 2◦ antibody, but with the targeted USPIOs there is indeed a
larger shift which is representative of binding. Note, the broad peak is due to the cells not
possessing the same level of expression of the protein accounted for by the inefficiency of
the transduction process, and this has also been observed when using J591 only [134]. This
result confirms an increase in uptake of the USPIOs, hence proving the concept of targeting
PSMA in vitro.
The initial approach for radiolabelling the targeted USPIOs was to use the His-tag se-
quences on the J591 to directly radiolabel (scheme 2.7a) with the technetium tricarbonyl
as it is known that His-tags are excellent [99mTc(CO)3]
+ coordinators [141, 142]. This was
attempted alongside the radiolabelled BP method (scheme 2.7b) previously described. Both
samples were incubated for 1 h at 37 ◦C (it was not possible to use the temperature gradient
as before as higher temperatures would cause the protein to unfold and hence reduce binding
capability). The particles were then purified as before using size exclusion columns, how-
ever a combination of a PD MiniTrap (Sephadex G-25 medium) was used followed by a PD
MidiTrap (Sephadex G-25 medium) in order to acquire a more concentrated radiolabelled
NP sample. Radiolabelling yields were poor for both, direct conjugation resulting in 1 %
and BP conjugation gave 4 %, nonetheless this was sufficient enough to enable a cell binding




Figure 2.56: In vitro characterisation of J591 targeted Fe3O4 NPs: FACS data showing






Scheme 2.7: Graphical representation for the methods of radiolabelling of targeted mal-
PEG(5)-BP-USPIOs via (a) direct conjugation to Histags, and (b) conjugation using a BP.
The radiolabelled sample (using the BP method) was incubated with DU145 and DU145-
PSMA cells, half at 37 ◦C and half on ice for same period of time. These temperatures
were chosen so the binding of the particles to the cell membrane could be investigated (the
sample on ice) as well as the binding at the physiological temperature (the sample at 37 ◦C).
The plot in figure 2.57 shows higher activity present in the transduced cells, with increased
uptake exhibited by the cells incubated with the NPs at 37 ◦C. This result was expected
due to internalisation processes occurring.
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Figure 2.57: In vitro characterisation of radiolabelled J591 targeted Fe3O4 NPs: Cell binding
of radiolabelled J591-PEG(5)-BP-USPIOs.
2.8.3 Vascular Cell Adhesion Protein 1
The next target to be investigated was vascular cell adhesion protein 1 (VCAM-1). This is
expressed on activated endothelial cells and its role is to recruit lymphocytes and monocytes
during the early stages of inflammation and atherogenesis, leading to plaque formation.
This makes VCAM-1 an attractive target for early imaging and therapy of atherosclerosis
[143–149]. The conjugation method was identical to that of PSMA (scheme 2.6), however
in this case the antibody fragment used was called 6C7.1 [150]. Due to the successful
separation of excess antibody fragment from the targeted USPIOs above, purification was
performed using the A¨KTA. Again, two distinct peaks were observed very similar to previous
observations, as can be seen in figure 2.58.
Cell binding studies were implemented in same way as for the PSMA studies. The cell
line chosen was HEK 293T, a derivative of the human embryonic kidney 293 cells. One
main reason this cell line was selected is due to the fact that they are highly transfectable
[151] allowing for high levels of expression of VCAM-1 (this cell line has been labeled HEK
293T VCAM). As before, the samples run were (1) sample containing cells only, (2) sample
containing cells incubated with the secondary antibody (as before) only, and (3) sample
incubated with targeted USPIOs (6C7.1-PEG(5)-BP-USPIOs) followed by the secondary
antibody. However, an additional control of the antibody fragment tagged with fluorescein
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Figure 2.58: Characterisation of 6C7.1 targeted Fe3O4 NPs: Size exclusion chromatogram
(intensity plot) of 6C7.1 conjugated to mal-PEG(5)-BP-USPIOs in PBS.
was conducted. This is known to target VCAM-1 from previous work in the group, and
was used to verify any uptake detected was as a consequence of binding to the correct
receptor.
Figure 2.59a displays some non-specific binding of both the 2◦ antibody and 6C7.1-PEG(5)-
BP-USPIOs, yet no shift is observed for the fluorescein conjugated antibody fragment. Ex-
amining figure 2.59b reveals a significantly larger shift for both the targeted USPIOs and the
fluorescein conjugated particles confirming targeted binding of the particles. The notably
broad peak is due to the poor efficiency of transfection which leaves some cells expressing
none of the receptor, and others expressing VCAM-1 to a higher degree. Again, this has
been observed when using 6C7.1 only.
Once it was established that the targeting modality was successful, the next stage was to
introduce the radionuclide. This time only the bisphosphonate method was carried out due
to the slightly higher radiolabelling yield, again at 37 ◦C in order to prevent any damage to
the antibody fragment. Once radiolabelling was complete, the particles were purified using
the A¨KTA. Plot 2.60 shows two peaks, the first corresponds to radiolabelled NPs and the
second to unbound radiolabelled BP. The fractions were collected and the activity counted
(figure 2.61). It was found that the majority of the activity had not bound to the particles,
in fact only 0.5 MBq (radiolabelling yield of 0.4 %) appeared to have associated with the
USPIOs. It is assumed that this particularly low yield is a result of no longer being able to




Figure 2.59: In vitro characterisation of 6C7.1 targeted Fe3O4 NPs: FACS data showing
binding of 6C7.1-PEG(5)-BP-USPIOs to (a) HEK 293T cells, and (b) HEK 293T cells
transfected to express VCAM-1.
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Figure 2.60: Characterisation of radiolabelled 6C7.1 targeted Fe3O4 NPs: Size exclusion
chromatogram (intensity plot) of radiolabelled 6C7.1-PEG(5)-BP-USPIOs.
Figure 2.61: Characterisation of radiolabelled 6C7.1 targeted Fe3O4 NPs: Elution profile of
radiolabelled 6C7.1-PEG(5)-BP-USPIOs
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A cell binding experiment was performed thereafter with the radiolabelled NP fractions ob-
tained (fraction A9 in figure 2.61), again to ensure the radiolabel was having no detrimental
effect on the targeting abilities of the particles. As was confirmed with PSMA studies, in-
troducing 99mTc did not impair VCAM-1 targeting. Figure 2.62 shows a higher count is
present in the transfected cells, with some activity in the control cells due to nonspecific
uptake which was previously established by FACS. This indicates the targeted USPIOs bind
to the VCAM-1 positive cells to a far greater degree than to the VCAM-1 negative cells. The
data collected here confirms that after radiolabelling, the targeting aspect of the USPIOs
remains.
Figure 2.62: In vitro characterisation of radiolabelled 6C7.1 targeted Fe3O4 NPs: Cell
binding of radiolabelled 6C7.1-PEG(5)-BP-USPIOs
Despite the poor efficient of the radiolabelling procedure, no further investigation into routes
for improvement were conducted due to the limited quantities of the antibody fragment
available.
2.8.4 p32 receptor
The next targeting moiety chosen was a 9-amino acid cyclic peptide called LyP-1 [152].
Previous studies on MDA-MB-435 cells has identified that LyP-1 binds to tumours, in par-
ticular the receptor p32 [153–155]. Human p32 (also known as SF2-associated p32, p32/TAP,
and gC1qR) has a doughnut-shaped quaternary structure formed from three molecules re-
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sulting in a considerable central channel and an asymmetric charge distribution on the
surface [156]. This receptor is intracellular in normal cells but is extracellular and over
expressed not only in the tumour but in several compartments, for example the lymphatics
and tumour-associated macrophages [157, 158]. It has also been shown that LyP-1 has NP
tumour penetrating properties [159–162].
The method used for conjugating the LyP-1 peptide to the USPIOs was similar to the
previous two targeting functionalisations, however in this case the first step of reducing the
disulphide bonds with DTT was not required. As before, purification was performed using
the A¨KTA system. Figure 2.63 shows the profile of the eluted sample, with the distinct
separation of the particles and peptide as expected.
Figure 2.63: Characterisation of LyP-1 targeted Fe3O4 NPs: Size exclusion chromatogram
(intensity plot) of LyP-1-PEG(5)-BP-USPIOs.
In order to ensure introduction of the peptide wasn’t inducing particle core etching, TEM
imaging was performed. Figure 2.64 shows LyP-1-PEG(5)-BP-USPIOs and it can be seen
that there was no change in DTEM (5.7 ± 0.8 nm based on the measurement of 100 parti-
cles).
Fogal et al. identified several cell lines expressing p32 on the surface, including MDA-MB-
435, MDA-MB-231 and MCF7 (human breast cancer cell lines), and finally 4T1 (mouse
breast cancer cells) [159]. Due to the highest uptake being observed with MDA-MB-435
cells, these were the focus of the cell binding analysis, which were performed in same way
as for the PSMA and VCAM-1 studies. Several samples were run: (1) sample contain-
ing cells only, (2) sample containing cells incubated with LyP-1 tagged with a fluorescent
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Figure 2.64: Characterisation of LyP-1 targeted Fe3O4 NPs: TEM micrograph of a disper-
sion in water (DTEM = 5.7 ± 0.8 nm based on measurement of 100 particles). Scale bar is
20 nm.
component (carboxytetramethylrhodamine; TAMRA), (3) sample incubated with targeted
USPIOs (functionalised using the TAMRA tagged LyP-1), and (4) a blocking experiment
whereby the cells were initially incubated with a non-fluorescent version of the LyP-1 pep-
tide (85 µM) for 30 min at 37 ◦C, followed by incubation with the targeted NPs. The results
revealed maximum uptake from the blocking experiment which appears to be equivalent to
the shift detected with the targeted NPs plus the shift from the peptide only. The observed
increase in accumulation may have been a result of the blocking peptide aiding in NP uptake.
The FACS results were then corroborated using fluorescence microscopy. Images obtained
are of cells only (figure 2.66a), blocking peptide and the targeted NPs (figure 2.66b), then
two concentrations of targeted NPs, 25 µL (figure 2.66c) and 200 µL (figure 2.66d). The
images gathered from the fluorescent peptide only were too bright to show. It can be seen
that the microscopy confirms the results collected from FACS.
2.9 Conclusions
The phase transfer of a PEG polymer containing a bisphosphonate anchor for strong binding
to the surface of iron oxide materials has been described, and is capable of generating
hydrophilic USPIOs using a simple and fast method. Using this method, a colloidally stable
PEGylated USPIO has been synthesised that can be stored as a dispersion in water or
saline for several months without changes in DH. PEG(5)-BP-USPIOs could be used as
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Figure 2.65: FACs data showing binding of LyP-1-PEG(5)-BP-USPIOs to MDA-MB-435
cells.
an effective contrast agent for T 1-weighted imaging, which is attributed to the high r1 and
low r2 relaxivities, a result of the optimal size of the superparamagnetic iron oxide core and
stable hydrophilic coating. From reviewing the literature it appears these may be the highest
r1 and lowest r2/r1 (2.97) reported to date at B0 of 3 T. In vivo studies demonstrated the
potential of PEG(5)-BP-USPIOs as a contrast agent for MRI angiography. After intravenous
injection in mice, the signal in the blood increased 6-fold for the duration of the experiment
at a lower dose (4-fold) of contrast agent compared to other USPIOs to obtain a similar signal
enhancement. The MRI study revealed minor accumulation of USPIOs in the liver. PEG(5)-
BP-USPIOs could also be radiolabelled using a BP, 99mTc-DPA-ale, that allowed tracking
of the NPs using SPECT imaging with high sensitivity and quantification capabilities. The
in vivo imaging study confirmed the MRI results, showing long blood circulation times
(t1/2 = 2.97 h). In addition, the SPECT study provided important information about the
fate of PEG(5)-BP-USPIOs and its components. 99mTc-DPA-ale was slowly released into
the urine and the bloodstream and led to the hypothesis that the same maybe occurring
to PEG(5)-BP. Interestingly, uptake in the kidneys suggested this organ is playing a role
in the decomposition of PEG(5)-BP-USPIOs. Further studies, however, are warranted to
understand its excretion properties. Targeting studies were performed to examine the ability
to functionalise these particles in order to provide better detectability and quantification
capabilities of vascular targets involved in cardiovascular and oncologic diseases. In vitro
cell binding studies were performed on three individual targets, PSMA, VCAM-1 and p32,
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Figure 2.66: In vitro characterisation of LyP-1 targeted Fe3O4 NPs: Fluorescence mi-
croscopy images of (a) MDA-MB-435 cells only, (b) MDA-MB-435 cells incubated with
blocking peptide followed by 200 µL of LyP-1-mal-PEG(5)-BP-USPIOs, (c) MDA-MB-435
cells incubated with 25 µL of LyP-1-PEG(5)-BP-USPIOs, and (d) MDA-MB-435 cells incu-
bated with 200 µL of LyP-1-PEG(5)-BP-USPIOs.
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and revealed successful binding in all cases as proved by FACS and fluorescence microscopy.
In addition, once the radionuclide component had been introduced into the coating of the
targeted particles, cell binding was still observed, demonstrating the potential of this probe
to be used for targeted dual modality applications.
This work demonstrates that the surface functionalisation with PEG-BPs is an effective
method for developing highly stable USPIOs with low RES uptake and long blood circu-
lation times, which are the major limitations in the development of targeted USPIOs for
biomedical imaging. Furthermore, PEG(5)-BP-USPIOs represent a promising platform for
the development of agents for multimodal medical imaging and these compounds could find
applications with the new generation of multimodal clinical scanners.
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Once phase transfer of Fe3O4 NPs using PEG(5)-BP had been established and subsequent
in vivo imaging was successful, studies into whether this method of PEGylation was possible
with other materials, in particular CdZnSeS alloyed QDs, were performed. This particu-
lar material was chosen for several reasons, the principle being the longer wavelength red
emission is beneficial in in vivo applications as biological autoflurorescence, absorbance and
scattering is minimised in this region [1, 2]. In addition, tissue depth penetration is in-
creased [3].
This chapter will describe the synthesis used to produce the red emitting QDs, followed
by optical and size characterisation of the synthesised and PEGylated particles. Finally,
preliminary macrophage cell studies will be described.
3.2 Synthesis of CdZnSeS alloyed quantum dots
The synthesis used to prepare the CdZnSeS alloyed QDs was a modification of a single-
step method reported by Bae et al. which involved the thermolysis of precursor solutions
containing Cd, Zn, Se and S [4]. The developed scheme was accomplished by a collaborator
at the University of Oxford, and was chosen on account of previous results showing that
this facile procedure produced monodisperse, bright red emitting nanocrystals [5]. From
scheme 3.1 it can be seen that the synthesis involved preparation of a solution containing
Cd and Zn, followed by injection of a S-Se TOP solution which was maintained at a high
temperature for several minutes to allow for particle growth. The surfactant used in this
synthesis was oleic acid, and figure 3.1 illustrates both the oleic acid coated QD produced
and the binding of the molecule through the carboxyl group to the QD surface.
During the particle growth stage of the synthesis, aliquots of the reaction solution were
obtained and can be seen in figure 3.2. The colour photo clearly demonstrated the prevalent
size-tuneable fluorescent properties of semiconductor nanoparticles, ranging from ∼560 nm
to ∼610 nm [6]. This was further confirmed by TEM with a particle size of 3.4 ± 0.4 nm
(based on the measurement of 30 particles; figure 3.3a) measured for the aliquot taken at 2
min, and a final size of 4.2 ± 0.6 nm (based on the measurement of 86 particles; figure 3.3b).
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Scheme 3.1: Reaction scheme for the synthesis of CdZnSeS alloyed QDs [5].
Figure 3.1: Schematic representation of oleic acid binding to a quantum dot via the carboxyl
group.
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It was not possible to perform DLS studies on the particles to determine the hydrodynamic
diameters, presumably due to the similarity in emission wavelength of the QDs with the
zetasizer light source (a He-Ne laser with a wavelength of 633 nm [7]) resulting in inference
of the scattered laser beam and detection.
Figure 3.2: Aliquots of CdZnSeS alloyed QDs in hexane taken after injection of the sele-
nium/sulphur precursor solution at time points of 30 sec, 1 min, and every min thereafter
(vials arranged left to right).
(a) (b)
Figure 3.3: Characterisation of synthesised QDs: TEM micrograph of oleic acid coated
CdZnSeS alloyed QDs in hexane after (a) 2 min (DTEM = 3.4 ± 0.4 nm based on the mea-
surement of 25 particles), and (b) 5 min (DTEM = 4.2 ± 0.6 nm based on the measurement
of 86 particles). Scale bars are 20 nm.
For the remainder of this study only the final aliquot was analysed in view of the reasons
highlighted earlier related to emission wavelength. Figure 3.4 displays the absorption and
emission profiles for CdZnSeS QDs, with emission at a wavelength of 604.0 nm.
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Figure 3.4: Characterisation of synthesised QDs: Absorption and emission spectra of
CdZnSeS alloyed QDs in hexane (λabs = 593.5 nm, λems = 604.0 nm).
3.3 Polyethylene glycol phase transfer of CdZnSeS al-
loyed quantum dots
The scheme employed to PEGylate the alloyed nanocrystals was different to that for the
iron oxide NPs, and is represented in scheme 3.2. An immiscible mixture of QDs in hexane
and PEG(5)-BP in water was formed and left stirring overnight, after which ligand exchange
had occurred and the CdZnSeS particles were coated with PEG(5)-BP. This adjustment was
made due to the QDs being dispersed in hexane after synthesis, rather than in a dried state
as for the iron oxide. The molecular weight of the PEG-BP used was 5000 Da as before
owing to the favourable properties bestowed to the magnetite NPs proceeding PEGylation.
Figure 3.5 confirms PEGylation was successful. The vial on the left contains the alloyed
particles in hexane, and the vial on the right contains the particles in water. It is apparent
that the particles transferred to water displayed no significant shift in either absorption or
emission wavelengths with some reduction in the quantum yield. Optical characterisation,
figure 3.6, verified this finding (λabs = 592.0 nm, λems = 606.0 nm). Finally, TEM analysis
of the PEGylated quantum dots was performed and displayed no change in the core size
with the sample remaining spherical and monodispersed (figure 3.7).
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Scheme 3.2: Reaction scheme for the the method of PEGylation of CdZnSeS alloyed QDs
using DCM.
(a) (b)
Figure 3.5: Photograph of (a) CdZnSeS alloyed QDs coated with oleic acid in hexane (right
vial is photo excited at 365 nm in the dark), and (b) PEG(5)-BP coated CdZnSeS alloyed
QDs in water (right vial is photo excited at 365 nm in the dark).
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Figure 3.6: Characterisation of PEGylated QDs: Absorption and emission spectra of
PEG(5)-BP coated CdZnSeS alloyed QDs in water (λabs = 592.0 nm, λems = 606.0 nm).
Figure 3.7: Characterisation of PEGylated QDs: TEM micrograph of PEG(5)-BP coated
CdZnSeS alloyed QDs in water (DTEM = 4.4 ± 0.5 nm based on the measurement of 100
particles). Scale bar is 20 nm.
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3.4 In vitro cell uptake study
Once PEGylation of the CdZnSeS alloyed QDs had been established, in vitro confocal studies
with J774 murine macrophage cells were performed in order to determine the stability of
the particles in a biological environment. This study was performed in collaboration with
Dr. Lea Ann Dailey in the Institute of Pharmaceutical Science at Kings College London.
As it can be seen from figure 3.8, there is a certain measure of accumulation of the PEG(5)-
BP-QDs in the cells, with the z-stack image revealing some internalisation, suggested by
the bottom image of figure 3.8b which looks to show QDs throughout cells. Although
PEGylation of nanoparticles is well-known to reduce macrophage uptake, there will always
be a small degree of uptake [8–10]. This study confirmed the bond between the QD surface
and BP was stable in cell media. If PEG(5)-BP had detached from the particle surface,
aggregation would have occurred, resulting in all QDs being removed during the sample
preparation for confocal microscopy.
3.5 Introduction of maleimide-polyethylene glycol into
coating
To allow for potential targeted bioapplications, mal-PEG(5)-BP was introduced into the
phase transfer in the manner as the PEGylation in scheme 3.2, with the same ratio as
used for the iron oxide particles. The transfer of the QDs into an aqueous phase with the
combination of PEG molecules appeared to result in full dispersion in water. However, no
further characterisation was performed.
3.6 Conclusions
In conclusion, the simple method of PEGylation described in chapter 2 has been success-
fully applied to alloyed quantum dots. The emission profile of the particles remained largely
unchanged, with some reduction in the quantum yield. TEM characterisation of the re-
sulting water-soluble NPs displayed no change in morphology or core size. In vitro studies




Figure 3.8: In vitro characterisation of PEGylated QDs: Confocal imaging of J774 murine
macrophage cells incubated with PEG(5)-BP coated CdZnSeS alloyed QDs, with (a) showing
a top view, and (b) showing a top view and the corresponding z-stack. Scale bar is 11.9 µm.
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physiological temperature, with some macrophage cell uptake observed. In addition, the in-
troduction of the maleimide-PEG(5)-BP into the coating allows for the possibility of further
functionalisation by the addition of biomarkers.
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Once phase transfer and surface modification of Fe3O4 NPs and CdZnSeS alloyed QDs had
been accomplished, further investigation into an alternative coating was performed in the
hope that a simple method of functionalisation would be achieved involving a naturally oc-
curring amphiphile. In order to do this, a recombinant protein named H*Protein B (BASF)
which consists of the class I hydrophobin DewA (from the filamentous fungi A. nidulans) and
40 N-terminal amino acids of the Bacillus subtilis protein yaaD, with a molecular weight of
18.8 kDa and a size of ca. 1.2 nm [1,2] was used (for more details on hydrophobins see page
42 of the introduction). This particular protein was chosen due to its high stability [3] and
several reports stating that hydrophobins have previously been utilised to stabilise particles
of different materials, for example boehmite and silicon [4–6].
This chapter will describe the hydrophobin encapsulation of inorganic NPs with all associ-
ated optical and size characterisation. The in vitro and in vivo studies performed will be
detailed, concluding with the radiolabelling of the protein-coated QDs.
4.1.1 Protein passivation of nanoparticles
Several inorganic nanoparticles were used during this study, namely CdSe/ZnS core-shell
QDs coated with hexadecylamine (HDA; Lumidot 590) or HDA/TOPO (prepared in-house
using methods described by Qu et al. [7] and Talapin et al. [8]), CdSeS/ZnS core-shell QDs
coated with oleic acid and Fe3O4 coated with oleylamine (synthesised using the method
described in chapter 2). The previously synthesised CdZnSeS alloyed QDs were attempted
several times unsuccessfully, the reason for which is unknown. The phase transfer to water
involved a simple technique shown in scheme 4.1, and prior to this, the hydrophobin solution
was diluted in water and left standing to prevent self-assembly of the protein which has
previously been proved to occur (figure 4.1; for further details see experimental). To this
was added a non-polar organic solution of particles followed by sonication, producing a
cloudy emulsion. After a brief storage period at low temperature and filtration, centrifugal
concentration and further dilution with water, a transparent aqueous solution of particles was
obtained. Centrifugal concentration was found to be essential, as this step removed excess
protein and significantly increased cell viability when the particles were used in imaging
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applications. It is believed the amphiphilic nature of the protein was exploited by inter-
digitating the aliphatic chain of the protein with the hydrophobic capping agent of the
quantum dot, leaving the cysteine-rich hydrophilic region exposed to solution, making the
composite water-soluble and stable in a range of buffer solutions. Hydrophobins are known to
be robust and it is unlikely that sonication affected the structure. For example, it is suggested
that class II hydrophobins keep their secondary and ternary structure after exposure to
sodium dodecylsulphate, a compound routinely used to denature proteins [9]. In addition,
ultrasound treatment has been applied in some phase transfer reactions, showing no evidence
of protein unfolding [10].
Scheme 4.1: Reaction scheme for the method of encapsulation of particles with hydrophobin.
Figure 4.1: Characterisation of hydrophobin: DLS number distributions of 150 µL of
H*Protein B diluted with 3 mL of water. Measurements taken at 0 min (blue), 10 min




Once phase transfer was achieved, analysis of the resulting water-soluble QDs (in particular
CdSe/ZnS and CdSeS/ZnS) was performed to ensure there was no considerable change in
the optical properties. A typical example is shown in figure 4.2 and it is evident that the
particles transferred to water displayed no significant shift in either absorption or emission
wavelengths. Although generally the emission quantum yield was reduced by up to 50 %
due to a small degree of degradation of the surface, the solution still emitted brightly under
365 nm excitation (figure 4.3b).
Figure 4.2: Characterisation of hydrophobin-QDs: Absorption and emission spectra of Cd-
SeS/ZnS QDs before phase transfer in toluene (black solid line; λabs = 613.0 nm, λems =
625.5 nm), and after phase transfer with H*Protein B in water (grey dashed line; λabs =
613.0 nm, λems = 627.5 nm).
Transmission electron microscopy and dynamic light scattering
Once it had been established that there was no shift in emission wavelength once encapsu-
lation had occurred, the size of the particles needed to be determined. TEM revealed a high
proportion of the CdSeS/ZnS quantum dots remained as discreet individual particles after
phase transfer with no change in core size (figure 4.4b), although they were occasionally
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(a) (b)
Figure 4.3: Photograph of (a) CdSeS/ZnS QDs coated with oleic acid in toluene (right vial
is photo excited at 365 nm in the dark), (b) H*Protein B coated CdSeS/ZnS QDs in water
(right vial is photo excited at 365 nm in the dark).
observed to cluster (figure 4.4c). This was attributed to the hydrophobin encapsulating
multiple quantum dots into aggregates as shown in figure 4.5. In addition, encapsulation of
Fe3O4 NPs was performed, and it can be seen from figure 4.4d that again, some agglomerates
were formed but most particles continued to exist separately. DLS studies suggested that
the CdSeS/ZnS particles, 4.6 ± 0.8 nm in diameter as determined by electron microscopy
(based on the measurement of 50 particles), had an initial DH of 42.4 ± 24.9 nm (with a
PDI of 0.22) once coated, however it was observed that this value dropped to 14.2 ± 2.7 nm
(PDI of 0.25) after 2 months with no aggregation occurring. The reason for this is unknown.
For hydrophobin-coated CdSe/ZnS QDs (core size of ca. 5 nm), the DH was found to be
ca. 9 nm although diameters of up to ca. 60 nm were occasionally observed, attributed to
clustering in solution or free protein agglomerates.
Zeta potential
The zeta potential of the hydrophobin-capped quantum dots was -42.8 ± 8.8 mV, which is
in agreement with the charge expected of a protein and confirms good colloidal stability due
to the high degree of electrostatic repulsion [11].
Analytical ultracentrifugation
Hydrophobin-stabilised QDs (CdSe/ZnS) were subjected to analytical ultracentrifugation
(AUC) in order to compare the conjugates to freely dissolved hydrophobins [1]. This study




Figure 4.4: Characterisation of hydrophobin-QDs: TEM micrograph of (a) CdSeS/ZnS QDs
coated with oleic acid in toluene (DTEM = 4.6 ± 0.8 nm based on the measurement of 50
particles), (b) H*Protein B coated CdSeS/ZnS QDs in water (DTEM = 4.9 ± 0.8 nm based
on the measurement of 70 particles), (c) H*Protein B coated CdSeS/ZnS QDs in water
showing evidence of clustering on the grid, and (d) H*Protein B coated Fe3O4 NPs in water
(DTEM = 4.9 ± 0.5 nm based on the measurement of 80 particles). Scale bars are 20 nm
for (a,b) and 50 nm for (c,d).
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Figure 4.5: Schematic representation of hydrophobin encapsulation of multiple nanoparti-
cles.
coefficients was bimodal with a very small shoulder/feature at the lowest sedimentation
coefficients (figure 4.6). This shoulder corresponded to about 0.01 mg/mL of non-adsorbed
protein, as quantified by the refractive index detector during fractionation. The molar mass
of this fraction (as derived from the distribution of sedimentation coefficients) ranged from
50 kDa to 150 kDa and was hence comparable with free hydrophobin aggregates. Evaluating
the main peak of the distribution of sedimentation coefficients, a diameter distribution with
D50 = 4.2 nm, D90 = 9.7 nm was obtained (figure 4.7). An independent experiment with
a UV/VIS detector synchronised to the centrifuge, tuned to 520 nm, confirmed that this
distribution was selective for the QDs and did not contain signal from any macromolecules.
Since the hydrodynamic diameter values matched the diameters from TEM and dynamic
light scattering data, we can conclude that the QDs are extremely well-dispersed in water
without measurable agglomeration (<5 %). Using a refractive index increment of dn/dc =
0.163 mL/mg, we determined the actual dispersed concentration of QDs was 0.45 mg/mL
represented by the distribution shown in figure 4.7.
Secondary-ion mass spectrometry
Further, the stabilised QDs were also analysed by secondary-ion mass spectrometry (SIMS;
technique by which the mass/charge ratios of secondary ions ejected from a specimen sput-
tered by a primary ion beam are measured), in order to compare their surface to free quan-
tum dots and hydrophobins [12]. Apart from sodium salts, only traces of cadmium, zinc
and selenium were detected. However, significant and characteristic even-numbered protein
peaks were found in both positive and negative ion spectra (marked as blue dots in figure
4.8), which are characteristic of the hydrophobin [12]. Therefore, it is concluded that the
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Figure 4.6: Characterisation of hydrophobin-QDs: Raw data and fit of AUC of the QD
suspension after phase transfer, showing the bimodality of a small peak of slowly sedimenting
organics, identified by their molar mass as non-bound H*Protein B, and the main peak of
H*Protein B coated CdSeS/ZnS QDs.
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Figure 4.7: Characterisation of hydrophobin-QDs: Volume distribution of H*Protein B
coated CdSeS/ZnS QDs as derived from AUC (raw data shown in figure 4.6).
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QDs are effectively covered by hydrophobins, with vanishing physiological visibility of the
inorganic core.
Figure 4.8: Characterisation of hydrophobin-QDs: SIMS of H*Protein B coated CdSeS/ZnS
QDs after washing. Blue dots identify the characteristic hydrophobin ions (positive: 56 u,
62 u, 70 u, 72 u, 84 u, 104 u, 120 u; negative: 66 u, 70 u, 82 u, 84 u, 90 u, 100 u, 110 u, 124
u) [12].
4.2 In vitro/vivo studies
Hydrophobin-capped QDs were then used in labelling experiments in order to establish
the potential for using this system in in vivo applications such as imaging and drug deliv-
ery.
4.2.1 Ovarian and breast cancer cells
In vitro labelling was explored by incubating the hydrophobin-CdSe/ZnS QDs with ovarian
cancer cells (IGROV-1; figure 4.9), whilst in vitro labelling of breast cancer (MDA-MB-
231 cells) was carried out alongside in vivo imaging of intratumourly injected particles
administered to a live mouse model (figures 4.10 and 4.11). These studies were performed in
collaboration with Dr. Maya Thanou in the Institute of Pharmaceutical Science at King’s
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College London. In both cases, successful endocytosis of the particles was observed, with
strong QD emission clearly visible from the biological tissues. In the in vivo study, the
particles were clearly observed 3 hours post-injection but found to largely clear from the
tumour site after a further 24 hours, potentially via the lymphatic system as indicated by
possible popliteal lymph node uptake. A scab was observed (96 hours post-injection) on the
surface of the tumour that still exhibited a profile consistent with the presence of luminescent
quantum dots.
Figure 4.9: In vitro characterisation of hydrophobin-QDs: Ovarian cancer cells (IRGOV-1)
incubated with H*Protein B coated CdSe/ZnS QDs for 1 h.
4.2.2 HeLa cells
Crosslinking
It was found that in some cases, the simple hydrophobin-QD (CdSeS/ZnS) conjugates were
not stable in cell culture medium (in particular that used with HeLa cells), and this was
overcome by crosslinking the hydrophobins whilst on the surface of the QD with glutaralde-
hyde (an amine-reactive crosslinker [13]). This resulted in a stable protein shell on the
surface of the QDs which could withstand further processing, in a similar manner to the
crosslinking of amphiphilic shells of polymers on quantum dots [14, 15]. The method used
to crosslink the hydrophobin on to the QDs is shown in scheme 4.2 and involved simply
stirring the hydrophobin QDs with a glutaraldehyde solution for 1 h at room temperature.
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Figure 4.10: In vitro characterisation of hydrophobin-QDs: Breast cancer cells (MDA-MB-
231) incubated with H*Protein B coated CdSe/ZnS QDs for 1 h.
Figure 4.11: In vivo characterisation of hydrophobin-QDs: Time series images of H*Protein
B coated CdSe/ZnS QDs injected intratumourly in a mouse.
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The particles were then purified using a PD-10 column, and analysis of the brightest eluted
fraction performed. The emission profile (figure 4.12) clearly shows a peak corresponding
to gluataraldehyde present in the QD sample, with a smaller peak correlates to the found
of the hydrophobin-QDs in figure 4.2. TEM revealed no change in particle core size, while
DLS showed a slight increase and a shift of 20 mV in zeta potential was measured. All
observations led to the conclusion that the glutaraldehyde was present on the surface of the
protein coated QDs.
Scheme 4.2: Reaction scheme for the method of cross linking the hydrophobin on the surface
of the QDs.
Figure 4.12: Characterisation of crosslinked hydrophobin-QDs: Emission spectra of
H*Protein B coated CdSeS/ZnS QDs crosslinked with glutaraldehyde in water (black solid
line; λems = 439.0 nm and 627.5 nm), and glutaraldehyde only in water (grey dashed line;
λems = 438.5 nm).
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Figure 4.13: Characterisation of crosslinked hydrophobin-QDs: TEM micrograph of
H*Protein B coated CdSeS/ZnS QDs crosslinked with glutaraldehyde in water (DTEM =
4.5 ± 0.8 nm based on the measurement of 40 particles). Scale bar is 50 nm.
Fluorescence imaging
Samples of crosslinked hydrophobin-QDs were used in the labelling of live HeLa cells. These
studies were performed in collaboration with Dr. Dylan Owen in the Department of Physics
at King’s College London. Cells were stained and imaged using a spectral detector and
561 nm laser excitation. Fluorescence was collected over the range 570 nm to 740 nm.
Figure 4.14a shows a composite fluorescence image of HeLa cells generated by summing all
fluorescence channels. From this image, two points were selected. The first (blue) show the
spectrum of cellular autofluorescence only, whereas the second (red) shows the additional
fluorescence signal from QDs emitting in the 600 nm range which were also evident in the
fluorescence image. Figure 4.14b shows the normalised fluorescence spectrum from the two
regions of interest in figure 4.14a. Figure 4.14c shows an overlay of a fluorescence (610-650
nm) and bright-field image of HeLa cells incubated with hydrophobin coated QDs.
4.3 Functionalisation
The ability to add a further functionality to the hydrophobin-capped QDs then needed to
be proved, allowing for potential targeting or multimodal imaging applications. Previous
work by several groups has shown the feasibility of conjugating additional compounds to
these proteins, for example Valo et al. reported the introduction of mercaptosuccinic acid
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Figure 4.14: In vivo characterisation of hydrophobin-QDs: (a) Fluorescence image of live
HeLa cells stained with H*Protein B coated CdSeS/ZnS QDs. Fluorescence was collected
over the range 570 - 690 nm; (b) Normalised fluorescence emission spectrum from the two
regions of interest shown in (a). The bright punctate structure in the red region shows
the characteristic fluorescence signature of the nanoparticles in the 610 - 650 nm range, as
compared to the blue region which exhibits only autofluorescence; (c) Fluorescence image
collected in the 610-650 nm (red) range overlaid with a bright-field image of live HeLa cells
showing uptake of the nanoparticles.
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(MSA)-coated gold NPs on to the surface of hydrophobin coated beclomethasone dipropi-
onate (BDP) particles which could allow for improved localisation of the drug NPs in electron
microscopy [16]. Furthermore, Sarparanta et al. have described the successful 18F radio-
labelling of hydrophobin coated porous silicon NPs enabling PET imaging of the particle
distribution and easy quantification of NPs in tissues [17].
4.3.1 Radiolabelling
To demonstrate the suitability of hydrophobin-QDs (in particular CdSeS/ZnS) for further
conjugation, the exposed tyrosine residues on the exposed portion of the hydrophobin were
radiolabelled with iodine-131, 131I, (a well known radioiodination procedure [18, 19]) with
no detrimental effect on the optical properties, proving the availability of the amino acid
and incidentally resulting in a multimodal imaging agent. This was achieved by simple
incubation of the hydrophobin-QD conjugates with 131I, followed by TLC to give an initial
indication that radiolabelling was successful (figures 4.15 and 4.16; table 4.1). Prior to
purification, the % labelling efficiency was 36 %.
Figure 4.15: TLC characterisation of radiolabelled hydrophobin-QDs: Graphical represen-
tation of the TLC plate before purification (not integrated). The first peak corresponds to
radiolabelled H*Protein B coated CdSe/ZnS QDs, the second peak corresponds to unreacted
131I.
Purification through a PD-10 column was then performed, and it was found that isolated
samples were clearly both luminescent and radioactive (activity in each collected fraction is
given in table 4.2), confirming conjugation of the iodine to the free amino acid.
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Figure 4.16: TLC characterisation of radiolabelled hydrophobin-QDs: Graphical representa-
tion of the TLC plate before purification (integrated). Region 1 corresponds to radiolabelled
H*Protein B coated CdSeS/ZnS QDs, region 2 corresponds to unreacted 131I.
Region Rf % Total % ROI
1 0.155 35.26 35.95
2 0.882 62.81 64.05
Table 4.1: TLC characterisation of radiolabelled hydrophobin-QDs: Rf values for each region
of the TLC plate before purification (integrated). Region 1 corresponds to radiolabelled








Table 4.2: PD-10 characterisation of radiolabelled hydrophobin-QDs: Activity measured in
each radiolabelled H*Protein B coated CdSeS/ZnS QDs fraction after purification using a
PD-10 column.
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The purified fractions containing the majority of the activity were analysed by radio-TLC
(figures 4.17 and 4.19) as before. The most active fraction was fraction 3, consistent with the
size of the quantum dots. The counts were too low for detailed analysis on the TLC scanner
so both fraction plates were cut into 9 equal parts and each section counted in the gamma
counter, the results of which are shown in figures 4.18 and 4.20. The slight discrepancy
between the two strips is most probably due to slight differences in the running of the strips
as well as how they were cut, but essentially all activity is at the origin and none at the
solvent front, which would be expected if there was free 131I.
Figure 4.17: Radio-TLC characterisation of radiolabelled hydrophobin-QDs: Graphical rep-
resentation of the TLC plate on fraction 3 after purification using a PD-10 column. The
peak corresponds to radiolabelled H*Protein B coated CdSeS/ZnS QDs.
4.4 Conclusions
In conclusion, the simple encapsulation and phase transfer of quantum dots has been demon-
strated using a commercially-available amphiphilic protein. The particles retained a sig-
nificant amount of their emissive characteristics with no significant shift in the emission
wavelength (625.5 nm before phase transfer, 627.5 nm after). TEM analysis confirmed en-
capsulation had no detrimental effect on the morphology and size of the QDs, however it
was found that encapsulation of multiple particles into larger aggregates did occur occa-
sionally. In vitro and in vivo studies revealed the potential use of these QDs in imaging
with emission detected 24 h post injection. Finally, successful radiolabelling with 131I con-
firmed the possibility of simply utilising residues on the hydrophobin surface for further
Chapter 4 192
Figure 4.18: TLC characterisation of radiolabelled hydrophobin-QDs: Activity measured in
each part of the strip for fraction 3 (radiolabelled H*Protein B coated CdSeS/ZnS QDs =
99 %, free 131I = 1 %).
Figure 4.19: TLC characterisation of radiolabelled hydrophobin-QDs: Graphical represen-
tation of the TLC plate on fraction 4 after purification using a PD-10 column. The peak
corresponds to radiolabelled H*Protein B coated CdSeS/ZnS QDs.
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Figure 4.20: TLC characterisation of radiolabelled hydrophobin-QDs: Activity measured in
each part of the strip for fraction 4 (radiolabelled H*Protein B coated CdSeS/ZnS QDs =
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5.1 Ultrasmall superparamagnetic iron oxide nanopar-
ticles
Using this concept, multimodal USPIOs have been generated with exceptional imaging prop-
erties such as the lowest r2/r1 ratio reported to date at 3 T and long blood circulation times.
These USPIOs are now being further evaluated for enhanced MR angiography using T 1-
weighted sequences. Nonetheless, further work is required towards improving the targeting
properties. In vitro cell studies have confirmed specific binding to PSMA and VCAM-1 via
conjugation of single chain antibody fragments, but additional FACS studies are needed in
order to fully understand the mechanisms taking place during uptake involving the LyP-1
peptide. Initially, the results obtained will need to be repeated alongside a control cell line in
order to ensure that the uptake observed is a result of receptor-mediated endocytosis. From
here, investigation into the dependency of targeted USPIO uptake on blocking peptide con-
centration could be performed, providing new data which may allow for a more thorough
understanding of the processes occurring.
Moreover, analysis and quantification of the surface composition of the targeted-NPs is
necessary but will pose certain challenges. One potential technique that would allow for
evaluation of the individual components would be high performance liquid chromatography
(HPLC).
Furthermore, development of the radionuclide conjugation procedure is necessary, as the
radiolabelling yield is currently particularly low. A possible route to optimising the amount
of activity bound to the particles is to introduce a BP-anchored chelator for binding ra-
diometals into the initial phase transfer coating to which 99mTc can bind.
Finally, in vivo characterisation of the targeted USPIOs using the mouse models previously
investigated will need to be performed in order to complete a full picture of the potential of
these particles for molecular imaging in vivo. Obtaining images using a PET-MR instrument
would also be a favourable addition to this work.
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5.2 Polyethylene glycol phase transfer of CdZnSeS al-
loyed quantum dots
For the PEGylated QDs, it was found that the simple method of PEGylation previously
described allowed for the successful dispersion of these semiconductor nanoparticles in water
with few changes in the optical properties. However, a detailed analysis of the water-soluble
particles is required. The presence of PEG(5)-BP needs to be confirmed using a combination
of techniques, including IR spectroscopy, EDX and XPS. In addition, the amount of PEG(5)-
BP bound to the surface of the QDs should be quantified as it was for the PEG(5)-BP-
USPIOs, using TGA. Measurements for the quantum yield will also need to be performed in
order to deduce the reduction in optical emission after ligand exchange has occurred.
Once the PEG-coated QDs have been fully characterised, the same techniques should be
performed using the maleimide-PEGylated particles in order to determine the proportion of
mal-PEG(5)-BP to PEG(5)-BP conjugated to the surface.
5.3 Hydrophobin phase transfer of inorganic nanopar-
ticles
The objective of showing that an amphiphilic protein, a hydrophobin, could be used to suc-
cessfully produce water-soluble QDs has been demonstrated. Further work on the synthesis
is required to fully understand the mechanisms taking place in order to improve the yield
of hydrophobin-QDs. Quantification of amount of protein encapsulating the quantum dots
is necessary, and as it was shown that using tyrosine residues on the exposed region of the
hydrophobin allows for further functionalisation, more detail on the availability of these
regions is needed.
Once the above has been achieved, the next stage of this study will be to conjugate a
targeting molecule to the exposed residues and perform in vitro cell studies as has been ac-
complished with targeted USPIOs. Potentially, this could be achieved using the biomarkers







Reagent grade ethanol, hexane, methanol, DCM, dimethylformamide (DMF) and nitric acid
(TraceSelect Ultra) were purchased from commercial sources and used as received. Water
(type I, 18.2 MΩ·cm) was obtained from an ELGA Purelab Option-Q system, or a Millipore,
Direct-Q 3 UV Water Purification System. DMEM, Opti-MEM, and RPMI-1640 media
(Gibco, UK) were used for cell culture. For TLC studies, silica gel 60 F254 glass plates
(2.5 cm x 7 cm, Merck KGaA, Germany) were used. Size-exclusion filters (Vivaspin) and
columns (PD-10, PD MidiTrap and PD MiniTrap) were obtained from GE Healthcare, UK.
For cell studies, 16- and 24-well plates were obtained from Thermo Scientific. Millex IC 0.22
µm hydrophilic 13 mm polytetrafluoroethylene (PTFE) filters (Millipore, USA) and 0.2 µm
25 mm cellulose acetate filters (VWR, USA) were used throughout this study.
6.1.2 Ultrasmall superparamagnetic iron oxide nanoparticles
Iron(III) acetylacetonate, Fe(acac)3, (97 %), oleylamine (70 %), and benzyl ether (98 %)
were purchased from Sigma Aldrich. PEG-BP and mal-PEG-BP were prepared in-house
by Dr. Rafael Torres Martin de Rosales. Na[99mTcO4] in physiological saline was obtained
from a 99Mo/99mTc generator at the Radiopharmacy at Guy’s and St Thomas’ Hospital NHS
Trust, London, UK. [99mTc(CO)3(H2O)3]
+ was synthesised using Isolink kits (Mallinckrodt
Medical B.V., St. Louis, MO, USA). DPA-ale and 99mTc-DPA-ale were synthesised as
previously reported [1]. USPIO-1 particles were prepared in-house by Dr. Rafael Torres
Martin de Rosales. Human serum from human male AB plasma was obtained from Sigma
Aldrich. 5-((2-(and-3)-S -(acetylmercapto) succinoyl) amino) (SAMSA) fluorescein was pur-
chased from Life Technologies. Dialysis cassettes with a 2 kDa MWCO were purchased from
Fisher Scientific Ltd. J591, 6C7.1, and 6C7.1-fluorescein were prepared in-house by Dr.
Florian Kampmeier, and LyP-1 (fluorescent and non-fluorescent) was purchased from Pro-
teoGenix SAS, France. Penta · His Alexa Fluor 488 was purchased from Life Technologies.
Transfection DNA (pCMV-SPORT6 mouse VCAM-1, maxi prep DNA, 2.764 µg/µL in 10
mM Tris pH 8.5) was purchased from Life Technologies and Lipofectamine 2000 reagent was
obtained from Invitrogen.
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6.1.3 Polyethylene glycol phase transfer of CdZnSeS alloyed quan-
tum dots
Selenium powder (99.8 %), sulfur powder (99.5 %), trioctylphosphine (TOP, 90 %), cadmium
oxide (CdO, 99.5 %), zinc acetate (analytical reagent grade), oleic acid (90 %), and 1-
octadecene (ODE, 90 %) were obtained from Sigma Aldrich.
6.1.4 Hydrophobin phase transfer of inorganic nanoparticles
CdSe/ZnS (Lumidot 590) and CdSeS/ZnS quantum dots (QDs) were purchased from Sigma
Aldrich and used as received. CdSe/ZnS was also prepared in-house by Dr. Shohei Taniguchi;
the cores (CdSe) were prepared whilst referring to Qu et al. [2], whilst the ZnS shells were
deposited using the method described by Talapin et al. [3]. Fe3O4 particles were prepared
as described below. Hydrophobins (H*Protein B, 50 mg/mL) was obtained from BASF and
used as received. 131I was obtained from Perkin Elmer. Sodium phosphate buffer solution




Samples for TEM were prepared by evaporation of a drop of the aqueous colloidal suspensions
in ambient conditions onto a carbon-coated 3.05 mm copper grid (200 mesh, Agar Scientific,
UK or holey 300 mesh, TAAB Laboratories Equipment Ltd., UK). TEM was obtained from
a Tecnai T20 instrument (FEI, USA) with a LaB6 filament operating at 200 kV, or a Tecnai
F20 200 kV FEGTEM fitted with an Orius SC600 CCD camera (Gatan, USA) and an
80 mm2 X-Max SDD EDX detector (Oxford Instruments, UK). DLS and zeta potential
were performed with a Zetasizer Nano ZS instrument (Malvern Instruments, UK) at 25 ◦C.
TLC plates were scanned with a Mini-Scan TLC scanner equipped with a FC3600 detector
of γ photons (Lablogic, UK). Radioactivity in samples was measured with a CRC-25R
dose calibrator (Capintec, USA) or a 1282 CompuGamma gamma counter (LKB Wallac,
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Finland). Absorption spectroscopy measurements were taken using a Hitachi U-4100 UV-
Visible-NIR spectrophotometer in a 1 cm path length quartz cuvette. Emission spectra were
obtained using a Perkin Elmer LS 50B spectrometer.
6.2.2 Ultrasmall superparamagnetic iron oxide nanoparticles
Final synthesis of USPIOs performed using a 250 mL heating mantle connected to a digital
temperature monitor (J-KEM Scientific, USA). Lattice fringe spacing measurements made
using ImageJ. IR studies were performed with a Spectrum 100 spectrometer (Perkin-Elmer,
USA) equipped with a universal attenuated total reflection (ATR) sampling accessory. The
concentrations of iron in the dispersions of SPIO nanoparticles were calculated by ICP-MS
(Mass Spectrometry Service, King’s College London) after digestion in nitric acid for 16 h.
EDX was obtained from a Tecnai T20 instrument (FEI, USA) with a LaB6 filament operating
at 200 kV and equipped with a Genesis system EDAX spectrometer (EDAX, USA). XPS
were recorded using a Kratos AXIS ULTRA with monochromated Al KR radiation (10
kV anode potential, 15 A emission current) in fixed analyser transmission mode (80 eV
pass energy). TGA was performed under N2 flow (60 mL/min) with a heating rate of 10
◦C/min using a TA SDT-600 thermogravimetric analyser. XRD was recorded on a Bruker
D8 Advance powder diffractometer with a Cu KR X-ray source (λ = 1.54058 A˚) operating
at 40 kV and 40 mA and a Sol-X detector. Magnetisation data was obtained with a MPMS
SQUID-VSM instrument by Quantum Design (San Diego, USA), or a Mini High-Field VSM
(Cryogenics, UK), at 300 K. Relaxivity measurements were performed using a minispec
mq20 NMR analyser operating at 20 MHz (Bruker, Germany), a minispec mq60 NMR
analyser operating at 60 MHz (Bruker, Germany), a Spin Track analyser operating at 29
MHz and 39 MHz (Process NMR Associates, USA), an AMX 300 MHz (Bruker, Germany),
and a Spinmaster fast field cycling relaxometer operating from 0.015 MHz up to 40 MHz
(STELAR, Italy). Phantom relaxivity calculations were performed using a 3 T Philips
Achieva MR scanner (Philips Healthcare, Best, The Netherlands) equipped with a clinical
gradient system (30 mTm−1, 200 mT/m/ms) and a single-loop surface coil (diameter = 47
mm). NMR spectrum was obtained using a Bruker Avance 400 at 20 ◦C in Deuterated
chloroform,CDCl3, (Cambridge Isotope Laboratories).
1H resonances were referenced to the
residual protic impurity of the solvent (δH 7.26 ppm). Purification of targeted particles was
performed using an A¨KTA FPLC system (GE Healthcare, UK). FACS data was obtained
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using a FACSCalibur with Cellquest software (BD Biosciences UK), or a BD FACSAria III
cell sorter (BD Biosciences, UK).
6.2.3 Polyethylene glycol phase transfer of CdZnSeS alloyed quan-
tum dots
Microscopy was performed using a Leica confocal microscope (Leica Microsystems, UK).
6.2.4 Hydrophobin phase transfer of inorganic nanoparticles
DLS measurements of hydrophobins only were performed by Dr. Shohei Taniguchi using
Delsa Nano C Particle Analyser using 1 cm path length quartz cuvettes.
6.3 Ultrasmall superparamagnetic iron oxide nanopar-
ticles procedures
6.3.1 Synthesis of ultrasmall superparamagnetic iron oxide nanopar-
ticles
6.3.1.1 Initial synthetic method
Oleylamine-coated USPIOs were synthesised using a slight variation of the method of Xu et
al. [4]. Fe(acac)3 (1.042 g) was added to a mixture 15 mL of oleylamine and 15 mL of benzyl
ether, and was stirred using a magnetic stirrer. The solution was then dehydrated at 170
◦C for 1 h under a N2 flow followed by a temperature increase to 260
◦C over a period of 15
min, after which the heating appliance was removed. The solution was left to cool to room
temperature and the iron oxide NPs precipitated upon the addition of 24 mL of ethanol,
followed by centrifugation at 7000 rpm for 4 min. The supernatant was discarded and the
process repeated with another 20 mL of ethanol, then a further 48 mL.
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6.3.1.2 Development of synthesis
Fe(acac)3 (1.042 g) was added to a mixture 15 mL of oleylamine and 15 mL of benzyl ether,
and was stirred using a magnetic stirrer. The solution was then heated to 128 ◦C at a rate
of 363.5 ◦C/h under a N2 flow followed by a temperature increase to 180
◦C over a period
of 1 h, and finally heating to 260 ◦C at a ramping rate of 396 ◦C/h after which the heating
appliance was removed. The solution was left to cool to room temperature and the iron
oxide NPs precipitated upon the addition of 24 mL of ethanol, followed by centrifugation at
7000 rpm for 4 min. The supernatant was discarded and the process repeated with another
20 mL of ethanol, then a further 48 mL.
6.3.1.3 Changing ramping rate
Doubling ramping rate
Fe(acac)3 (1.060 g) was added to a mixture 15 mL of oleylamine and 15 mL of benzyl ether,
and was stirred using a magnetic stirrer rotating at 550 rpm. The solution was then heated
to 128 ◦C at a rate of 727 ◦C/h under a N2 flow followed by a temperature increase to
180 ◦C over a period of 30 min, and finally heating to 260 ◦C at a ramping rate of 792
◦C/h after which the heating appliance was removed. The solution was left to cool to room
temperature and the iron oxide NPs precipitated upon the addition of 35 mL of ethanol,
followed by centrifugation at 7000 rpm for 4 min. The supernatant was discarded and the
process repeated with another 40 mL of ethanol, then a further 56 mL.
Halving ramping rate
Fe(acac)3 (1.055 g) was added to a mixture 15 mL of oleylamine and 15 mL of benzyl ether,
and was stirred using a magnetic stirrer rotating at 550 rpm. The solution was then heated
to 128 ◦C at a rate of 181.75 ◦C/h under a N2 flow followed by a temperature increase
to 180 ◦C over a period of 2 h, and finally heating to 265 ◦C at a ramping rate of 198
◦C/h after which the heating appliance was removed. The solution was left to cool to room
temperature and the iron oxide NPs precipitated upon the addition of 35 mL of ethanol,
followed by centrifugation at 7000 rpm for 4 min. The supernatant was discarded and the
process repeated with another 40 mL of ethanol, then a further 56 mL.
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6.3.1.4 Changing precursor ratio
2:1 Oleylamine to benzyl ether
Fe(acac)3 (1.058 g) was added to a mixture 20 mL of oleylamine and 10 mL of benzyl ether,
and was stirred using a magnetic stirrer. The solution was then heated to 128 ◦C at a rate
of 363.5 ◦C/h under a N2 flow followed by a temperature increase to 180
◦C over a period
of 1 h, and finally heating to 270 ◦C at a ramping rate of 396 ◦C/h after which the heating
appliance was removed. The solution was left to cool to room temperature and the iron
oxide NPs precipitated upon the addition of 35 mL of ethanol, followed by centrifugation at
7000 rpm for 4 min. The supernatant was discarded and the process repeated with another
42 mL of ethanol, then a further 56 mL.
Oleylamine only
Fe(acac)3 (1.042 g) was added to 30 mL of oleylamine, and was stirred using a magnetic
stirrer rotating at 550 rpm. The solution was then heated to 128 ◦C at a rate of 345.9 ◦C/h
under a N2 flow followed by a temperature increase to 180
◦C over a period of 1 h, and
finally heating to 270 ◦C at a ramping rate of 396 ◦C/h after which the heating appliance
was removed. The solution was left to cool to room temperature and the iron oxide NPs
precipitated upon the addition of 30 mL of ethanol, followed by centrifugation at 7000 rpm
for 4 min. The supernatant was discarded and the process repeated with another 35 mL of
ethanol, then a further 56 mL.
6.3.1.5 Final synthetic method
Fe(acac)3 (1.042 g) was added to 30 mL of oleylamine, and was stirred using a magnetic
stirrer rotating at 550 rpm. The solution was then heated to 128 ◦C at a rate of 363.5 ◦C/h
under a N2 flow followed by a temperature increase to 180
◦C over a period of 1 h, and
finally heating to 270 ◦C at a ramping rate of 396 ◦C/h after which the heating appliance
was removed. The solution was left to cool to room temperature and the iron oxide NPs
precipitated upon the addition of 30 mL of ethanol, followed by centrifugation at 7000 rpm
for 4 min. The supernatant was discarded and the process repeated with another 35 mL of
ethanol, then a further 56 mL.
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6.3.2 Polyethylene glycol phase transfer of ultrasmall superparam-
agnetic iron oxide nanoparticles
6.3.2.1 Initial synthetic method
Oleylamine-coated USPIOs (5.4 mg) and PEG(2)-BP (10 mg) were added to 3 mL of H2O
in an open glass vial, and the mixture was sonicated for ∼15 min. The solution was left at
room temperature for 3 days, after which a pale brown dispersion remained with a small
amount of precipitate settled on the bottom of the vial. The solution was centrifuged at
4000 rpm for 10 min to remove the solid.
6.3.2.2 Final synthetic method
Oleylamine-coated USPIOs (1 mg) and PEG(5)-BP (10 mg) were added to 1 mL of DCM in
an open glass vial, and the mixture was sonicated until the solvent evaporated (∼15 min).
To the remaining residue was added 2 mL of water resulting in a clear brown solution. This
mixture was washed with 2 mL of hexanes to remove the oleylamine. This process was
repeated two more times followed by removal of hexanes by evaporation under a N2 flow.
The final mixture was filtered through a 0.2 µm hydrophilic PTFE filter, followed by several
cycles of washing/concentrating using a Vivaspin 2 centrifugal filter (30 kDa MWCO) using
water to remove excess PEG(5)-BP. The washings collected during this purification stage
were dried to measure the mass of PEG(5)-BP bound. The final amber solution was removed
from the filter and stored at 4 ◦C in a glass vial.
6.3.3 Radiolabelling
6.3.4 Conjugation of 99mTc to dipicolylamine-alendronate
DPA-ale (1 mg) was added to 1 mL of a 100 mM carbonyl buffer (pH 9), and 100 µL of this
solution was the diluted up to 1 mL with 100 mM carbonyl buffer (pH 9). To prepare the
radiolabel, 99mTcO4
− was added to an Isolink kit and heated for 30 min at 100 ◦C, which
produced [99mTc(CO)3(OH2)3]
+ with a pH of 9-10. TLC was used to confirm this using a
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mobile phase of 1 % HCl in methanol. 120 µL of 1 M HCl was used to lower the pH to 7.
500 µL of the DPA-ale solution was added to 500 µL of [99mTc(CO)3(OH2)3]
+ (pH 7), and
then heated for 30 min at 90 ◦C. TLC was then re run as before to confirm formation of
99mTc-DPA-ale.
6.3.4.1 Radiolabelling yield dependence on molecular weight and mass of polyethy-
lene glycol
To a dispersion of PEG-BP-USPIOs (100 µL of solution containing 4 µmol Fe for USPIO-1
samples, 100 µL of solution containing 0.2 µmol of Fe for USPIO-2 sample) in saline was
added to ∼2 MBq of 99mTc-DPA-ale in 20 µL. The mixture was mixed and incubated at
room temperature at pH 7 in a sealed vial for 30 min. The contents were then washed by
centrifugation with 100 µL saline at 10000 rpm for 1.5 min using a Vivaspin 500 with a 10
kDa MWCO. This cycle was repeated several times.
6.3.4.2 Radiolabelling yield dependence on reaction time
To a dispersion of PEG-BP-USPIOs (10 µL of solution containing 0.3 µmol Fe) in saline
was added to ∼0.5 MBq of 99mTc-DPA-ale in 30 µL. The mixture was mixed and was either
washed immediately, or incubated at room temperature at pH 7 in a sealed vial for 30 min.
The contents were washed by centrifugation with 100-200 µL saline at 10000 rpm for 3 min
using a Vivaspin 500 with a 10 kDa MWCO. This cycle was repeated several times.
6.3.4.3 Radiolabelling yield dependence on heating
To a dispersion of PEG-BP-USPIOs (20 µL of solution containing 0.6 µmol Fe) in saline was
added to ∼7 MBq of 99mTc-DPA-ale in 100 µL. The mixture was mixed and was incubated
at 37 ◦C at pH 7 in a sealed vial for 10 min, or heated from 25 ◦C to 90 ◦C during 10 min
at pH 7. The reaction solution was cooled to room temperature and the contents were then
washed by centrifugation with 200 µL saline at 10000 rpm for 3 min using a Vivaspin 500
with a 10 kDa MWCO. This cycle was repeated several times.
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6.3.4.4 Radiolabelling yield dependence on filter
To a dispersion of PEG-BP-USPIOs (20 µL of solution containing 0.6 µmol Fe) in saline
was added to ∼0.5 MBq of 99mTc-DPA-ale in 100 µL. The mixture was mixed and was
heated from 25 ◦C to 90 ◦C during 10 min at pH 7. The reaction solution was cooled to
room temperature and the contents were then washed by centrifugation with 100 µL saline
at 10000 rpm for 3 min using either a Vivaspin 500 with a 10 kDa MWCO, or a Vivaspin 2
with a 3 kDa MWCO. This cycle was repeated several times.
6.3.4.5 Radiolabelling yield dependence on purification method
To a dispersion of PEG-BP-USPIOs (50 µL of solution containing 1.5 µmol Fe) in saline
was added to ∼500 MBq of 99mTc-DPA-ale in 1 mL. The mixture was mixed and was
heated from 25 ◦C to 90 ◦C during 10 min at pH 7. The reaction solution was cooled to
room temperature and the contents were then washed by centrifugation with 200 µL saline
at 10000 rpm for 3 min using either a Vivaspin 500 with a 10 kDa MWCO. This cycle
was repeated several times. Once the excess unbound 99mTc-DPA-ale had been removed,
the remaining radiolabelled NP solution was passed through a PD-10 desalting column with
saline as the eluent in 0.5 mL fractions. The fraction containing the NPs was then centrifuged
further as before to ensure all free radiolabel had been removed.
6.3.4.6 Finalised standard radiolabelling method
To a dispersion of PEG(5)-BP-USPIOs (20 µL of solution containing 0.6 µmol Fe) in saline
was added to 1000 MBq of 99mTc-DPA-ale in 600 µL. The mixture was mixed and heated
from 25 ◦C to 90 ◦C during 10 min at pH 7. The reaction solution was cooled to room
temperature, and the contents were separated using two PD-10 columns with saline as the
eluent in 0.5 mL fractions.
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6.3.4.7 Characterisation of radiolabelled ultrasmall superparamagnetic iron ox-
ide nanoparticles
To assess the in vitro stability of radiolabelled PEG(5)-BP-USPIOs in human serum, a 20 µL
aliquot containing approximately 100 kBq of 99mTc in saline was incubated in human serum
(500 µL) at 37 ◦C and constant shaking for 48 h. At the end of the experiment, the samples
were filtered using the size-exclusion filters (MWCO of 10 kDa) and the radioactivity of the
filtrate and retentate measured in a gamma-counter. Thus, if 99mTc-DPA-ale dissociated
from the USPIOs, it would elute with the filtrate.
6.3.5 In vivo studies
In vivo studies were carried out in accordance with British Home Office regulations governing
animal experimentation. Male BALB/c mice (8-10 weeks old) were used. Before the imaging
procedure and contrast agent administration, mice were anesthetised with isoflurane and
kept under its influence for the duration of the experiment (maximum 4 h) and culled by
cervical dislocation at the end of the imaging session. The contrast agents used were injected
intravenously through the tail vein using 0.5 mL insulin syringes. The doses used in these
studies were 10 µmol Fe/kg (20 MBq of 99mTc) in 100 µL saline (PEG(5)-BP-USPIOs) or
40 µmol Fe/kg (3 MBq of 99mTc) in 100 µL saline (Feraspin XS).
6.3.5.1 Magnetic resonance imaging
In vivo MR imaging was performed using a 3 T Philips Achieva MR scanner (Philips Health-
care, Best, The Netherlands) equipped with a clinical gradient system (30 mTm−1, 200
mT/m/ms) and a single-loop surface coil (diameter = 47 mm). Anesthesia was induced
with 5 % and maintained with 12 % isoflurane during the MRI experiments. Mice were
imaged in prone position. Dynamic contrast enhanced (DCE) magnetic resonance angiog-
raphy (MRA), and T 1 and T 2
∗ mapping protocols were acquired before and after injection
of the nanoparticles. Following a 3D GRE scout scan, coronal 3D fast-field echo DCE-MRA
images were acquired with TR = 10 ms, TE = 4.2 ms, flip angle = 40 ◦, FOV = 40 x 36 x
12 mm3, acquired matrix = 160 x 144, slice thickness = 0.5 mm, resolution = 0.25 mm x
0.25 mm, reconstructed resolution = 0.1 mm x 0.1 mm, slice number = 25, averages = 1,
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temporal resolution = 20 s, number of dynamic scans = 20, duration = 6.7 min.
T 1 mapping was performed using a sequence that employs two nonselective inversion pulses
with inversion times ranging from 20 to 2000 ms, followed by eight segmented readouts for
eight individual images. The two imaging trains result in a set of 16 images per slice with
increasing inversion times. For T 1 mapping the acquisition parameters were: TR = 5.8 ms,
TE = 2.7 ms, flip angle = 10 ◦, FOV = 31 x 31 x 13mm3, acquired matrix = 80 x 77,
measured slice thickness = 0.5 mm, acquired resolution = 0.4 mm x 0.4 mm, reconstructed
resolution = 0.12 mm x 0.12 mm, slices = 26, averages = 1.
T 2
∗ mapping was performed using a 3D fast-field echo sequence. Coronal images were
acquired with TR = 248 ms, TE = 4.6 ms, echo spacing = 6.9 ms, six echoes, flip angle
= 25 ◦, FOV = 31 x 31 x 13 mm3, acquired matrix = 77 x 77, acquired resolution = 0.41
mm x 0.41 mm, reconstructed resolution = 0.11 mm x 0.11 mm, slice thickness = 0.5 mm,
slices = 26, averages = 1. Similar acquisition protocols were used to scan vials containing
different concentrations of the nanoparticles to calculate the r1 and r2 relaxivities.
MR images were analysed using the software OsiriX (OsiriX Foundation, Geneva, Switzer-
land). The dynamic contrast enhanced magnetic resonance angiogram (DCE-MRA) images
were used to monitor the changes in the signal intensity of blood before and after injection
of the nanoparticles. A region of interest (ROI) was manually drawn in the inferior vena
cava and propagated over the different time points. T 1 mapping images were used to calcu-
late the relaxation rate (R1) of the liver and blood on a pixel-by-pixel basis using in house
software (Matlab, Natick, MA) [5]. Similarly, the T ∗2 mapping images were used to calculate
the relaxation rate (R∗2) of the corresponding tissues.
6.3.5.2 Single photon emission computed tomography-computed tomography
imaging
SPECT-CT images were obtained with a NanoSPECT/CT PLUS preclinical animal scanner
(Mediso, Hungary) equipped with four heads, each with nine 1 mm pinhole collimators, in
helical scanning mode in 20 projections over 20 min. The CT images were obtained with a 45
kV X-ray source, 1000 ms exposure time in 180 projections over 10 min. Images were recon-
structed in a 256 x 256 matrix using the HiSPECT (Scivis GmbH) reconstruction software
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package, and fused using InVivoScope (IVS) software (Bioscan, France). Quantification was
performed by selecting the desired organs as ROIs using the quantification tool of the IVS
software.
6.3.6 Targeting
6.3.6.1 Maleimide-polyethylene glycol phase transfer of ultrasmall superpara-
magnetic iron oxide nanoparticles
Oleylamine-coated USPIOs (1.1 mg), PEG(5)-BP (7.2 mg) and mal-PEG(5)-BP (3.8 mg)
were added to 1 mL of DCM in an open glass vial, and the mixture was sonicated until the
solvent evaporated. To the remaining residue was added 1 mL of water resulting in a clear
brown solution. This mixture was washed with 2 mL of hexanes to remove the oleylamine.
This process was repeated two more times followed by removal of hexanes by evaporation
under a N2 flow. The final mixture was filtered through a 0.2 µm hydrophilic PTFE filter,
followed by several cycles of washing/concentrating using a Vivaspin 2 centrifugal filter (30
kDa MWCO) using water to remove excess PEG(5)-BP and mal-PEG(5)-BP. The final
amber solution was removed from the filter for use in targeting studies.
6.3.6.2 Characterisation of maleimide-polyethylene glycol-coated ultrasmall su-
perparamagnetic iron oxide nanoparticles
Preparation of fluorescent component
Fluorescein-mal-PEG(5)-BP was synthesised by dissolving SAMSA fluorescein (22.329 mg)
in 1.19 mL of 0.1 M NaOH and incubating for 15 min at room temperature. The solution
was neutralised with ∼15 µL of concentrated HCl. Meanwhile, mal-PEG(5)-BP (8 mg) was
dissolved in 5.952 mL of Tris buffer (0.5 M) at pH 6.8. The fluorescein solution was incubated
with the mal-PEG(5)-BP solution for 2 h at room temperature, and then overnight at 4 ◦C.
The reaction solution was then purified for 36 h at 4 ◦C using a dialysis cassette with a 2
kDa MWCO. The contents were then freeze dried.
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Preparation of fluorescent polyethylene glycol-coated and maleimide-polyethylene glycol-coated
ultrasmall superparamagnetic iron oxide nanoparticles
For cell studies, two samples were prepared. For PEG(5)-BP-USPIOs, oleylamine-coated
USPIOs (1.5 mg) and PEG(5)-BP (9 mg) were added to 0.5 mL of DCM in an open glass
vial. Fluorescein-mal-PEG(5)-BP (0.5 mg) was dissolved in 40 µL of dimethylformamide
(DMF) and 0.5 mL of DCM. Both solutions were mixed an sonicated until all the solvent had
evaporated. For mal-PEG(5)-BP-USPIOs, oleylamine-coated USPIOs (1.7 mg), PEG(5)-BP
(7 mg) and mal-PEG(5)-BP (3 mg) were added to 0.5 mL of DCM in an open glass vial.
Fluorescein-mal-PEG(5)-BP (0.5 mg) was dissolved in 40 µL of DMF and 0.5 mL of DCM.
Both solutions were mixed an sonicated until all the solvent had evaporated. The washings
steps were the same for both phase transfers. To the remaining residue was added 1 mL of
water resulting in a yellow-brown solution. This mixture was washed with 2 mL of hexanes
to remove the oleylamine. This process was repeated two more times followed by removal
of hexanes by evaporation under a N2 flow. The final mixture was filtered through a 0.2
µm hydrophilic PTFE filter, followed by several cycles of washing/concentrating using a
Vivaspin 2 centrifugal filter (30 kDa MWCO) using water to remove excess PEG(5)-BP and
mal-PEG(5)-BP. The final solution was removed from the filter for use in cell studies.
Fluorescence-activated cell sorting study
Samples of ∼400,000 MDA-MB-435 cells were prepared. The following specimens were
investigated: (1) cells only, (2) cells incubated with fluorescent PEG(5)-BP-USPIOs, and
(3) cells incubated with fluorescent mal-PEG(5)-BP-USPIOs. The volume for each sample
was kept at 250 µL, and initially 250 µL of 0.1 % medium was added to all three samples, 2
µL of fluorescent PEG(5)-BP-USPIOs was added to (2), and 2 µL of fluorescent mal-PEG(5)-
BP-USPIOs was added to (3). All samples were incubated for 1 h at 37 ◦C and shaken at
20 min intervals. After which time, each sample was washed by the addition of 2 mL of
cold PBS, followed by centrifugation at 350 rcf for 3 min and removal of the supernatant.
This process was repeated a further 2 times. The samples were then redispersed in 250 µL
of cold PBS and kept on ice for performance of FACS.
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Microscopy study
For microscopy studies, 5 µL of Hoechst 33342 was diluted up to 5 mL using PBS, and 100
µL of this solution was added to each of the above samples. These were then left for 15 min
at room temperature. Washing was performed three times using 2 mL of cold PBS followed
by centrifugation at 350 rcf for 3 min. The samples were redispersed in 100 µL PBS, and
10 µL of each was dropped on to a microscope slide. A cover slip was then fixed over the
sample once dried.
6.3.6.3 Prostate-Specific Membrane Antigen
J591 conjugation
Oleylamine-coated USPIOs (1.1 mg), PEG(5)-BP (3.4 mg) and mal-PEG(5)-BP (2.1 mg)
were added to 1 mL of DCM in an open glass vial, and the mixture was sonicated until the
solvent evaporated. To the remaining residue was added 1 mL of water resulting in a clear
brown solution. This mixture was washed with 2 mL of hexanes to remove the oleylamine.
This process was repeated two more times followed by removal of hexanes by evaporation
under a N2 flow. The final mixture was filtered through a 0.2 µm hydrophilic PTFE filter,
followed by several cycles of washing/concentrating using a Vivaspin 2 centrifugal filter (30
kDa MWCO) using water to remove excess PEG(5)-BP and mal-PEG(5)-BP. Meanwhile
J591 was reduced. DTT (15.4 mg) was added to 1 mL of water and to achieve a 20 molar
excess, 3.46 µL of this solution was added to 320 µL of J591 (21.6 nM) and left for 1 h at
room temperature. The mixture was purified using a PD MiniTrap column followed by a PD
MidiTrap column, both equilibrated with 2 mM ethylenediaminetetraacetic acid (EDTA) in
PBS. J591 was eluted in a 1 mL fraction directly into 250 µL of the above mal-PEG(5)-
BP-USPIOs, and left to react for 2 h at room temperature. The reaction solution was then
purified using an A¨KTA chromatography system previously equilibrated for at least 1 h with
PBS. Fractions of 1 mL were collected.
Fluorescence-activated cell sorting study
Samples of ∼500,000 DU145 and DU145-PSMA cells were prepared. For each cell line, the
following specimens were investigated: (1) cells only, (2) cells incubated with 2◦ antibody,
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and (3) cells incubated with J591-PEG(5)-BP-USPIOs followed by 2◦ antibody. The volume
for each sample was kept at 250 µL, and initially 250 µL of PBS was added to (1), 250 µL
of PBS was added to (2), and a mixture of 100 µL of J591-PEG(5)-BP-USPIOs and 150
µL of PBS was added to (3). All samples were incubated for 30 min on ice, followed by the
addition of 2 mL of cold PBS, followed by centrifugation at 350 rcf for 3 min and removal
of the supernatant. This process was repeated a further 2 times. 250 µL of PBS was then
added to (1), with 1 µL of 2◦ antibody and 250 µL of PBS added to (2) and (3). All samples
were incubated for 30 min on ice, followed by the addition of 2 mL of cold PBS, followed by
centrifugation three times as before. The samples were then redispersed in 250 µL of cold
PBS and kept on ice for performance of FACS.
Radiolabelling study
[99mTc(CO)3(OH2)3]
+ and 99m-DPA-ale prepared as previously described. For the directly
labeled particles, 15 µL of the [99mTc(CO)3(OH2)3]
+ stock solution (∼40 MBq) was added
to 100 µL of J591-PEG(5)-BP-USPIOs. For the particles labeled via the BP, 45 µL of 99m-
DPA-ale (∼70 MBq) was added to 300 µL of J591-PEG(5)-BP-USPIOs. Both samples were
incubated for 75 min at 37 ◦C whilst shaking at 450 rpm. Purification was performed using
a PD MiniTrap column followed by a PD MidiTrap column.
Cell studies were performed using the particles radiolabelled via the BP only. Samples of
∼1,900,000 DU145 and DU145-PSMA cells were prepared. For each cell line, the follow-
ing specimens were investigated: (1) cells incubated with radiolabelled J591-PEG(5)-BP-
USPIOs on ice, and (2) cells incubated with radiolabelled J591-PEG(5)-BP-USPIOs at 37
◦C, both performed in triplicate. To each cell sample, 116 µL of radiolabelled J591-PEG(5)-
BP-USPIOs was added, followed by incubation for 45 min at the appropriate temperature.
All samples were washed by the addition of 2 mL of cold PBS, followed by centrifugation at
350 rcf for 3 min. This process was repeated a further 2 times and each time the supernatant
was kept. The remaining pellet and collected supernatant were then gamma counted.
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6.3.6.4 Vascular Cell Adhesion Protein 1
6C7.1 conjugation
Oleylamine-coated USPIOs (1.4 mg), PEG(5)-BP (6.9 mg) and mal-PEG(5)-BP (3.8 mg)
were added to 1 mL of DCM in an open glass vial, and the mixture was sonicated until the
solvent evaporated. To the remaining residue was added 1 mL of water resulting in a clear
brown solution. This mixture was washed with 2 mL of hexanes to remove the oleylamine.
This process was repeated two more times followed by removal of hexanes by evaporation
under a N2 flow. The final mixture was filtered through a 0.2 µm hydrophilic PTFE filter,
followed by several cycles of washing/concentrating using a Vivaspin 2 centrifugal filter (30
kDa MWCO) using water to remove excess PEG(5)-BP and mal-PEG(5)-BP. Meanwhile
6C7.1 was reduced. DTT (15.4 mg) was added to 1 mL of water and to achieve a 20 molar
excess, 3.99 µL of this solution was added to 360 µL of 6C7.1 (1.6 mg/mL) and left for 1
h at room temperature. The mixture was purified using a PD MiniTrap column followed
by a PD MidiTrap column, both equilibrated with 2 mM ethylenediaminetetraacetic acid
(EDTA) in PBS. 6C7.1 was eluted in a 1 mL fraction directly into 250 µL of the above mal-
PEG(5)-BP-USPIOs, and left to react for 2 h at room temperature. The reaction solution
was then purified using an A¨KTA chromatography system previously equilibrated for at
least 1 h with PBS. Fractions of 1 mL were collected.
Transfection of cell line
To transfect HEK 293T cells to express high levels of VCAM-1, 7.2 µL of DNA (20 µg)
was diluted in 1.5 mL of Opti-MEM and 50 µL of Lipofectamine 2000 reagent was diluted
in 1.5 mL of Opti-MEM. The two solutions were then mixed and left for 20 min at room
temperature. This solution was made up to 8 mL with Opti-MEM. The HEK 293T cells were
washed with Opti-MEM by centrifugation at 350 rcf for 3 min. The DNA/Lipofectamine
solution was then incubated with the cells for ∼3.5 h at 37 ◦C, after which the cell media
was replaced with normal media.
Fluorescence-activated cell sorting study
Samples of ∼500,000 HEK 293T and HEK 293T VCAM cells were prepared. For each cell
line, the following specimens were investigated: (1) cells only, (2) cells incubated with 2◦
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antibody, (3) cells incubated with 6C7.1-fluorescein, and (4) cells incubated with 6C7.1-
PEG(5)-BP-USPIOs followed by 2◦ antibody. The volume for each sample was kept at 250
µL, and initially 250 µL of PBS was added to (1), 250 µL of PBS was added to (2), a
mixture of 1 µL of 6C7.1-fluorescein and 249 µL of PBS was added to (3), and a mixture
of 200 µL of 6C7.1-PEG(5)-BP-USPIOs and 50 µL of PBS was added to (4). All samples
were incubated for 30 min on ice, followed by the addition of 2 mL of cold PBS, followed
by centrifugation at 350 rcf for 3 min and removal of the supernatant. This process was
repeated a further 2 times. 250 µL of PBS was then added to (1) and (3), with 1 µL of 2◦
antibody and 250 µL of PBS added to (2) and (4). All samples were incubated for 30 min
on ice, followed by the addition of 2 mL of cold PBS, followed by centrifugation three times
as before. The samples were then redispersed in 250 µL of cold PBS and kept on ice for
performance of FACS.
Radiolabelling study
99mTc-DPA-ale prepared as previously described. a small amount of 99mTc-DPA-ale was
added to the 6C7.1-PEG(5)-BP-USPIOs. The sample was incubated for 75 min at 37 ◦C
whilst shaking at 450 rpm. Purification was performed using the A¨KTA chromatography
system.
Samples of ∼2,000,000 HEK 293T and HEK 293T VCAM cells were prepared. For each cell
line, the cells incubated with radiolabelled 6C7.1-PEG(5)-BP-USPIOs at 37 ◦C performed
in triplicate was investigated. To each cell sample, 166 µL of radiolabelled 6C7.1-PEG(5)-
BP-USPIOs was added, followed by incubation for 45 min at 37 ◦C. All samples were
washed by the addition of 2 mL of cold PBS, followed by centrifugation at 350 rcf for 3 min.
This process was repeated a further 2 times and each time the supernatant was kept. The
remaining pellet and collected supernatant were then gamma counted.
6.3.6.5 p32 receptor
LyP-1 conjugation
Oleylamine-coated USPIOs (1.2 mg), PEG(5)-BP (7.2 mg) and mal-PEG(5)-BP (3.8 mg)
were added to 1 mL of DCM in an open glass vial, and the mixture was sonicated until the
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solvent evaporated. To the remaining residue was added 1 mL of water resulting in a clear
brown solution. This mixture was washed with 2 mL of hexanes to remove the oleylamine.
This process was repeated two more times followed by removal of hexanes by evaporation
under a N2 flow. The final mixture was filtered through a 0.2 µm hydrophilic PTFE filter,
followed by several cycles of washing/concentrating using a Vivaspin 2 centrifugal filter
(30 kDa MWCO) using water to remove excess PEG(5)-BP and mal-PEG(5)-BP. 250 µL
HEPES buffer was added to 250 µL of mal-PEG(5)-BP-USPIOs. To this NP solution, 20
µL of fluorescent LyP-1 in degassed water (200 µg) was added and left for 2 h at room
temperature. The reaction solution was then purified using an A¨KTA chromatography
system previously equilibrated for at least 1 h with 0.9 % saline. Fractions of 1 mL were
collected.
Fluorescence-activated cell sorting study
Samples of ∼3,100,000 MDA-MB-435 cells were prepared. The following specimens were
investigated: (1) cells only, (2) cells incubated with LyP-1-PEG(5)-BP-USPIOs, (3) cells
incubated with a blocking peptide followed by LyP-1-PEG(5)-BP-USPIOs, (4) cells incu-
bated with mal-PEG(5)-BP-USPIOs, and (5) cells incubated with LyP-1. The volume for
each sample was kept at 250 µL, and initially 250 µL of PBS was added to (1), (2), (4)
and (5), and a mixture of 27 µL of blocking peptide (non-fluorescent LyP-1; 85 µM) and
223 µL of PBS was added to (3). All samples were incubated for 30 min at 37 ◦, followed
by the addition of 2 mL of PBS and centrifugation at 350 rcf for 3 min and removal of the
supernatant. This process was repeated a further 2 times. 250 µL of PBS was then added
to (1), 150 µL of LyP-1-PEG(5)-BP-USPIOs and 100 µL of PBS added to (2) and (3), 20
µL of mal-PEG(5)-BP-USPIOs and 230 µL of PBS added to (4), and a mixture of 0.5 µL
of LyP-1 (5 µg) and 249.5 µL of PBS was added to (5). All samples were incubated for 1 h
at 37 ◦, followed by the addition of 2 mL of PBS, followed by centrifugation three times as
before. The samples were then redispersed in 250 µL of PBS and kept on ice for performance
of FACS.
Microscope study
Cell samples containing 100,000 cells were prepared on to cover slips in a 24 well plate.
The samples were rinsed with PBS at room temperature and fixed using 0.5 mL of 4 % FA
for 15 min at room temperature, followed by three rinses with 0.5 mL of glycerine in PBS
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(100 mM). Each well was covered with 500 µL of NaBH4 solution (1 mg/mL) for 5 mins,
and then rinsed twice with PBS. This was followed by incubation with 400 µL of blocking
solution (1 % bovine serum albumin, BSA, in 25 mM Tris-buffered saline) for 15 min at room
temperature. The following specimens were investigated: (1) cells only, (2) cells incubated
with a blocking peptide (non-fluorescent LyP-1) followed by LyP-1-PEG(5)-BP-USPIOs,
(3) cells incubated with a low concentration of LyP-1-PEG(5)-BP-USPIOs, and (4) cells
incubated with a high concentration of LyP-1-PEG(5)-BP-USPIOs. The volume for each
sample was kept at 250 µL, and initially 250 µL of PBS was added to (1), (3) and (4), and
a mixture of 27 µL of blocking peptide (85 µM) and 223 µL of PBS was added to (2). All
samples were incubated for 30 min at 37 ◦C, followed by three rinses with PBS. 250 µL of
PBS was then added to (1), 25 µL of LyP-1-PEG(5)-BP-USPIOs and 225 µL of PBS added
to (3), and a mixture of 200 µL of LyP-1-PEG(5)-BP-USPIOs and 50 µL of PBS was added
to (2) and (4). All samples were incubated for 1 h at 37 ◦C, followed by three rinses with
PBS. Each well was rinsed with water twice, and then the cover slips were fixed to a slide
using 6.5 µL of Fluoroshield.
6.4 Polyethylene glycol phase transfer of CdZnSeS al-
loyed quantum dots procedures
6.4.1 Synthesis of CdZnSeS alloyed quantum dots
QDs were synthesised using a modified version of the synthesis by Bae et al. [6]. Se (7.9 mg)
and S (3.3 mg) were dissolved in 3 mL TOP and stirred overnight under N2 at 600 rpm. CdO
(51.4 mg) and Zn acetate (733.9 mg) were added to a mixture of 5.6 mL of oleic acid and 20
mL ODE (90 %) and stirred at 550 rpm. This solution was degassed at for ∼1 h at 100 ◦C
under vacuum. The solution was then placed under N2 and heated to 310
◦ at a ramping
rate of 400 ◦C/h. Once at this temperature, 3 mL of the S-Se TOP solution was injected
and the temperature was kept at 300 ◦C for 5 min. The heating appliance was removed
and the reaction solution was left to cool to room temperature. The QDs were extracted
by dispersing the cooled solution in 8 mL of chloroform and excess acetone, followed by
centrifugation at 4000 rpm for 10 min. 2 mL of hexane and 2 mL of a hexane/methanol
solution was added, and the solution was again centrifuged as before. This process was
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repeated a further two times.
6.4.2 Polyethylene glycol phase transfer of CdZnSeS alloyed quan-
tum dots
500 µL oleic acid-coated QDs in hexane was added to PEG(5)-BP (2.4 mg) and mal-PEG(5)-
BP (1.1 mg) in 2 mL water. The solution was left stirring for 48 h at room temperature. The
remaining solution was centrifuged at 4000 rpm for 5 min using a Vivaspin 2 centrifugal filter
(30 kDa MWCO). 0.5 mL of water was added and the centrifugation process was repeated.
This process was performed several times more. The final mixture was filtered through a
0.2 µm hydrophilic PTFE filter and stored at 4 ◦C.
6.4.3 In vitro study
This study was performed in collaboration with Dr. Lea Ann Dailey. J774 murine macrophage
cells were incubated with PEG(5)-BP-QDs at 37 ◦C, and imaging was performed using a
confocal microscope.
6.4.4 Introduction of maleimide component into coating
500 µL oleic acid-coated QDs in hexane was added to PEG(5)-BP (1.8 mg) and mal-PEG(5)-
BP (1.1 mg) in 2 mL water. The solution was left stirring for 48 h at room temperature. The
remaining solution was centrifuged at 4000 rpm for 5 min using a Vivaspin 2 centrifugal filter
(30 kDa MWCO). 0.5 mL of water was added and the centrifugation process was repeated.
This process was performed several times more. The final mixture was filtered through a
0.2 µm hydrophilic PTFE filter and stored at 4 ◦C.
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6.5 Hydrophobin phase transfer of inorganic nanopar-
ticles procedures
6.5.1 Protein passivation of nanoparticles
In a typical reaction, 100 µL of as-received H*Protein B (50 mg/mL) was dissolved in 2
mL water, and the mixture was sonicated for 15 min to ensure that the hydrophobins were
dispersed in the solution. This mixture was then left for 1 h at room temperature. To the
hydrophobin solution, 50 µL of QDs/hexane solution (5 µM) was added and the solution
was sonicated for 30 min, resulting in a cloudy emulsion. After storing the emulsion for
at least 3 h at 4 ◦C, the solution was centrifuged at 4,000 rpm for 2 min, resulting in two
phases: a relatively clear solution phase and a turbid foam. The solution layer was taken
and filtered through a filter paper (particle retention of 11 µm) and was then charged in a
Vivaspin 4 centrifugal concentrator with a 100 kDa MWCO. After which the solution was
centrifuged at 4,000 rpm for 5 min, separating a few mL of the solvent from the solution.
The centrifugation process was repeated until the solution volume reduced to 200 µL in the
centrifugal concentrator. The concentrated solution was diluted with 3.5 mL water and the
concentration process was repeated again, resulting in brown solution with a slight turbidity.
The solution was then filtered through a 0.2 µm cellulose acetate syringe filter.
6.5.2 Analytical ultracentrifugation
AUC was performed by BASF. The particle size distribution was determined by AUC using
∼500 µL of the QD-hydrophobin solution. Simultaneous detection by synchronised interfer-
ence optics (Beckmann, model XLI) quantified the amount and the diameter of each fraction
independently from 1 nm up to several microns in diameter [7].
6.5.3 Secondary-ion mass spectrometry
Static TOF-SIMS spectra were recorded using a TOF-SIMS V spectrometer (Iontof GmbH,
Germany) by BASF. A pulsed mass-filtered primary ion beam of 25 keV singly charged
bismuth (Bi+) was used. This primary ion beam, resulting in a spot size of typically 5 µm
Chapter 6 221
on the sample surface, was raster scanned over an area of 250 x 250 µm to record spectra
of positive and negative secondary ions. The rastered area integrates over more than 106
particles. The primary ion dose density was always kept well below 10-12 ions cm2 and thus
in the static SIMS regime. To prevent charging of the sample surface, a low-electron energy
flood gun was used. The sample particle sediments were prepared for SIMS analysis by their
placing on clean silicon wafers.
6.5.4 In vitro/vivo studies
6.5.4.1 Ovarian and breast cancer cells
These cell studies were performed by Dr. Maya Thanou. Ovarian carcinoma, IGROV-1 cells
were propagated in RPMI-1640 media supplemented with 10 % FBS and antibiotics (1 %
penicillin/streptomycin) and maintained under standard conditions, 37 ◦C with 5 % CO2.
On the day prior to the experiment the cells were plated in 16 well glass chamber slides at a
density of 30,000 cells/well. The slide had been coated with gelatin by incubation overnight
at 4 ◦C with 1 % gelatin in PBS. On the day of the experiment the media was replaced with
Opti-MEM with or without QDs at a concentration of 0.3 µM. After 1 h incubation at 37
◦C, the media was removed; cells were washed three times with PBS with Ca2+/Mg2+, fixed
with 1 % paraformaldehyde (FA) for 15 min at room temperature, washed and incubated
with DAPI for 10 min at room temperature for nuclei staining. Imaging of cells was done
using a Leica TCS SP2 confocal microscope with a spectral detector. Images were adjusted
for contrast and brightness using Image J software and each image was modified with the
same settings. Each sample was performed in duplicates.
6.5.4.2 HeLa cells
Crosslinking
QD/hydrophobins (1 mg) were washed with 1 mL 10 mM sodium phosphate buffer at pH 7
three times (centrifuged at 3000 rpm for 1 min each time). The reaction solution was then
made up to 500 µL with buffer containing 1 % glutaraldehyde. This was allowed to react
for 1 h at room temperature whilst stirring. The solution was then purified using a PD-10
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column (that had been blocked by washing with 0.5 mL of 1 % BSA), collecting 0.5 mL
fractions with 10 mM sodium phosphate buffer as the eluent. The crosslinked QDs eluted
in fractions 1, 2 and 3, with the strongest emission from fraction 2.
Fluorescence imaging
This cell study was performed by Dr. Dylan Owen. HeLa cells were cultured in DMEM
media supplemented with 10 % FBS and maintained under standard conditions, 37 ◦C with
5 % CO2 before being plated into Lab-Tek 8-well coverslip-bottomed dishes. Cells were
incubated with QDs for 30 min prior to imaging. Imaging of cells was done using a Nikon
AR-1 confocal microscope with a spectral detector and 561 nm laser excitation and a X63
objective lens. Imaging was performed at 37 ◦C.
6.6 In vivo imaging
This in vivo study was perfomed by Dr. Maya Thanou. All experiments were performed
in accordance with the local ethical regulation of Kings College and the UK Home Of-
fice Animals Scientific Procedures Act, 1986. Xenografts were generated in BALB/c nude
athymic mice (Harlan) by subcutaneous injection of MDA-MB-231 cells (3 x 1010 cells mixed
with Geltrex 1:1 ratio). Three to four weeks later when the tumours reached sizes of ap-
proximately 50 mm3, QDs were injected intratumourly. The distribution of the dots was
monitored using in vivo imager, Maestro (Caliper). Images were collected at four time
points: right after injection, 3, 27 and 96 h post injection. Images were acquired with Mae-
stro Imaging System (Caliper) using the NIR filter setting. To separate the background
signal from the QD signal the images were unmixed using previously defined spectra.
6.6.1 Functionalisation
6.6.1.1 Radiolabelling
Radiolabelling was performed by Dr. Margaret Cooper. 500 µL of the hydrophobin-QDs
were placed in an Iodogen tube and 131I (14 MBq in 10 µL) was added. The reaction was
allowed to proceed at room temperature for 15 min with mixing. TLC was carried out using
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ITLC-SG as the solid phase and 85 % aqueous methanol as the mobile phase. The TLC
plate was scanned on a TLC scanner and the areas under the curve determined. Purification
was carried out using a PD-10 column (that had been blocked by washing with 0.5 mL 1 %
BSA) which was eluted with 5 x 0.5 mL PBS at pH 7.
The labelled QDs were also put down a BioSep-SEC-S 2000 HPLC size exclusion column
with 0.1 M phosphate buffer as the mobile phase and no activity was observed.
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A.1 Developed oleylamine-coated Fe3O4 nanoparticle syn-
thesis
Figure A.1: DLS number-weighted size distribution of oleylamine coated Fe3O4 NPs in




Figure A.2: DLS number-weighted size distribution of oleylamine coated Fe3O4 NPs in DCM
synthesised using the final developed method.
A.2 Final synthetic oleylamine-coated Fe3O4 nanopar-
ticle method
A.3 Stability studies of polyethylene glycol-coated Fe3O4
nanoparticles
Figure A.3: DLS number-weighted size distribution of PEGylated Fe3O4 NPs stored in
water for several months.
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Figure A.4: DLS number-weighted size distribution of PEGylated Fe3O4 NPs stored in
saline for several months.
Figure A.5: DLS number-weighted size distribution of PEGylated Fe3O4 NPs in 10 % human
serum.
Figure A.6: DLS number-weighted size distribution of PEGylated Fe3O4 NPs in 10 % human
serum after incubation at 37 ◦C for 1 h.
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Figure A.7: DLS number-weighted size distribution of PEGylated Fe3O4 NPs in 10 % human
serum after incubation at 37 ◦C for 24 h.
Figure A.8: DLS number-weighted size distribution of PEGylated Fe3O4 NPs in 10 % human
serum after incubation at 37 ◦C for 48 h.
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A.4 Radiolabelled polyethylene glycol-coated Fe3O4 nanopar-
ticles
Figure A.9: DLS number-weighted size distribution of radiolabelled PEGylated Fe3O4 NPs
in water.
Appendix B
Hydrophobin phase transfer of
inorganic nanoparticles
B.1 Hydrophobin-coated CdSeS/ZnS quantum dots




Figure B.2: DLS number-weighted size distribution of hydrophobin-coated CdSeS/ZnS QDs
stored in water for two months.
Figure B.3: Zeta potential distribution of hydrophobin-coated CdSeS/ZnS QDs in water.
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B.2 Crosslinked hydrophobin-coated CdSeS/ZnS quan-
tum dots
Figure B.4: DLS number-weighted size distribution of crosslinked hydrophobin-coated Cd-
SeS/ZnS QDs in water.
Figure B.5: Zeta potential distribution of crosslinked hydrophobin-coated CdSeS/ZnS QDs
in water.
